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SUMMARY
At the end of 2002, human immunodeficiency virus (HIV) had infected 42 million people
worldwide. The morbidity and mortality rate, as well as the epidemic proportions of the
disease have led to concentrated scientific efforts to reveal the disease's pathogenesis
and develop effective preventative and treatment measures. Advances have been made
to inhibit viral replication by suppressing the virus' ability to replicate by developing anti-
retroviral treatments, although development of a save and effective vaccine is the only
way to stem the pandemic. Advances in vaccine design, animal models and clinical
research have led to the creation of promising candidate vaccines to counter this
rampage, but most of these vaccines entering phase I-III clinical trials are based mainly
only subtype B genomes. HIV-1 subtype C is the most commonly transmitted subtype
worldwide, and is the predominant subtype in India, China, East and Southern Africa. A
subtype C vaccine is critical for the developing nations such as South Africa, where anti-
retroviral therapies are largely unaffordable. The envelope gene (env) is an attractive
target as immunogen to be included in a HIV vaccine. The envelope protein (Env) elicits
neutralising antibodies and cytotoxic T-Iymphocyte (CTl) responses. This protein will
therefore be useful in creating a humoral and cellular immune response in the host. A
shortage in characterised subtype C env gene sequences from South Africa was
recognised, and this study focussed on the characterisation of generated sequences, as
well as the expression of selected env genes. These immunogens were created for
possible use in a prime-boost vaccine modality. The env genes from recent circulating
strains in South Africa were amplified by polymerase chain reaction (PCR). The genes
were then cloned for sequencing and expression purposes. Phylogenetic relationships
were determined by comparing the sequences to reference subtype strains and subtype
C strains. Expression of the genes was assessed by Western Blot in 293 cells with HIV-
1 positive patient sera.
Sequence analysis showed a more conserved third variable (V3) loop in South African
subtype C sequences, with a more variable region downstream from the loop. The
crown sequence (GPGQ) and positions of uncharged or negatively charged residues in
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the V3 loop indicated a non-syncytium-inducing (NSI) phenotype for the isolates.
Phylogenetic analysis showed the sequences to all belong to the C subtype, and further
that the sequences were not recombinant, which was confirmed by recombination
analysis. The intersample diversity observed for strains from South Africa was
significantly higher than distances observed to the subtype C consensus sequence. The
South African sequences were distributed across several subclusters in a subtype C
phylogenetic tree, highlighting the concept that these infections represent a more
longstanding epidemic with multiple introductions from different geographic areas.
Western Blot with HIV-1 positive patient sera showed the expression of uncleaved
gp160 Env proteins, which were Rev dependent.
This study has generated much needed subtype C South African env gene sequences
that can be used as basis for modification for use as immunogens in a South African
vaccine.
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OPSOMMING
Teen die einde van 2002 was 42 miljoen mense wêreldwyd geïnfekteer met die
menslike immuniteitsgebrekvirus (MIV). Die dode- en sterfte syfers, asook die skaal van
die epidemie, het gelei tot 'n wetenskaplike poging om die siekte se patogenese te
openbaar en om effektiewe voorkomende en terapeutiese middels te ontwikkel.
Vordering is reeds gemaak om die virus se replikasie te hinder deur die ontwerp van
antivirale middels, alhoewel die ontwikkeling van 'n doeltreffende en veilige entstof die
enigste manier is om die pandemie te stuit. As gevolg van die vordering in entstof
ontwerp, diere modelle en kliniese navorsing is belowende kandidaat entstowwe wat die
infeksie kan teenwerk ontwikkel, maar die meeste van hierdie enstowwe wat vir fase I-III
kliniese proewe gebruik word is gebaseer op subtipe B genome. MIV-subtipe C is
wêreldwide die algemeenste subtipe wat oorgedra word en is die oorheersende subtipe
in lande soos Indië, China, oostelike en suidelike Afrika. 'n Subtipe C entstof word
dringend benodig in ontwikkelende lande soos Suid-Afrika waar antivirale middels
onbekostigbaar is. Die membraangeen is 'n aanloklike teiken om as immunogeen in 'n
MIVentstof te dien. Die membraanproteïen lok neutraliserende teenliggame en
sitotoksiese T-limfosiet reaksies uit. Die proteïen sal dus 'n humorale en sellulêre
immuunrespons in die gasheer ontlok. 'n Tekort aan gekarakteriseerde subtipe C
membraangeen volgordes van Suid-Afrika is opgemerk, en dus fokus hierdie studie op
die karakterisering van gegenereerde volgordes, asook die uitdrukking van
geselekteerde membraangene. Die immunogene is geskep om moontlik gebruik te word
in 'n stimuleer-versterkingsenstof toedieningstrategie. Die membraangene van onlangs
sirkuierende virusstamme in Suid-Afrika was geamplifiseer deur polimerase
kettingreaksie (PKR). Die gene is daarna gekloneer vir beide volgordebepalings en
uitdrukkingdoeleindes. Filogenetiese verhoudings is uitgewerk deur die volgordes met
verwysingsstamme en subtipe C stamme te vergelyk. Uitdrukking van die gene is
waargeneem in 293 selle deur die Westerse kladtegniek te gebruik met MIV-1 positiewe
pasiëntsera as teenliggaam.
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Volgorde-analise het aangetoon dat die derde varieerbare (V3) lus meer gekonserveer
is, en dat die gedeelte wat op die lus volg meer varieerbaar is. Die kroonvolgorde
(GPGQ) asook posisies van ongelaaide of negatief gelaaide aminosure in die V3 lus het
aangedui dat die isolate 'n nie-syncytia induserende fenotipe het. Filogenetiese analise
het aangedui dat al die volgordes subtipe C is en dat die volgordes nie rekombinant is
nie. Dit is ook deur rekombinasie analise bewys. Die inter-monster diversiteit van die
Suid-Afrikaanse volgordes was hoër as die waargenome afstand vanaf die subtipe C
konsensus volgorde. Die Suid-Afrikaanse volgordes is versprei oor verskeie subgroepe
in 'n subtipe C boom, wat die konsep dat hierdie infeksies 'n meer gevestigde epidemie
voorstel waar veelvuldige infeksies met verskillende geografiese oorspronge
plaasgevind het beklemtoon. Die Westerse klad het ongeprosesseerde gp160
membraanproteïne aangetoon wat Revafhanklik was.
Hierdie studie het hoogs benodigde subtipe C Suid-Afrikaanse volgordes van
membraangene geproduseer. Die volgordes kan as basis dien om die gene te
modifiseer sodat dit gebruik kan word as immunogene in 'n entstof vir Suid-Afrika.
vi
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INTRODUCTION
Twenty-one years have past since the discovery of the most devastating disease
humankind has ever faced. The first clinical evidence of acquired immunodeficiency
syndrome (AIDS) was reported in 1981 (Gottlieb et al., 1981). Since the epidemic
began, the virus has infected more than 65 million people. At the end of 2002,42 million
people were living with HIV globally. AIDS killed 2.4 million African people in 2002 and
the estimated 3.5 million new infections in sub-Saharan Africa in the past year mean that
29.4 million Africans now live with HIV (UNAIDS and WHO, 2002). Of these infected
patients, 4.74 million reside in South Africa, which translates to approximately one in
every nine South Africans (Department of Health, 2001).
The extreme morbidity, mortality, and epidemic proportions of the disease have led to
concentrated scientific efforts to reveal the disease's pathogenesis and develop effective
preventative and treatment measures. Advances have been made to inhibit viral
replication by suppressing its ability to replicate, and these nucleoside analogue
reverse-transcriptase - (e.g. AZT and 3TC), non-nucleoside reverse-transcriptase - (e.g.
nevirapine) and protease inhibitors (e.g. sequinavir and indinavir) (Kearney B, 1995)
have shown to lower the death rate of HIV infected individuals in the USA by 42% in
1996-1997 (UNAIDS and WHO, 2001). South Africa as part of sub-Saharan Africa is a
developing nation, where these therapies are largely unaffordable. Historically, vaccines
are the only way to stop an epidemic, and a safe and effective vaccine could be the only
way to halt the pandemic in developing nations such as South Africa.
As the outer shell of all viruses are considered to be the predominant target for
neutralising antibodies (Nab) from the host, as well as being able to elicit CTL responses
to specific epitopes, the envelope gene of HIV has been studied in order to include this
gene in candidate vaccines. Most of these candidate vaccines being used in Phase I-III
trials are based mainly on subtype B genomes. Only a few subtype C candidate
vaccines are in pre-clinical development (Johnston and Flores, 2001). Research on
subtype C envelope genes is necessary as this subtype is the predominant subtype
6
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found in India, China, East and Southern Africa, and is the most commonly transmitted
subtype worldwide (Esparza and Bhamarapravati, 2000; Osmanov et aI., 2002).
In this chapter the discovery and epidemiology of HIV-1 is described as background to
the specific structure and function of the envelope gene in the life cycle of the virus.
Recent advances in HIV-1 vaccine design incorporating the envelope gene are also
highlighted in the Literature Review.
1.1 DISCOVERY
Unexplained cases of immunosupression, accompanied by opportunistic infections
in the early 1960s and 1970s, were the start of what would become the recognition
of a new syndrome (Huminer et aI., 1987). In June of 1981, a short report in the
Morbidity and Mortality Weekly Report of the United States Centers for Disease
Control described five cases of Pneumocystis Carinii pneumonia (PCP) occurring
in previously healthy men in the Los Angeles area (Centers for Disease Control,
1981). The first peer-reviewed article recognising AIDS was published 4 months
later when Gottlieb et al. (1981) detected PCP in four previously healthy
homosexual men. The clinical manifestations and studies of cellular immune
function in the patients showed severe acquired T-cell deficiency. There was no
indication of spontaneous recovery of cellular immunocompetence in the surviving
patients, and all continued to have a severe wasting syndrome despite intensive
supportive measures.
In 1983 and 1984, Barre-Sinoussi et al. (1983) and Montagnier et al. (1984)
isolated retroviruses from the lymph node cells of a homosexual man who
presented with signs and symptoms often preceding AIDS. Accordingly, this virus
was designated lymphadenopathy-associated virus (LAV). After the report of LAV,
Gallo et al. (1983 and 1984) described the isolation of a cytopathic T-Iymphotropic
retrovirus from peripheral blood lymphocytes of patients with AIDS. Montagnier
7
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reported that the virus isolated by Gallo in 1983 was in fact given to him by their
group from the Institute Pasteur laboratory (Montagnier, 1984). Levy et al. (1984)
at the University of California in San Francisco cultured an AIDS-associated
retrovirus (ARV) from peripheral blood mononuclear cells (PBMCs) of an AIDS
patient. In the same year, Popovic et al. (1984) propagated Human T-cell
Iymphotropic virus (HTLV) isolated from patients with AIDS in an immortalised T-
cell population. These cytopathic variants differed from HTLV-I and HTLV-II not
only in their biological effects, but also in several immunological assays and in their
morphology (Schupbach et aI., 1984). The new HTLV isolates were collectively
designated HTLV-III (Popovic et aI., 1984; Schupbach et aI., 1984).
Rabson and Martin (1985) set out to determine the divergence between the
sequences of LAV, HTLV-'" and ARV. Molecular cloning (Alizon et aI., 1984; Luciw
et aI., 1984; Hahn et aI., 1984) and nucleotide sequence analysis revealed that the
genomes of LAV and HTLV-II' were nearly identical (Wain-Hobson et aI., 1985;
Muesing et aI., 1985; Ratner et aI., 1985; Sanchez-Pescador et ai., 1985),
exhibiting 1.4% to 2.2% divergence. In contrast, the ARV envelope nucleotide
sequence differed from the LAV sequence by 21% (Rabson and Martin, 1985).
1.2 EPIDEMIOLOGY
1.2.1 Classification of HIV into a family and genus
The family Retroviridae comprises animal viruses containing a ribonucleic
acid (RNA) dependent deoxyribonucleic acid (DNA) polymerase or reverse
transcriptase. The reverse transcriptase enzyme discovered by Temin and
Mizutani (1970), as well as Baltimore (1970) works by synthesising a DNA
representation of the viral RNA. These viruses integrate into the host
genome. In a study conducted by Gonda et al. (1985) molecular
hybridisation and heteroduplex analysis indicated a great extent of
nucleotide sequence homology between HTLV-III and Visna virus; a
8
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pathogenic lentivirus. The morphogenesis and fine structure of the two
viruses also demonstrated distinct similarities, as determined by electron
microscopy. Therefore, strong evidence was created for a close taxonomic
and thus evolutionary relation between HTLV-III and the Lentivirinae genus
belonging to the Retroviridae family. Comparison of genomic sequences
supported the notion that the human retroviruses associated with AIDS
were related to lentiviruses of other animals (Sonigo et aI., 1985).
The designation Human Immunodeficiency Virus was proposed for the
lentivirus of humans by Coffin et al. (1986). The name conforms to
common nomenclature for retroviruses, beginning with the host species
("human") ending with "virus" and containing a word that denotes a major
pathogenic property of the prototypic members of the group
("immunodeficiency").
1.2.2 Origin of the HIV virus
Classifying HIV as a lentivirus was supported when evidence indicated that
HIV is a zoonoses. This means that the virus crossed species from
nonhuman primates, which are the natural host, to humans. Five lines of
evidence have been used to substantiate the zoonotic origins of HIV.
These include: (i) similarities in viral genome organisation, (ii) phylogenetic
relatedness, (iii) prevalence in the natural host, (iv) geographic
coincidence, and (v) plausible routes of transmission. HIV-2 originated
from the cross-species transmission from sooty mangabeys (Cercocebus
atys) to humans, and the five sets of criteria were met as follows: (i) HIV-2
and simian immunodeficiency virus (SIV)sm share identical genome
structure and both these viruses encode for an accessory protein called
Vpx which has not been found in any other primate lentivirus, (ii) trees
constructed from the sequences of the 2 viruses indicate that SIVsmand
HIV-2 strains cannot be separated into distinct phylogenetic lineages
9
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according to their species of origin. Geographic and phylogenetic linkage
of the strains has also been indicated at local level (Chen et aI., 1996),
which means that sequences of the viruses from humans and primates
were the most related in the same immediate geographical area, (iii) the
sooty mangabey monkeys habitat includes many west African countries
and the infection rate of SIVsm reaches 22% in some groups, (iv) the habitat
of the sooty mangabey is in close proximity to the epicentres of the HIV-2
epidemic in Senegal, Guinea-Bissau, Guinea "Conkary" and Cote d'ivoire,
and it overlaps with Sierra Leone and Liberia where the most divergent
HIV-2 strains have been identified (Gao et aI., 1992; Schim van der Loeft
and Aaby, 1999), and (v) sooty mangabeys are hunted for food and
orphans are kept as pets (Chen et aI., 1996). There is therefore ample
opportunity for frequent human contact with infected animals.
The criteria have also been met for transmission of HIV-1. The genome
organisation of SIVcpz from the chimpanzee Pan troglodytes troglodytes is
identical to the HIV-1 genome, containing the vpu gene not found in any
other lentivirus. HIV-1 is closely related to SIVcpz at phylogenetic level
(Gao et aI., 1999). P. t. troglodytes represents a natural host for the virus.
The phylogenetic relatedness presented indirect evidence of a higher
prevalence of natural SIVcpz infection based on the discovery of viral
recombination between SIVcpz viruses of different lineages. A
geographical linkage of human and chimpanzee viruses was found in
Cameroon and its immediate vicinity (Corbet et aI., 2000a). Furthermore
hunting and field dressing (a common practice in West Africa) is a
plausible route of zoonotic transmission.
It is predicted that HIV-2 subtypes (A-F) arose from separate cross-species
transmissions (Hahn et aI., 2000) and that HIV-1 groups M, Nand 0
resulted from no fewer than 3 separate SIVcpz transmission events. The
phylogeny exemplified by HIV-1 group M viruses arose as the
10
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consequence of a single SIVcpz transmission event. This should help to
estimate the timing of the onset of the pandemic by calculating the date of
the last common ancestor of HIV-1 group M.
Earlier estimates placed the origin of HIV-1 group Maround 1960 (Li et a/.,
1988). This was contradicted when HIV-1 isolated from a 1959 plasma
sample from a patient in Kinshasa was characterised as belonging to
group M (Zhu et a/., 1998). Predictions indicating the estimated time of
onset are now 1931 (range 1915 to 1941) (Korber et a/., 2000).
1.2.3 Causes and outcomes of diversity in the virus
Retroviruses possess the ability to rapidly alter their genomes by mutation
and recombination and thus to change in response to altered
environmental conditions. This alteration has lead to very high levels of
variation between strains of HIV-1 and HIV-2 (HIV Sequence
Compendium, 2001). These two HIV types are genetically distinct, notably
with respect to the regulatory genes vpu and vpx, which are unique to HIV-
1 and HIV-2 respectively. The variation is due to the error prone reverse
transcriptase enzyme, which lacks exonucleolytic (proof reading) activity
(Bebenek et a/., 1989; Boyer et a/., 1992), recombination (Robertson et a/.,
1995), as well as negative and positive selection pressure. Recombinant
viruses are created when recombination occurs between viruses with
different subtypes in individuals co-infected with multiple divergent HIV-1
strains. Both negative and positive selection pressures are directed against
certain regions in the HIV genome to ensure infectivity and survivability. In
the env gene, negative selection operates against amino acid changes on
sites for receptor binding, therefore ensuring infectivity, and positive
selection operates against amino acid changes at antigenic sites, therefore
ensuring that the virus survives as it is able to escape recognition by the
host immune system (Yamaguchi-Kabata and Gojobori, 2000). The env
11
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gene is the most divergent among all the genes in the HIV genome
(Rabson and Martin, 1985) and a nucleotide divergence of up to 35% has
been recorded for these proteins (Gaschen et al., 2002). This diversity has
allowed the gene to be used to differentiate between different groups and
subtypes in the nomenclature. HIV-2 found predominantly in West Africa
(De Cock and Brun-Vezinet, 1989; De Cock et al., 1991; De Cock et al.,
1993) is currently subdivided into subtypes A-F, and the HIV-1 sequences
are divided into three main groups, M (major), 0 (outlier), and N (non-M
and -0), which are defined as distinct clusters on phylogenetic trees
(Figure 1) (HIV Sequence Compendium, 2001; Loussert-Ajaka et al.,
1995; Simon et al., 1998).
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Figure 1. Evolutionary relationships among non-recombinant HIV strains from the HIV-
1/SIVcpz lineage based on neighbour joining phylogenetic analysis of nearly full-length
genome sequences. The phylogenetic tree shows the different HIV-1 groups, subtypes
and sub-subtypes. Each of the internal branches defining a subtype or sub-subtype is
supported by 100% of bootstraps (Peeters, 2000).
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The viruses of group M are currently subdivided into subtypes A - D, F - H,
J, K, and circulating recombinant forms (CRFs) (HIV Sequence
Compendium, 2001). Subtype E is now referred to as CRF01_AE and
subtype I has been dropped from the nomenclature (Carr et aI., 1996;
Kostrikis et aI., 1995; Gao et aI., 1996b).
1.2.4 The global epidemic
The spread of HIVand subtype distribution worldwide is diverse (HIV
Sequence Compendium, 2001). Subtype B is the most predominant
subtype found in the Americas, Western Europe and Australia (Figure 2)
(Osmanov et aI., 2002). North America had 980 000 people living with
HIV/AIDS at the end of 2002, and in Latin America, 1.5 million people were
infected (UNAIDS and WHO, 2002). The B subtype is predominantly
transmitted by intravenous drug use and by men having sex with men .
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Figure 2. The map represents the distribution of subtypes for each country using a pie chart.
The list of subtypes presented on the map are: A, B, C, D, F, G, H, J, K, CRF01_AE,
CRF02_AG, CRF03_AB, CRF04_cpx, group Nand ° (HIV Sequence Compendium, 2001)
(http://hiv-web.lanl.gov/content/hivdb/geography/geography.comp).
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Countries along the central belt of Africa and some North African countries
have a subtype A distribution. The leading mode of transmission of
subtype A strains is predominantly heterosexual contact. Subtype A
infections have also started to spread globally outside Africa and have
already been reported in Eastern Europe, East Asia, and the Pacific.
Eastern Europe, and East Asia are also affected by subtype B viruses
(Osmanov et aI., 2002). The epidemic only started in Eastern Europe and
Central Asia in the early 1990s and 1.2 million people were reported to
have HIV/AIDS at the end of 2002. South and South-East Asia have a
predominantly B subtype distribution. In these areas 6.0 million people are
reported to be infected with HIV/AIDS (UNAIDS and WHO, 2002). Almost
all the subtypes and CRFs are found in central Africa. Subtype C is the
most predominant subtype in India (South Asia), East and Southern Africa
(Figure 3). Subtype C also circulates in China together with CRF07_BC
and CRF08_BC. Subtype C viruses are mostly spread by heterosexual
contact (Williamson et aI., 1995; Osmanov et aI., 2002), and these viruses
constitute 47.2% of all circulating viruses and are the most commonly
transmitted subtype worldwide (Osmanov et aI., 2002; Esparza and
Bhamarapravati,2000).
1.2.5 The South African epidemic
The initial AIDS epidemic in South Africa in the early 1980s affected mainly
the homosexual/bisexual population (Sher, 1989) and HIV-1 subtype B
was predominant (Williamson et aI., 1995). The epidemic later shifted to a
predominantly heterosexual orientation with HIV-1 subtype C being the
most common subtype circulating the country (Engelbrecht et aI., 1999;
Williamson et aI., 1995; van Harmelen et aI., 1999; van Harmelen et aI.,
1997; Moodley et aI., 1998; Bredell et aI., 1998). The subtype B epidemic,
although a lot smaller than the subtype C epidemic, is still observed in the
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homosexual population. Subtype B isolates have recently been discovered
in the heterosexual population as well (Janse van Rensburg et aI., 2002).
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Figure 3. Maps of Africa representing the: A) subtype distribution per country indicated
by a pie chart, and B) percentage of viruses in each country classified as belonging to
subtype C (http://bioafrica.net/subtype/i ndex.htm I).
Given the high levels of migrancy and the explosive HIV-1 epidemic in the
Southern African region as well as the isolation of subtypes A, 0, G and
intersubtype recombinants in South Africa from 1995-2000 (Bredell et aI.,
2000; Bredell et aI., 2002), indications are that the number of genetic
subtypes in South Africa will increase with time.
Seventeen years after the isolation of the first HIV-1 virus in South Africa
(Becker et aI., 1985), infection rates have reached epidemic proportions.
The National HIVand Syphilis sero-prevalence survey of woman attending
public antenatal clinics in South Africa indicate that 4.74 million people
were infected with HIV-1 by the end of 2001 (Department of Health, 2001).
Although the report indicates that a plateau has been reached, infection
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rates of pregnant woman are still predicted to be as high as 24.8% (Figure
4).
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Figure 4. National HIV prevalence trends among antenatal clinic attendees in South
Africa: 1990-2001 (Department of Health, 2001).
1.3 HIV-1 STRUCTURE AND REPLICATION
1.3.1 Virion structure and viral genome organisation
As reviewed (Luciw, 1996), HIV virions are spherical in shape and are
about 110 nm in diameter (Figure 5). A lipid bilayer membrane or envelope
surrounds the cone-shaped nucleocapsid, which spans the entire diameter
of the virion with a wide free end and narrow end connected to the lipid
bilayer. The nucleocapsid within each mature virion contains two
molecules of viral single-stranded RNA, which are encapsulated by
proteins proteolytically processed from the gag precursor polypeptide.
These gag gene products are the matrix protein (MA or p17), the major
capsid protein (CA or p24), the nucleocapsid protein (NC or p7), as well as
p1, p2 and p6, which bind tightly to the viral genome.
16
Stellenbosch University http://scholar.sun.ac.za
Figure 5. A cartoon depicting the structure of the HIV-1 virion. Adapted from Freed
(1998). Structural and accessory gene products have been indicated.
Viral enzymes protease (PR), reverse transcriptase (RT) and integrase (IN)
are derived from the pol gene precursor polypeptide and are packaged into
the virions. RT is a heterodimer composed of a p51 and p66 subunit. An
additional enzymatic activity, Rnase H (ribonuclease specific to RNA in
RNA-DNA hybrids), is an independent domain in the RT heterodimer. RT,
Rnase H and IN are contained within the nucleocapsid in mature virions.
The env gene products comprise the seventy-two spikes (Ozel et al., 1988)
that protrude from the HIV virion in a triangular symmetry fashion. The
spikes consist of a trimeric gp120 protein knob and are linked to the lipid
bilayer by a gp41 protein stalk. The gp120 of HIV contains a domain that
recognises and binds cell receptors and co-receptors vital to virus entry.
The receptor for HIV-1 is the CD4 antigen, a cell surface protein on T-
helper lymphocytes (Dalgleish et al., 1984; Klatzmann et al., 1984). The
gp41 mediates fusion of viral and cellular membranes to allow viral
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contents to enter the host cell. Together the pol, env and gag genes form
the structural genes (Figure 6).
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Figure 6. Diagram showing the structural genes gag, pol and env in the HIV-1 genome.
Starting positions of genes relative to B.FR.HXB2 (subtype, followed by an abbreviation
for the country of isolation, followed by the common name of the strain) have been
indicated in the top left corners, and the end positions in the bottom right. Diagram
adapted from the Los Alamos HIV sequence database (HIV Sequence Compendium,
2001).
As reviewed (HIV Sequence Compendium, 2001), the transcriptional
activator (tat) and regulator of viral expression (rev) genes are each
encoded by two overlapping exons and produce small non-virion proteins
which are essential for viral replication. Tat acts as transactivator of HIV
gene expression by binding to a TAR element and activating transcription
initiation and elongation from the long terminal repeat (LTR) promoter. Rev
is a phosphoprotein localised primarily in the nucleus of the host cell. Rev
acts by binding to a Rev responsive element (RRE), which promotes the
nuclear export, stabilisation and utilisation of viral messenger ribonucleic
acid (mRNA) containing RRE. Rev is considered the most functionally
conserved regulatory protein of lentiviruses. Rev rapidly cycles between
the nucleus and cytoplasm. Accessory genes encoded by HIV-1 are vif,
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vpr, vpu and net. Vif is the viral infectivity factor, which promotes infectivity
of the virus, but not the production of the virus. Vpr or Viral protein R
targets the nuclear import of preintegration complexes, arrests cell growth,
acts as transactivator of cellular genes and induces cellular differentiation.
Vpu or Viral protein U degrades CD4 in the endoplasmic reticulum (ER)
and enhances virion release from the plasma membrane of HIV-1 infected
cells. Vpu is further involved in Env maturation. Nef down regulates CD4
and MHC class I molecules and increases viral infectivity.
1.3.2 HIV-1 life cycle
The HIV-1 life cycle can be considered as a sequence of events divided
into early and late events as demonstrated in Figure 7.
1.4 THE ENVELOPE GLYCOPROTEIN
1.4.1 Synthesis and assembly of the envelope glycoprotein
The synthesis and processing of the Env glycoprotein occurs during the
secretory pathway of the host cell. This pathway is also utilised for
producing cellular secreted and membrane proteins as well as glycoprotein
of other enveloped viruses (Doms et ai., 1993). The env mRNA is
translated to envelope glycoprotein on membrane-bound ribosomes as
846- to 868-amino acid precursors. These precursors are only synthesised
after the hydrophobic signal peptide is cleaved during translocation into the
rough ER of an infected cell. These infected cells include T-cells,
monocytes or macrophages, dendritic cells and brain microglia (Klatzmann
et ai., 1984; Schnittman et ai., 1989; Koenig et ai., 1986; Wiley et ai., 1986;
Nicholson et ai., 1986; Ho et ai., 1986; Gendelman et ai., 1985).
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Figure 7. The HIV-1 viral life cycle is shown in this diagram. Adapted from Freed (1998).
Steps in the early and late phase have been indicated by numbers 1 through 13: 1,
binding of gp120; 2, fusion initiated by gp41; 3, uncoating; 4, reverse transcription of
viral RNA; 5, transport of pre-integration complex; 6, integration by IN; 7, transcription; 8,
synthesis and transport of Env; 9, synthesis and transport of Gag and Gag-pol
precursor; 10, membrane curvature; 11, incorporation of Env into budding virions; 12,
completion of budding; 13, cleavage of Gag and Gag-pol precursor and condensing of
the core leads to maturation of virion.
20
Stellenbosch University http://scholar.sun.ac.za
This precursor is designated the gp160 (based on apparent molecular
mass) after asparagine-linked, high-mannose sugars are added to the
precursor (Robey et al., 1985; Allan et al., 1985). The gp160 monomers
are then inserted into the lumen of the ER where they oligomerise into
trimers (Sodroski, 1999; Weiss et al., 1990; Chan et al., 1997;
Weissenhorn et al., 1997). A group has also shown a tetrameric envelope
structure (Pinter et al., 1989). The protein is now competent to bind CD4
(Fennie and Lasky, 1989). The oligomerisation process is thought to be
required for transport of the oligomeric protein to the cis compartment of
the Golgi apparatus (Willey et al., 1991), where high mannose ER-acquired
N-linked oligosaccharide side chains are modified to more complex forms
(Ratner, 1992; Dewar et al., 1989; Stein and Engleman, 1990).
The gp160 is then proteolytically cleaved by a host furin or furin-like
protease (Hallenberger et al., 1992) at an Arg-X-Lys/Arg-Arg motif (where
X is any amino acid) (Hosaka et al., 1991), which is a highly conserved
area among viral Env precursors (McCune et al., 1988; Freed et al., 1989).
The cleavage yields the mature exterior surface envelope protein (SU or
gp120) (Allan et al., 1985), and transmembrane glycoprotein (TM or gp41)
(Veronese et al., 1985). The gp120 and gp41 glycoproteins are maintained
in an assembled trimer by noncovalant interactions (Helseth et al., 1990)
and these complexes are then transported to the cell surface. At the cell
surface, the envelope protein is destined for one of three fates. First, due
to the weak association of gp120 and gp41, some of the gp120 protein is
released or shed for the virion (Helseth et al., 1990) and capable of binding
CD4 expressed on uninfected or infected lymphocytes (Siliciano et al.,
1988). Second, surface expressed gp120-gp41 complexes are capable of
binding CD4 on uninfected lymphocytes, resulting in fusion of uninfected
with infected lymphocytes (giant cell formation or syncytia) (Lifson et al.,
1986a; Lifson et al., 1986b). Third, a fraction of these envelope
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glycoproteins are incorporated into budding virus particles by the
interaction of gp120-gp41 complexes with Gag and Gag-Pol precursor
proteins (Ratner et aI., 1991; Wyatt and Sodroski, 1998; Freed, 1998).
1.4.2 The gp120 subunit or SU
The gp120 monomer is a highly glycosylated and variable hydrophobic
protein which, after oligomerisation is positioned as a trimer (spike) on the
external surface of the HIV-1 virion membrane. Sequence heterogeneity is
a characteristic of the env gene and five variable domains (V1-V5)
interspersed with more conserved regions (C1-C5) have been identified
(Figure 8) (Stareich et aI., 1986). The first four variable regions (V1-V4)
form surface-exposed loops that contain disulfide bonds at their bases.
The disulfide bonds are generated between 18 cysteine residues, which
are highly conserved in the glycoproteins of HIV-1. The conserved gp120
regions (C1-C5) form discontinuous structures important for the interaction
with the gp41 ectodomain and with the viral receptors on the target cell
(Kwong et aI., 1998). Both conserved and variable gp120 regions are
extensively glycosylated. Approximately 50% of the apparent molecular
mass of gp120 is carbohydrate and the number of N-linked glycosylation
sites in gp120 ranges from 18-33, with a median of 25 (Korber et aI.,
2001). Twenty-four potential sites for N-linked glycosylation (Asn-X-
Ser/Thr) have been shown in HIV-1 gp120 of B.FR.HXB2 (HIV Sequence
Compendium, 2001). The 24 sites are largely conserved between viral
isolates. leonard et al. (1990) showed that less fully processed (i.e.
endoglycosidase H-susceptible) oligosaccharides of gp120 are found
preferentially at the most conserved glycosylation sites and the remaining
sites are relatively conserved although many of them occur in the
hypervariabie domains. The positions of these sites may shift or be
deleted, but there is always one or more new site(s) within 5-10 residues of
the reference HIV-1 Ills sequence.
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Glycosylation appears to affect intracellular processing and influences both
functional and immunological properties of the mature protein.
Posttranslational modification governs the transport and eventual
maturation of the glycoprotein (Ratner, 1992). Glycosylation also affects
viral infectivity (Lee et al., 1992). Most importantly for vaccine purposes,
carbohydrate moieties may appear as 'self' to the immune system and the
extensive glycosylation of the outer domain surfaces may render it less
visible to immune surveillance (Wyatt et al., 1998). Glycosylation also
occludes peptide epitopes, therefore providing a mechanism for the virus
to escape antiviral immune responses.
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Figure 8. Structure of the gp160 precursor. The gp120 unit is shown in blue and grey,
and the gp41 unit is shown in purple, olive and black. The arrow indicates the Arg-X-
Lys/Arg-Arg cleavage site. Conserved regions in the gp120 are delineated as C1-C5
(grey), whereas the variable loops are indicated as V1-V5 (blue). The purple bar
represents the fusion domain in the gp41 unit, and the black bar represents the
transmembrane domain. This diagram was adapted from Helseth et al. (1991).
1.4.3 The gp41 subunit or TM
The N-terminus of the gp41 contains a hydrophobic fusion domain, and
mutagenesis of this domain leads to fusion-incompetent virions (Freed et
al., 1990; Bergeron et al., 1992). Within the hydrophobic fusion region
there is a FLG tandem repeat beginning 7 or 8 residues from the N-
terminus depending on the virus isolate, and it is hypothesised that this
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repeat is the fusogenic site of gp41 (Gallaher, 1987; Schaal et ai., 1995).
The fusion peptide region of the ectodomain is followed by two regions with
a 4-3 hydrophobic (heptad) repeat, a sequence which is characteristic of
coiled coils (Chambers et ai., 1990; Delwart et ai., 1990). These heptad
repeats of leucine or isoleucine residues form a soluble, a.-helical core
consisting of a trimer of antiparallel dimers, and crystallographic analysis of
this gp41 core confirmed that it is a six-helix bundle (Chan et al., 1997;
Weissenhorn et ai., 1997; Tan et ai., 1997). It is suggested that this six-
helix bundle represents the fusion-active gp41 and plays and essential role
in membrane fusion (Wang et ai., 2002; Sackett and Shai, 2002). This view
has been confirmed by antibody-binding studies (Jiang et ai., 1998).
The RRE has been mapped to a region that comprises 240 nucleotides
and has the propensity to form extensive secondary structure (Cochrane et
ai., 1990; Dayton et ai., 1988). This region starts in the 3' end of the gp120,
48 nucleotides before the cleavage site of gp120 and gp41 (HIV Sequence
Compendium, 2001). The interaction of Rev and the RRE has been shown
to regulate the expression of the env gene at posttranscriptional level
(Dayton et ai., 1988; Hadzopoulou-Cladaras et ai., 1989; Hammarskjold et
ai., 1989). The Rev-mediated transport to the cytoplasm of unspliced and
singly spliced mRNA possessing a RRE, is dependent on direct binding of
Rev (Malim et ai., 1989).
A second hydrophobic region, the membrane-spanning region, is found at
amino acids 684-706 (positions in the B.FR.HXB2 strain) (HIV Sequence
Compendium, 2001) and this region stops translocation through the lipid
bilayer of the ER and serves to anchor the protein during fusion of the viral
and cellular membranes. A conserved tryptophan-rich motif in the region
adjacent to the membrane-spanning region is predicted to form a a.-helix,
and deletion of this region abrogates the ability of the envelope
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glycoprotein to mediate both cell-cell fusion and virus entry (Salzwedel et
al., 1999).
The next readily identifiable region is marked by two or three cysteine
residues (Cys-598, Cys-604, and Cys-764) (positions in B.FR.HXB2),
which are highly conserved in different HIV-1 isolates (HIV Sequence
Compendium, 2001). Cys-764 is located downstream from the hydrophobic
membrane anchor region of gp41 and presumed to be in the intracellular
domain of gp41. In contrast, both Cys-598 and Cys-604 are located
upstream from the membrane anchor region and are believed to be in the
extracellular domain of gp41. Mutagenesis of the latter mentioned cysteine
residues resulted in the loss of viral infectivity, which could be attributed to
severe impairment in the processing of gp160 precursor to gp120 (Syu et
al., 1991). This region containing the Cys-598 and Cys-604 further
comprises the principal epitope recognised by antibodies to the TM (Wang
et al., 1986; Gnann Jr. et al., 1987), and is designated the
immunodominant region (amino acids 588-605) (HIV Sequence
Compendium, 2001). A conserved glycosylation site follows the
immunodominant region, and is one of a possible 5-6 glycosylation sites in
the gp41 (Gallaher et al., 1989; HIV Sequence Compendium, 2001).
A long cytoplasmic tail of approximately 150 amino acids in length is found
at the C-terminus of the gp41. Studies have indicated that the tail is
required for infectivity (Dubay et al., 1992; Yu et al., 1993) as well as
incorporation of envelope proteins into virions in a cell type-dependent
manner (Murakami and Freed, 2000; Gabuzda et al., 1992).
1.4.4 The role of the envelope glycoprotein in HIV-1
The envelope protein plays an essential role in the lifecycle of HIV-1. The
protein is responsible for the entry of the virus into a target cell by the
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action of the gp120 in its trimeric form, which binds to the CD4 receptor of
the target cell. The gp120 further specifies the tropism of the virus, which
determines the type of host cell, which will be infected. The gp41 is
responsible for fusion of the viral and host membranes, therefore allowing
the viral genome to enter the host cell. The envelope protein further elicits
antibodies from the host as neutralising epitopes are exposed on the
surface of the protein.
1.4.4.1 CD4 binding
The primary step in the HIV-1 infection involves the binding of the gp120
CD4 binding domain (Kowalski et a/., 1987; Lasky et a/., 1987) to the host
cell surface molecule CD4, which serves as the major receptor for HIV-1
(Dalgleish et a/., 1984; Klatzmann et a/., 1984; Maddon et a/., 1986). The
more conserved regions in gp120 are folded into the core, which is
composed of two domains: an inner and outer domain, and a p sheet
(Figure 9) (Wyatt and Sodroski, 1998). Elements of both domains and the
bridging (p) sheet contribute to CD4 binding. Genetic, biochemical and
immunochemical studies have indicated regions in the gp120, which
interact with the CD4 receptor. Site-specific mutations and the analysis
thereof indicated a limited number of conserved amino acids in different
regions of the gp120, which are required for efficient binding to the CD4
receptor. Trp427 and VaI430-Pr0438 in hydrophobic regions, as well as
Asp368/Glu370 and Asp457 in hydrophilic regions are the contact amino
acids for CD4 in the gp120 protein (HIV Sequence Compendium, 2001). In
addition to binding CD4 on the cell surface, HIV-1 Env associates with CD4
intracellularly soon after gp160 synthesis in the ER by adopting a
conformation suitable for CD4 binding (Fennie and Lasky, 1989). This
leads to the down-regulation of CD4 expression from the cell surface of
Env-expressing cells (Hoxie et a/., 1986; Kawamura et a/., 1989), which
may reduce the ability of these cells to become infected with additional
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virions. This is known as super-infection interference (Stevenson et al.,
1988).
The binding of gp120 to CD4 induces conformational changes in the
gp120, which contributes to the exposure of the binding site for the
chemokine receptors (Sattentau and Moore, 1991; Sattentau et al., 1993).
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Figure 9. A ribbon diagram depicting the core gp120 structure. The inner and outer
domain as well as the bridging sheet, which playa role in CD4 binding is indicated
(Kwong et al., 1998).
1.4.4.2 Tissue tropism and chemokine receptor usage
An additional function of the HIV-1 Env glycoprotein is to determine the
cell-type specificity of virus infection. Most primary virus isolates of HIV-1
obtained from infected individuals during the early, asymptomatic phase of
infection are NSI and macrophage-tropic. These isolates use the CCR5
chemokine receptor as co-receptor for entry into cells of monocyte or
macrophage lineage (Deng et al., 1996; Dragic et al., 1996; Alkhatib et al.,
1996; Choe et al., 1996; Wu et al., 1996). HIV-1 isolates capable of
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infecting T-cell lines tend to arise late in infection after the onset of AIDS-
defining symptoms. These isolates are syncytium-inducing (SI) and often
use other chemokine receptors, frequently CXCR4, in addition to CCR5 as
co-receptors (Schuitemaker et al., 1992; Connor et al., 1997; Zhang et al.,
1996; Bjërndal et al., 1997). There appears to be subtype-dependent
differences in frequency of usage for certain chemokine receptors. A dual
tropism for both CXCR4 and CCR5 has been more rare among subtype D
isolates, and the CXCR4-positive phenotype was significantly more rare
among subtype C isolates (Tscherning et al., 1998). Subtype C isolates
obtained from late-stage Ethiopian AIDS patients showed no CXCR4
usage in any of the isolates, unlike other subtypes, which have been
indicated to start using CXCR4 in later stages of the disease progression
(Bjërndal et al., 1999). The discovery that subtype C isolates from patients
in later stages of disease progression did not use CXCR4, but remained
NSI and CCR5-tropic was also reflected in isolates obtained by our group
in 1998 (Treurnicht et al., 2002). Our group also studied the phenotype of
more recent subtype C isolates (obtained in 2000-2001), and these studies
indicate that subtype C viruses are now following the same trend as other
subtypes by switching to CXCR4 usage (Janse van Rensburg et al., 2002).
Studies involving chimeric envelope glycoproteins have demonstrated that
the third variable loop (V3) in the gp120 plays a central role in determining
cell tropism and chemokine receptor usage (Speck et al., 1997; Chesebro
et al., 1991; Chesebro et al., 1992; Cheng-Mayer et al., 1990; Willey et al.,
1994). Versions of the gp120 protein where the V3 loop has been deleted
do not bind CCR5, although CD4 binding occurs at wild-type levels.
Antibodies to the V3 loop have also been shown to interfere with gp120-
CCR5 binding (WU et al., 1996). Basic amino acids in one or more of
positions 305,321 or 327 confer a SI phenotype (positions in B.FR.HXB2),
whereas hydrophobic amino acids in these positions correlate with aNSI
phenotype (Bjërndal et al., 1999). The net charge in the V3 loop of SI and
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NSI variants generally have an overall charge of >+5 and =<+5
respectively. Therefore the position and charge of a particular residue
influences the overall phenotype of a variant. A tetrapeptide crown
sequence located at the apex of the V3 loop is highly conserved motif
among HIV-1 isolates (Gly311-Pro312-Gly313-Arg314 for strain
B.FR.HXB2) (HIV Sequence Compendium, 2001). The sequence of the
crown is indicative of the viral phenotype as well. NSI sequences mostly
have a GPGQ sequence, where as SI viruses have a positively charged
residue replacing the Q with either an H or R (Abebe et ai., 1999).
Phenotypes are further influenced by sequences outside the V3 loop. A
functional interaction between the V3 loop and V1/V2 loops has been
detected, which is important for infectivity as well as syncytium formation
and cell tropism (Koito et ai., 1994). Stamatatos and Cheng-Mayer (1993)
suggest that the overall conformation of the envelope glycoprotein
determines the phenotype of the virus.
1.4.4.3 Membrane fusion
The receptor binding-mediated activation of membrane fusion is postulated
to involve a conformational change in the envelope protein complex from a
native (nonfusogenic) to a fusion-active (fusogenic) state. The hydrophobic
(heptad) repeats following the fusion domain form a six-helix bundle, which
represents the fusion-active gp41 as described earlier. The bundle has a
coiled-coil structure (Wild et ai., 1994), the identical structure which in an
influenza virus system induces fusion in a pH-dependent process (Carr
and Kim, 1993). In an HIV system, the transition from native to fusogenic
by the formation of the coiled-coil is a result of conformational change after
binding of the gp120 to CD4, and is pH-independent (Stein et ai., 1987;
McClure et ai., 1988; McClure et ai., 1990). The conformational change
facilitates the exposure of the hydrophobic, glycine-rich fusion peptide
(Sattentau and Moore, 1991) and insertion of the peptide into the
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membrane of the target cell (Wyatt and Sodroski, 1998). Viral and cellular
membranes are then fused by an unknown mechanism allowing the virus'
genetic material to enter the host cell. Mutagenic analysis (Cao et al.,
1993; Freed et al., 1990) and crystal structures of the HIV-1 gp41
ectodomain support this model (Chan et al., 1997; Weissenhorn et al.,
1997).
1.4.4.4 Neutralisation
The envelope protein is a prime target for the human immune system. The
trimeric protein elicits several different groups of antibodies during the
course of infection (Figure 10) (Wyatt, 2002). Early after infection occurs
non-neutralising antibodies are created by the host, which are directed to
the gp41 protein as well as the C1 and CS domains in the gp120. It has
been proposed that these antibodies are non-neutralising because the
epitopes are either not exposed as a result of gp120 shedding from the
virions (Helseth et al., 1990), or the conformation of the protein doesn't
allow the exposure of the epitopes at this stage of the infection (Wyatt,
2002).
The next group of antibodies raised in the host is strain-restricted Nab
directed mainly at the V3 loop in the gp120. A few antibodies are also
directed at the V2 loop. These antibodies are relatively potent, but the
viruses aren't neutralised because escape mutants are created relatively
easy by point mutations as a result of the error prone reverse transcriptase
enzyme (Bebenek et al., 1989; Boyer et al., 1992), and antibodies
therefore can't recognise the altered epitopes.
Potent broadly Nab are elicited much later in infection and 4 classes of
antibodies have been identified so far. The first class comprises antibodies
directed at the CD4 binding site (CD4BS). The CD4BS antibodies cross
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compete with the gp120 protein to bind to the CD4 binding site expressed
on the surface of host cells (Zwick et a/., 2001a).
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Figure 10. A cartoon depicting the different antibodies elicited by the envelope
glycoproteins during infection (Wyatt, 2002).
More than 50 of these antibodies have been identified so far, but only the
IgGb12 antibody first identified by Burton et al. (1994) has been shown to
neutralise primary strains, and these are extremely rare in hosts (Kessler
et a/., 1997). The second class contains the CD4 induced (CD4i)
antibodies 17b, 4Bd, A32 and CG10 (Thali et a/., 1993; Weinberg et a/.,
1997; Sullivan et a/., 199B), which bind to conserved regions in the C4
region and portions of the V3 loop. They are V3 dependent and seem to
bind to these sites with a greater affinity after gp120 has attached to the
CD4 molecule. These antibodies have been shown to neutralise T-cell line
laboratory adapted (TCLA) strains, but aren't potent against primary
strains. The very rare 2G12 antibodies recognise a complex discontinues
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epitope involving the C3-C4 region of the gp120 (Trkola et a/., 1996) and
are classified in the third class. The epitope is formed by mannose
residues contributed by glycans attached to N295 and N332 and other
glycans playing an indirect role in maintaining epitope conformation
(Scanlan et a/., 2002), therefore making the antibodies carbohydrate
dependent (Sanders et a/., 2002).
The fourth class contains antibodies directed at the gp41 region. They are
7-8 amino acids in length and are conformation dependent. This class
contains the 2F5 antibodies (Muster et a/., 1993), as well as Z13 and 4E10
which recognise a region immediately C-terminal of the 2F5 epitope (Zwick
et a/., 2001b; Buchacher et a/., 1994). The Z13 and 4E10 antibodies are
able to neutralise selected primary isolates (Zwick et a/., 2001b).
Although the envelope contains epitopes to elicit all the above-mentioned
antibodies, viruses aren't neutralised efficiently in the host. Spontaneous
shedding of the gp120 from the virions are a likely mechanism of immune
evasion as the envelope either doesn't present these epitopes after
shedding, or exposes "decoy" epitopes to force the immune system to
create the wrong non-neutral ising antibodies (Wyatt, 2002). Potent and
broadly Nab are relatively rare in infected individuals, and some are more
subtype specific than others. 2F5 antibodies have been shown to
neutralise subtype C viruses to a lesser extent than subtype B, and
subtype C viruses have shown to resist neutralisation by 2G12 antibodies
(Bures et a/., 2002). This poses a major challenge for HIV vaccine design.
1.4.5 Envelope cloning and protein expression in transfected cell-lines
Several envelope genes have previously been cloned and transiently
expressed in cell-lines. Clones were generated for full-length gp120 and
gp160 env genes from isolates obtained from the World Health
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Organisation (WHO)- and National Institute of Allergy and Infectious
Diseases (NIAID)-sponsored Networks for Virus isolation and
Characterisation and represent viruses collected at potential vaccine
evaluation sites. Env proteins were expressed after transient transfection
into Hela cells. Only unprocessed gp160 proteins were detected as a
result of experimental conditions used, and the proteins varied
considerably in size and carbohydrate content (Gao et al., 1996a; Bjorndal
et al., 1997; WHO Network for HIV Isolation and Characterization, 1994).
1.5 HIV-1 VACCINE STRATEGIES AND DESIGN
A safe, highly effective, and affordable preventative vaccine is the only way to halt
the HIV-1 pandemic worldwide. Although early host immune responses against
HIV would ordinarily portend a successful quest for a vaccine, the quest is
hampered by various factors, which provide the virus with the ability to escape from
the immune system during the course of infection.
These include extensive glycosylation, conformational flexibility, variable domains
and unstable subunit association, which causes shedding of gp120. Carbohydrate
moieties render the virus less visible to the immune system and together with
hypervariabie loops camouflage neutralising epitopes providing a mechanism for
the virus to escape antiviral immune responses (Wyatt and Sodroski, 1998; Wyatt,
2002). Furthermore, as a retrovirus, HIV-1 is capable of rapidly altering its genome
by mutation and recombination and thus changes in response to altered
environmental conditions. A vaccine would therefore have to be designed with all
these limitations in mind.
Preventative vaccines establish immunological memory for antigenic structures
presented by a pathogen or by infected cells, therefore including elements of the
adaptive immune responses in the recipient (Graham, 2000). The basic cellular
elements of the adaptive immunity include B-Iymphocytes, which produce
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antibodies (humoral immune response), and T lymphocytes. Cytolytic activity
(cellular immune response) is mediated primarily by CD8+ T cells. Soluble factors
produced by activated CD4+ and CD8+ T cells have anti-viral activity and can
influence the differentiation, expansion and duration of T cell responses. Antibodies
are the only component of the adaptive immune response that can neutralise a
virus prior to infection of a cell, and CD8+ T cells are the principal effector
mechanism to clear cells already infected with virus and therefore controls viral
replication during early infection (Koup et aI., 1994). This suggests that a HIV-1
vaccine should stimulate both the cellular and humoral arms of the immune
system.
In the natural history of HIV-1 (Figure 11), primary viremia lasts 3 months after the
initial infection. Thereafter a set point is reached which is described as the steady
state in which virus clearance matches virus production (Graham, 2000). Viral RNA
levels increase after seroconversion at a rate of 0.11 log10 copies/ml per year
(Sabin et aI., 2000) until the patient develops AIDS (Henrard et a/., 1995). The level
of CD4+ T cells initially decreases during primary viremia, but recovers and
stabilises during the asymptomatic period of the disease only to deplete when
AIDS develops. A CD8+ memory T-cell response develops after 3-6 months of
infection, declines after 6-8 months and stabilises after 12 months (Musey et aI.,
1997). Nab are produced after approximately 8 months of infection. If the
production of CD8+ T-cell and Nab responses can be shifted towards the time
point at which infection takes place, an adaptive immune response will most likely
be able to clear virus before the infection can take place (Montefiori, D.C. (2002),
personal communication, Duke University, Durham, North Carolina, USA).
Strategies to prevent infection have been directed toward the development of
vaccine regimens that can elicit effector T-cell responses to eliminate viral infected
cells and antibody responses to neutralise cell-free virus. As the envelope of HIV-1
contains both neutralising antibody binding sites (Chanh et aI., 1986) and CTL
34
Stellenbosch University http://scholar.sun.ac.za
epitopes (Takahashi et ai., 1988), the gene has been studied in order to be
included in candidate vaccines .
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Figure 11. Schematic drawing showing the course of HIV-1 infection. The viral load is
indicated by the solid blue line. CD4+ T-cell levels are shown by the dashed green line.
CD8+ CTl responses develop after approximately 3-6 months of infection, and is
indicated by the dotted red line. Nab only develop after 8 months of infection and is
shown by the dashed dotted black line. The red and black arrows indicate that shifting of
CTl and Nab responses may be able to prevent infection. Figure adapted from Mindel
and Tenant-Flowers (2001), Sabin et al. (2000) and Musey et al. (1997).
Several adjuvant recombinant monovalent HIV envelope proteins (e.g. gp160 or
mature gp120) based on TClA isolates of subtype B HIV have shown to induce
Nab in virtually all volunteers, but these antibodies exhibited little cross-reactivity
against primary isolates of HIV (Mascola et ai., 1996). Subsequently, bivalent
candidates containing two subtypes of gp120 (one from a TClA subtype B, and
one from a subtype B or E primary isolate) have been designed by VaxGen, and
Phase III trial results are expected within the next 2-3 years (Esparza et ai., 2002;
Johnston and Flores, 2001; Esparza and Bhamarapravati, 2000).
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Live recombinant vectors expressing HIV genes are promising candidates for
vaccines. Attenuated vaccinia expressing the HIV gp160 protein, and additional
more complex vaccinia vectors expressing env and gag-pol, boosted with
recombinant envelope proteins induced Nab in vaccine recipients. CTl activity
could not be measured accurately in these trials because sensitive assays to
detect CTl responses were not available at the time (Corey et aI., 1998; Johnston
and Flores, 2001).
The risk associated with potential virulence of vaccinia in immune deficient
individuals has directed attention to the design of recombinant viral vectors, such
as the recombinant canarypox vector or AlVAC. This vector induces HIV-specific
CTl responses in approximately one third of volunteers, and a boost with gp120
subunit vaccines further induces Nab and makes this prime-boost strategy a
promising approach (Clements-Mann et aI., 1998).
A recombinant adenoviral vector has also been created to act as a boost in a
prime-boost regimen where a plasmid encoding a codon-optimised subtype B gag
serves as prime (Shiver et aI., 2002). The replication-defective adenoviral vector
expressing the optimised Gag (identical to gag from plasmid vector) regimen has
shown significant and persistent CD8+ and CD4+ cellular immune responses in
monkeys, which mitigate simian human immunodeficiency virus (SHIV) infection
following challenge. Preliminary data from Phase I safety and immunogenicity trials
in HIV-uninfected individuals suggest that both the Gag expressing DNA plasmid
and adenoviral vector are tolerated well, the Gag plasmid vector in saline can elicit
a moderate Gag-specific cellular immune response and the Gag expressing
adenoviral vector can elicit a persistent CD8+ and CD4+ response. The
immunogenicity of the adenoviral vector may be compromised by high levels of
pre-existing anti-adenoviral neutralising antibody titres in the host, but this can be
overcome by increasing the dose of the vector. Another recombinant pox vector,
modified vaccinia Ankara (MVA) expressing HIV Gag and a number of CTl
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epitopes is currently being evaluated in a Phase I clinical trial in the United
Kingdom and Kenya.
Peptide based vaccines comprising viral envelope or internal proteins have failed
to elicit a high frequency and strength of Nab and CTL responses, but lipopeptides
derived from Env, Gag and Nef proteins promise to improve immunogenicity
(Gahéry-Ségard et ai., 2000). A peptide vaccine representing the variable regions
of the envelope glycoprotein has been shown to induce HIV-1 Nab in mice, rabbits
and rhesus macaques monkeys (Carlos et ai., 2000). The use of adjuvants,
cytokines and co-stimulatory molecules which will augment vaccines, as well as
peptides based on predictions of epitopes representing immunodominant,
conserved epitopes are also under development (Evans et ai., 2001; Wilson et ai.,
2001; Gherardi et ai., 2000).
The concept of DNA immunisation against viral diseases offers several advantages
compared to the concept of conventional subunit vaccines. With DNA, both
humoral and cell mediated immune responses can be generated, and the protein
antigens of interest are synthesised in the host cell resulting in authentic
glycosylation and processing (Donnelly et ai., 1997). This technology has shown
that cytotoxic immunity is induced against various agents in experimental animals
as well as humans (Boyer et ai., 2000). DNA vaccines based on corresponding
recombinant gp120 proteins alone have failed to protect individuals against
infection in Phase 1/11 trials (Bolognesi and Matthews, 1998). This has lead to the
design of different vaccine approaches where the immunogenicity of the envelope
DNA is increased after an additional boost with subunit proteins.
Vaccination with HIV-1 gp120 DNA in experimental animals has been shown to
induce antibody responses to gp120, which were elevated after the addition of a
recombinant gp120 subunit boost, which also increased neutralising antibody titres.
Furthermore, strong CTL responses against the Env V3 epitope were induced
(Barnett et ai., 1997). Several groups further hope to increase the immunogenicity
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of the envelope by constructing modified envelopes which are codon optimised
(Corbet et aI., 2000b), and which reveal conserved conformational epitopes critical
to HIV entry (Chakrabarti et aI., 2002; Chowet aI., 2002). Attempts have also been
made to stabilise oligomeric envelopes in order to resemble the functional
envelope glycoprotein on the surface of the virion (therefore creating an oligomeric
gp140 or o-gp140) (Binley et aI., 2000; Zhang et aI., 2001; Stamatatos et aI.,
2000). Biochemical, structural and immunological characterisations of the o-gp140
have indicated that the purified proteins are in a stable trimeric conformation with
critical neutralising epitopes exposed. Preliminary vaccine studies with rabbits
demonstrated that the o-gp140 protein was highly immunogenic and induced high-
avidity and predominantly conformationally directed antibody responses
(Srivastava et aI., 2002). Stabilised o-gp140 derived from primary isolates was able
to induce Nab against primary isolates and TClA HIV strains (Yang et aI., 2001).
Envelopes lacking V1 and V2 loops have been constructed (Stamatatos et al.,
1998), as it has been indicated that these loops mask the CD4 binding site and
neutralising epitopes 0Nyatt et aI., 1995). Deletion of the V2 loop renders a virus
more susceptible to neutralisation (Cao et aI., 1997; Stamatatos et aI., 1998).
Deletion of the V2 loop of a gp140 envelope resulted in a candidate vaccine which
induced both envelope-specific T-cell Iymphoproliferative responses and potent
Nab in macaques monkeys (Cherpelis et aI., 2001a; Cherpelis et aI., 2001b).
Immunogens with the V2 deletion were further more successful in eliciting Nab
than its gp140 counterpart with V2 intact (Barnett et aI., 2001). Vaccination with
these V2 deleted immunogens offered partial protection from pathogenic SHIV
challenge in rhesus macaques monkeys (Cherpelis et aI., 2001b).
Several other approaches are also under investigation. Removing carbohydrates
from the envelope has shown to strongly prime antibody responses (although non-
neutralising), as well as T-cell responses (Bolmstedt et aI., 2001). Single-chain
polypeptide analogues of the gp120-CD4 complex are also under investigation as
targets for anti-HIV vaccines and therapies as these are intermediate structures
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with distinct conformational, functional and antigenic features (Weinberg et aI.,
1997; Sullivan et aI., 1998; Fouts et aI., 2000).
Genes such as env need to be modified to enhance their immunogenicity and
basic molecular research is needed to gain knowledge on how to modify these
genes to be used in vaccine strategies. As only one full-length subtype C envelope
sequence from South Africa had been described in a near full-length molecular
clone (Rodenburg et aI., 2001) at the start of this study, the goal was to generate
envelope reference reagents for further use in vaccine research.
1.6 GOAL
To characterise and express env immunogens for possible use in a prime-boost
vaccine modality.
In order to achieve this goal, the following two objectives were identified:
1.6.1 Objectives
1.6.1.1 Clone, sequence and phylogenetically analyse subtype C env
genes from recent circulating strains in South Africa.
1.6.1.2 Express the proteins from selected isolates in mammalian cells to
confirm intact genes and open reading frames.
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INTRODUCTION
This chapter describes the different techniques and methods that were used to
characterise and express the env gene from selected isolates. The genes were
amplified by PCR and cloned into bacterial and mammalian expression vectors. The
bacterial plasmids were sequenced to determine the nucleotide sequence of the
selected env genes. The acquired sequences were analysed phylogenetically. The
expression plasmids were transiently transfected into mammalian cells to determine
whether Env proteins were expressed, and further whether these proteins were
expressed at higher levelswhen Revwas present.
2.1 VIRUS ISOLATES
HIV-1 isolates were from HIV positive patients attending the Infectious Disease Clinic
at the Tygerberg hospital from 1998 to 1999. A summary showing the clinical data of
the patients can be viewed in Table 1. Ethical aspects of the study were approved by
the University of Stellenbosch under project number 98/158. The subtypes of the
viruses were determined by serotyping using a V3 competitive peptide enzyme-linked
immunosorbent assay (cPEIA) (Engelbrecht et ai., 1999). Fifteen of the 18 isolates
were serotyped as subtype C. TV017 reacted to subtype B-specific peptides, and
TV016 reacted to both B- and D-specific peptides. TV015 was non-reactive to any of
the peptides used.
A total of 18 isolates were expanded to high concentrations of virus stock in our
department (Claassen, 1999). Briefly, PBMCs were isolated from both HIV-
seronegative donors, as well as the above-mentioned HIV-1 positive patients. The
HIV-seronegative donor blood was received from the Western Province Blood
Transfusion Services. The PBMCs were co-cultured and the HIV-1 virus was allowed
to grow to high concentrations (Gartner and Popovic, 1990). High molecular weight
DNA was isolated (Sambrook et ai., 1989) and sequencing of a 650 bp fragment in
the gp120 envelope, including the V3 loop, genotyped TV015, TV016 and TV017 as
subtype B. The remainder of the isolates was genotyped as subtype C (Treurnicht et
ai., 2002). All the isolates were of the NSI phenotype as determined by MT-2 cell
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assays, and used CCRS as their principal coreceptor as determined in HOS-CD4 cell
lines expressing different coreceptors (Treurnicht et aI., 2002).
Table 1. Patient demographics
Ic~
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TV001 36 M MR Het Dermatitis 196 C C CT, WCP, RSA
TV002 35 M MR Het Oral Candidiosis 309 C C CT, WCP, RSA
TV003 38 M BI
ECP / CT, WCP,
Het Pulmonary TB 117 C C
RSA
TV004 38 F BI Het TB adenitis 435 C C Unknown
Oral/tracheal
TV005 36 F MR Het 64 C C CT, WCP, RSA
Candidiosis
TV006 26 F MR Het TB pleuritis 116 C C CT, WCP, RSA
TV007 24 F BI Het Dermatitis 363 C C Gauteng, RSA
TV008 31 F MR Het Bladder infection 125 C C Zimbabwe
TV009 31 M BI Het Pulmonary TB 171 C C CT, WCP, RSA
TV010 21 F BI Het Lymphadenopathy 167 C C CT, WCP, RSA
TV012 32 M Ca Het
Oral/ nasopharyngeal
3 C C CT, WCP, RSA
Candidiosis, diarrhoea
TV013 43 F MR Het Pneumonia 765 C C CT, WCP, RSA
TV014 33 M BI Het Pulmonary TB Un C C Namibia
TV015 28 M Ca Hom
Wasting, stomach
420 NR B Unknown
ulcers
TV016 39 M MR Bi Loose stools 421 BO B Unknown
TV017 22 M Ca
Glandular fever,
Het 200 B B Unknown
Candidiosis, wasting
TV018 56 M BI Het Pulmonary TB 201 C
ECP / CT, WCP,
C
RSA
TV019 37 F BI Het Asymptomatic 100 C C CT, WCP, RSA
TV number indicates the Tygerberg Virology number issued to the specific patient. No TV011 was issued.
a: M = Male, F = Female; b: MR = Mixed Race, BI = Black, Ca = Caucasian; c: Het = Heterosexual, Hom =
Homosexual, Bi = Bisexual, d: CT = Cape Town, WCP = Westem Cape Province, RSA = Republic of South
Africa, ECP = Eastem Cape Province
42
Stellenbosch University http://scholar.sun.ac.za
2.2 BACTERIAL STRAINS
Both One Shot TOP10 (Invitrogen Corporation, Carlsbad, CA, USA) and Max
Efficiency STBL2 (Gibco, Invitrogen Corporation, Carlsbad, CA, USA)
competent cells were used for transformation procedures. The genotype for the
TOP10 cells is F - mcrA L1.(mrr- hsdRMS - mcrBC) <j>80lacZL1.M15L1./acX74
deoR recA1 araD139 L1.(ara-/eu)7697 ga/U galK rpsL (St,R) endA1 nupG. The
STBL2 cells are derived from JM109/J5 and have a genotype of mcrA L1.(mcrBC
- hsdRMS - mrr) recA 1.
2.3 PLASMID VECTORS AND CONSTRUCTS
2.3.1 pCR3.1
The pCR3.1 vector (Invitrogen Corporation, Carlsbad, CA, USA) was
used in cloning procedures, which was needed in subsequent
sequencing of the full-length env gene. The 5060 bp vector contains a
Cytomegalovirus (CMV) immediate early promoter, T7 promoter and
priming site, TA cloning site, polylinker, bovine growth hormone (BGH)
reverse priming site, BGH polyadenylation signal, SV40 early promoter,
SV40 origin, neomycin/kanamycin resistance gene, ampicillin
resistance gene, pUC origin and f1 origin.
2.3.2 pCMVLink
The pCMVLink mammalian expression vector (Chiron Corporation,
Emeryville, CA, USA) (Chapman et a/., 1991) was used for directional
cloning procedures in order to express Env proteins. The 4351 bp
vector contains a CMV major immediate-early (IE1) promoter, an intron
A which acts as an enhancer for expression of proteins, especially
glycoproteins from HIV-1, a BGH polyadenylation signal for termination,
a SV40 origin and a kanamycin resistance gene.
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2.3.3 Constructs received from outside sources
Clones were generated for native env genes of isolates TVOO1
(TV001c8.2 and TV001c8.5), TV002 (TV002c12.1), TV006 (TV006c9.1
and TV006c9.2), TV008 (TV008c4.3 and TV008c4.4), TV012
(TV012c2.1), TV014 (TV014c6.3 and TV014c6.4), and TV019
(TV019c5) by Chiron Corporation (Emeryville, CA, USA). The full-length
env gene sequences obtained from the clones were used in sequence
analysis and in determining phylogenetic relationships.
Codon-optimised versions of TV001 where the V2 loop had been
deleted were received from Chiron Corporation (Emeryville, CA, USA).
These included an oligomeric gp140 clone (pCMVLink o-gp140dv2
modified) of which the cleavage site was mutated to prevent cleavage
into a gp120 and gp41, and a gp120 clone (pCMVLink gp120dv2
modified). The native gp160 env clone from TV001 (TV001c8.2), as
well as the modified/codon-optimised clones was used in expression
experiments. The pCMVLink o-gp140dv2 modified and pCMVLink
gp120dv2 modified constructs served as positive controls in expression
studies, as these constructs had already been shown to express at high
levels (Barnett, S. (2002), personal communication, Chiron Corporation,
Emeryville, CA, USA).
A rev construct consisting of the pCMVKm2 vector (Chiron Corporation,
Emeryville, CA, USA) and a TV010 rev gene was used for co-
transfection experiments (received from Scriba, T.J., Department of
Medical Virology, University of Stellenbosch).
2.4 CELL LINESAND CELL CULTURE
The 293 cell line (Cat no. 11631 from Gibco, Invitrogen Corporation, Carlsbad,
CA, USA) was used as host cell line for transfection procedures. The cell line is
a permanent line established from primary embryonal human kidney, which was
transformed with sheared human adenovirus type 5 DNA. Cells were recovered
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from cryogenically frozen vials for culturing following manufacturers instructions.
The cells were maintained in Dulbecco's Modified Eagle Medium (OME)
(Sigma-Aldrich, Atlasville, RSA) containing 4500 mglL glucose and L-Glutamine
supplemented with 3.7 gIL NaHC03, 0.109 gIL NaH2P04 (anhydrous), 0.1 mM
MEM Non-Essential Amino Acids (Gibco, Invitrogen Corporation, Carlsbad, CA,
USA), 10% Foetal Bovine Serum (Delta Bioproducts, Kempton Park, RSA), 100
mglL penicillin (Novo-Pen, Novo Nordisk (Pty) Ltd, Johannesburg, RSA), and
100 mglL streptomycin (Novo-Pen, Novo Nordisk (Pty) Ltd, Johannesburg,
RSA). The cultures were maintained in an Autoflow C02 water-jacketed
incubator (NuAire Inc., Plymouth, MN, USA) at 37°C containing a humidified
atmosphere and 5% C02. The T-75cm2 disposable sterile T-flasks with 0.2 urn
vented caps were used for culturing (Corning Incorporated, NY, USA). The
media was changed every 3-4 days and cells were sub cultured when a
confluence of 80-90% was reached (approximately once a week). Sub culturing
or trypsinisation was accomplished by incubating the cells in a 10% active
trypsin versine (ATV) solution (135 mM NaCl, 5 mM KCI, 5.6 mM Glucose, 7
mM NaHC03, 0.5% Trypsin, 0.5 mM EDTA) for 2 minutes at room temperature,
or until the cells detached from the flask wall, where after OME was added to
inactivate the ATV. The cell suspension was centrifuged at 1000 x g for 5-10
minutes and supernatant was removed and discarded. The cells were then
resuspended in OME and placed into T-75cm2 disposable sterile T-flasks with
0.2 um vented caps and maintained in an Autoflow C02 water-jacketed
incubator (NuAire Inc., Plymouth, MN, USA) as described.
2.5 DNA CONSTRUCTS
2.5.1 Constructs for sequencing purposes
Constructs of native gp160 env genes in pCR3.1 vectors of selected
isolates (TV003, TV004, TV006, TV007, TV010, TV013, TV018) were
generated. These plasmids were then sequenced in order to obtain the
full-length native env gene sequences.
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2.5.2 Constructs for expression experiments
Constructs containing native env genes in pCMVLink were generated
(TV004, TV006 and TV018) for transfection studies in order to observe
protein expression.
2.6 PCR AMPLIFICATION
2.6.1 Full-lengthgp160 env genes for pCR3.1 cloning
Near full-length 9 kb fragments of the HIV-1 genome from isolates
TV003, TV004, TV006, TV007, TV010, TV013 and TV018 were
received from Engelbrecht, S., (Department of Medical Virology,
University of Stellenbosch). Briefly, the Expand Long Template Kit
(Roche Molecular Biochemicals, Mannheim, Germany) was used to
amplify the fragment from high molecular weight DNA together with the
primer pair UP1A and LOW2 (Gao et aI., 1998). The QIAEX II Gel
Extraction kit (QIAGEN, GmbH, Germany) was used to purify the
fragments, which were excised after separation on an electrophoresis
gel. The prepared 9 kb PCR products served as template for
amplification of env gene fragments using the Expand High Fidelity
PCR System (Roche Molecular Biochemicals, Mannheim, Germany).
The Expand high fidelity PCR system was used for all amplifications, as
the yield is increased two-fold and the fidelity of the enzyme (8.5 x 10-6)
is three times greater than the fidelity observed for Taq DNA
polymerase (2.6 x 10-5) (Barnes, 1994). The primer pair Env-st:
GAAAGAGCAGAAGACAGTGGCAAand Env-end: CTTTTTGACCACT
TGCCACCCAT was used. The PCR was carried out in a total volume
of 100 !-II, containing 1.5 mM MgCI2, 200 IJM deoxynucleoside
triphosphates, 40 pmol of each primer, and 3.5 U of Expand High
Fidelity PCR System enzyme mix. Samples were subjected to a
denaturing step at 94°C for two minutes, followed by 40 cycles of a
denaturing step at 94°C for 30 seconds, an annealing step at 50°C for
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30 seconds, and an extension step at 72°C for 3 minutes. Extended
elongation followed for 15 minutes at 72°C.
PCR products were visualised by agarose gel electrophoresis on a
0.8% agarose gel in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA)
containing 5 IJg/ml ethidium bromide in the agarose gel. A 1 kb DNA
ladder (Promega, Madison, WI, USA) was included in the
electrophoresis to compare DNA fragment sizes, unless stated
otherwise.
2.6.2 Native env genes for directional cloning
The TV004cC300, TV006cE9 and TV018cF1027 pCR3.1 clones served
as template for amplification of env gene fragments to generate
directional clones to use in expression experiments using the Expand
High Fidelity PCR System (Roche Molecular Biochemicals, Mannheim,
Germany). Primer pairs for TV006cE9 and TV018cF1027 were
designed, which contained restriction sites to enable directional cloning.
Chiron Corporation (Emeryville, CA, USA) designed a primer pair for
TV004cC300. The 5'- primers contained an EcoRI restriction site, and
the 3'- primers contained a Xhol site. The primers are listed in Table 2.
The PCR was standardised by performing a MgCb concentration
titration. Concentrations included 1.0 mM, 1.5 mM, 2.0 mM, 2.5 mM, 3.0
mM, 3.5 mM and 4.0 mM. The standardised PCR was carried out in a
total volume of 100 IJl, containing 4.0 mM MgCI2, 200 IJM
deoxynucleoside triphosphates, 40 pmol of each primer, and 2.6 U of
Expand High Fidelity PCR System enzyme mix.
Samples were subjected to a denaturing step at 94°C for two minutes,
followed by 10 cycles of a denaturing step at 94°C for 30 seconds, an
annealing step at 65°C for 30 seconds, and an extension step at 72°C
for 2 minutes. Thirty cycles followed consisting of a denaturing step at
94°C for 30 seconds, an annealing step at 65°C for 30 seconds, and an
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extension step at 72°C for 2 minutes with a 10 second increment per
cycle. Extendedelongation followed for 10 minutes at 72°C.
PCR products were visualised by agarose gel electrophoresis as
described earlier.
Table 2. Primers used for PCR amplification
Template 5'· primer 3'· primer
TVOO4cC300 5'- AGCACGGMTTCATG 5'- AGCACGCTCGAGTTA
AGAGTGAGGGAGATAC TAGCAMGCTGCTTCM
CGAGGMTTGGCMCA -3' AGCCCTGTCTT ATTC -3'
TVOO6cE9 5'- AGCACGGMTTCATG 5'- AGCACGCTCGAGTTA
AGAGTGACGGGCATAC TAGTAMGCAGTTTCAA
TGAGGAA TTATCCACA -3' AGCCCTGTCTT ATTC -3'
TV018cF1027 5'- AGCACGGMTTCATG 5'- AGCACGCTCGAGTTA
AGAGTGATGGGGATCA TAGCAMGCTGCTTCM
AGAGGAA TTGTCAACA -3' AGCCCCGTCTT ATTC -3'
2.7 CLONING EXPERIMENTS
2.7.1 Ligation and transformation reactions
Plasmid vectors and inserts were prepared for ligation for both pCR3.1
and pCMVLink cloning. TA-cloning was used for cloning of PCR
products into the pCR3.1 vectors, as the system eliminates any
enzymatic modifications of the PCR product and does not require the
use of PCR primers that contain restriction sites. Because the Expand
high fidelity PCR system generates PCR products, which resemble a
mixture of 3' single A-overhang products and blunt ended products
analogues to Taq DNA polymerase, 3' A-overhangs were added post
amplification to ensure that all the products contained a 3' A-overhang
by adding 1 U of Taq polymerase (Promega, Madison, WI, USA) to the
PCR tubes on ice. The samples were incubated at 72°C for 8 to 10
minutes. The DNAwas purified using the QIAquick PCR Purification Kit
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(QIAGEN, GmbH, Germany) following the manufacturer's protocol. The
manufacturers of pCR3.1 (Invitrogen Corporation, Carlsbad, CA. USA)
supply the plasmid vector in a linear form containing T-overhangs and
no preparationswere therefore needed before ligation.
The PCR products generated for pCMVLink eloning were separated by
electrophoresis on a large 0.8% agarose gel. The gel was run at
30V/cm for 18 hours. The gel was stained with TAE buffer (O.04MTris-
acetate, 0.001M EDTA) containing 5 IJg/ml ethidium bromide for 30
minutes. The 2.5 kb env gene PCR products were excised from the
agarose and purified with the QIAGEN Gel extraction kit (QIAGEN,
GmbH, Germany) following manufacturers instructions. Both the
pCMVLink mammalian expression vector and the purified gel extracted
PCR products were digested with EcoRI and Xhol in Buffer H (90 mM
Tris-HCI, 10 mM MgCI2, 50 mM NaCl, pH 7.5) for 2 hours at 37°C
(Promega, Madison, WI, USA). The DNA was purified using the
QIAquick PCR Purification Kit (QIAGEN, GmbH, Germany) following
the manufacturers protocols.
The PCR products were ligated to the pCR3.1 and pCMVLink vectors at
vector:insert ratios of 1:10 and 1:2 respectively using T4 DNA Ligase
(Promega, Madison, WI, USA). The ligation reaction, with a total
reaction volume of 10 IJl, was incubated at 15°C in an incubator
(Memmert, Schwabach, Germany) overnight for optimal ligation results.
The plasmids containing the ligated PCR products were transformed
into both One shot TOP10 and Max Efficiency STBL2 competent cells.
The TOP10 cells were originally used for the transformation procedures
until it was found that, in DNA prepared form bacteria on a large scale,
the gene was repeatedly excised or deleted from the plasmid. The
excision of the gene generated bacteria resistant to the selective
antibiotic present in the LB agar plates and liquid growth media. This
reaction has been reported for palindromic sequences (Collins, 1981;
Hagan and Warren, 1983) and sequences containing short direct
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repeats (Collins et ai., 1982; Jones et ai., 1982) in Escherichia coli
plasmids. Another group has reported deletions in the gp41 region
extending into their cloning vector, suggesting instability of the
recombinant plasmid during large-scale growth in bacteria (Gao et ai.,
1994). The deletion of the gene was prevented by using the STBL2
strain for transformation procedures, as this strain was manufactured
for the use of unstable retroviral sequences (Trinh et ai., 1994). The
deletion was also prevented by reducing the growth temperature to
30°C when working with the TOP10 cells. Lowering the growth
temperature has been shown to minimize the instability of plasmids
containing HIV-1 proviral genomes (Joshi and Jeang, 1993).
One Shot TOP10 as well as Max Efficiency STBL2 competent cells was
transformed with 2 IJlof the ligation mixtures. Control reactions included
a positive pUC19 ligation reaction from the competent cell kits, a
negative reaction were linear vector was transformed into the cells, a
second negative reaction where vector was ligated with T4 DNA ligase
without adding prepared PCR product insert, and a cell only control
reaction. Manufacturers instructions from the Eukaryotic TA Cloning Kit
(Invitrogen Corporation, Carlsbad, CA, USA) were followed for
transformation of the TOP10 cells with the following modification: the
vials containing the cells and ligation mixture were incubated in Labcon
shaking incubator (Labmark, Roodepoort, RSA) at 225 rpm and 30°C
for one and a half hours after the heat shock treatment, instead of
incubating the vials at 37°C for one hour. After adding SOC media (2%
Tryptone, 0.5% Yeast extract, 0.05% NaCI, 2.5 mM KCI, 10 mM MgCI2,
20 mM Glucose) to the one and half hour incubated vials, cells were
pelleted by centrifugation at 6000 x g for 2 minutes. The supernatant
was removed allowing approximately 50 IJl to remain in the vials and
the pellet was then resuspended in the 50 IJlof supernatant and plated
onto Luria-Bertani (LB) agar plates (10 gIL bacto-tryptone, 5 gIL bacto-
yeast extract, 10 gIL NaCI, 15 gIL bacto-agar) containing 50 mglml
ampicillin. The LB agar plates were incubated at 30°C overnight. The
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STBL2 cells were transformed as per manufacturers instructions, but
cells were also pelleted by centrifugation as described above before
plating onto LB plates containing 50 mglml kanamycin. The cells were
pelleted before plating to ensure that all possible transformed bacterial
cells were includedwhen plating the mixture onto LB plates.
2.7.2 Screening of recombinant clones
Colonies from the LB agar plates were inoculated into 2 ml LB media
(10 gIL bacto-tryptone, 5 gIL bacto-yeast extract, 10 gIL NaCI)
containing the appropriate antibiotic and incubated in a Labcon shaking
incubator (Labmark, Roodepoort, RSA) at 225 rpm and 30°C for 16
hours. DNA was isolated on a small scale for screening purposes
following the Small-scale preparations of plasmid DNA protocol
(Sambrook et aI., 1989). The plasmid DNA was separated by gel
electrophoresis on 0.8% agarose gels. A Supercoiled DNA ladder
(Promega, Madison, WI, USA) was added as reference for fragment
size. Fragments migrating at a slower pace compared to vector alone
indicate possible positive clones and were digested with restriction
enzymes to verify insert presence. Samples were separated by gel
electrophoresis to visualise excised inserts.
The pCR3.1 plasmid DNA samples of these longer fragments were
digested with the restriction enzyme EcoRI (Promega, Madison, WI,
USA) in Buffer H (90 mM Tris-HCI, 10 mM MgCb, 50 mM NaCI, pH
7.5).
The pCMVLink plasmid DNA was digested with EcoRI and Xhol,
(Promega, Madison, WI, USA) in Buffer H (90 mM Tris-HCI, 10 mM
MgCI2,50 mM NaCI, pH 7.5).
Orientation of the genes present in the pCR3.1 vectors was determined
by restriction mapping with Ndel (Promega, Madison, WI, USA) in
Buffer 0 (6 mM Tris-HCI, 6 mM MgCI2,150 mM NaCI, 1 mM OTT, pH
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7.9). Digestion with Ndel yields a distinct fragment pattern, which is
indicative of insert orientation. The C.BW.96BW0502 subtype reference
sequence (the subtype is followed by a 2 letter abbreviation of the
isolation country, followed by the sequence name) (HIV Sequence
Compendium, 2001) was restriction mapped with Ndel do determine
which patterns would be observed for an insert in the correct as well as
reversed orientation. The reference strain has a Ndel restriction site at
position 177, while the pCR3.1 sequence has a Ndel restriction site at
position 260. If the reference sequence were inserted into the pCR3.1
plasmid, 2 fragments of 655 and 6970 bp each would indicate that the
gene was inserted into the vector in the correct orientation. Two
fragments of 2869 and 4758 bp each would be indicative of the insert
being inserted into the vector in a reversed orientation. Digested
samples were separated by gel electrophoresis as described before.
DNA was isolated from bacteria on a larger scale after confirmation of
env gene presence in the plasmid DNA using a QIAfilter Midiprep Kit
(QIAGEN, GmbH, Germany). The manufacturer's instructions were
followed. The concentration, as well as the purity of the plasmid DNA
isolated was determined using the following calculations (Sambrook et
aI., 1989):
DNA concentration = 00260 x dilution factor
20
DNA urit = 00260
P Y 00280
Glycerol stocks were prepared from all positive clones by adding 0.15
ml sterile glycerol to 0.85 ml bacterial culture (Sambrook et aI., 1989).
The cultures were transferred to sterile screw cap cryogenic vials and
stored at -70°C.
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All constructs to be used in expression experiments were screened to
confirm env insert presence. The TV001c8.2, LinkTV004cC300,
LinkTV006cE9, LinkTV018cF1027, pCMVLink o-gp140dv2 modified
and pCMVLink gp120dv2 modified constructs were digested with EcoRI
and Xhol. The rev construct was digested with EcoRI and Sail. The
restricted DNAwas visualised on an agarose gel as described earlier.
2.8 EXPRESSION EXPERIMENTS
2.8.1 Transfection of env and rev constructs
The 293 cell line was recovered, cultured and maintained as described
earlier for use in transfection using DNA constructs. The 293 cells were
seeded at 7 x 105 cells/ml and 1.4 x 106 cells were plated per well in
sterile cell culture cluster 6-well plates (Coming Incorporated, NY, USA)
one day before transfections commenced. Transfections were
performed with cells which were 70-80% confluent.
The experiment was set up to include 2 wells per transfection for each
construct. The cells were transfected with 1 I-Igplasmid DNA using the
Transfast transfection reagent (Promega, Madison, WI, USA) according
to manufacturers instructions. All the wild type native gp160 env
constructs (TV001c8.2, LinkTV004cC300, LinkTV006cE9 and
LinkTV018cF1027) were co-transfected with the TV010 rev construct to
determine Rev dependence. These experiments included the
transfection of 1 I-Igplasmid DNA from the env and rev constructs each.
Negative/mock reactions were included as controls where the cells were
treated with the Transfast reagent without the addition of plasmid DNA
constructs.
2.8.2 Harvesting of SNF and Iysates
Supernatant fluid (SNF) was harvested from the culture 72 hours post
transfection. The SNF was filtered through FP30/0.2 CA-5 disposable
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filter units (Schleicher & Schuell, Germany) to remove cell debris.
Proteins were isolated from the filtered SNF (4 ml from duplicate wells)
by adding Galanthus Nivalis-agarose (GNA) (Vector Laboratories, CA,
USA) and incubating the mixture on a Orbital shaker (Stuart Scientific,
Bibbi, UK) at 4°C for a minimum of 3 hours (Srivastava et ai., 2002).
Glycoproteins in the SNF bound to the agarose as a result of the affinity
to the lectin. The proteins were eluted by the addition of Methyl
Mannose Pyranoside (MMP) (10 mM NaH2P04, 100 mM NaCI, pH 7.4).
The MMP buffer is a sugar solution, which inhibits the binding of the
lectin to the glycoproteins. The SNFs were stored in aliquots at -20°C
until further use.
Cell Iysates were prepared by washing the cells with phosphate
buffered saline (PBS) (80 giL NaCI, 2 giL KCI, 9.1 giL Na2H2P04
(anhydrous), 1.2 giL KH2P04). The wash mixture was transferred to a
microcentrifuge tube and centrifuged at 6000 x g for 3 minutes. The
supernatant was discarded. Lysis buffer (0.14 mM NaCI, 1.5 mM MgCI2,
10 mM Tris-HCI at pH 7.4, Nonident-P40) was added to the cells and
incubated for 30 minuets at room temperature. The lysis mixture was
then centrifuged at 10 000 x g for 3 minutes to remove cell debris. The
Iysateswere stored in aliquots at -70°C until further use.
2.8.3 Detection of expressed proteins
SNF and cell Iysates were prepared for electrophoreses to separate
proteins by sodium dodecyl-sulphate polyacrylamide gel
electrophoresis (SOS-PAGE) by adding NuPage LOS sample buffer
(Invitrogen Corporation, Carlsbad, USA) and Nupage sample reducing
agent (Invitrogen Corporation, Carlsbad, USA). The samples were
denatured by boiling at 95°C for 10 minutes and then placed on ice.
The samples were loaded onto 4-12% Bis-Tris polyacrylamide gels
(Invitrogen Corporation, Carlsbad, USA) and proteins were separated
for one and a half hours under denaturing conditions at 115 mA in
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NuPage MOPS SDS running buffer supplemented with NuPage
Antioxidant (Invitrogen Corporation, Carlsbad, USA). A positive control
included the HIV-1 SF2 recombinant gp120 (Haigwood, 1990; levy et
ai., 1984; Sanchez-Pescador et ai., 1985; Scandella et ai., 1993)
(received from the NIH AIDS Research & Reference Reagent Program)
and negative controls comprised the negative transfection control SNF
and cell Iysates. A full range rainbow marker (Amersham Pharmacia
Biotech Limited, Buckinghamshire, England) was included in the
electrophoresis to compare protein fragment sizes.
The polyacrylamide gels were trimmed and soaked in Towbin transfer
buffer (25mM Tris, 192mM Glycine, 10% methanol) for 5 minutes. The
transfer electroblot sandwich from the Mini VE vertical electrophoresis
system blot model (Hoeffer Scientific Instruments, San Francisco, CA,
USA) was assembled according to manufacturers instructions. The
proteins were transferred to Hybond ECl nitrocellulose membrane
(Amersham Pharmacia Biotech Limited, Buckinghamshire, England) for
1 hour at 350 mA.
The membranes were blocked in PBS-T (20 mM Tris-CI at pH 7.5, 150
mM NaCI, 0.5% Tween-20) containing 3% bovine serum albumin (BSA)
for 16 hours at room temperature with gentle agitation on a STOVAll
Belly dancer (Life Science incorporated, Greensboro, NC, USA). HIV-1
positive patient sera (primary antibody) were diluted 1:100 with PBS-T
and added to the membranes for a two-hour incubation with gentle
agitation on a STOVAll Belly dancer (Life Science incorporated,
Greensboro, NC, USA). Washing commenced consisting of 3 washes
of 3 minutes each with PBS-T. Goat Anti-Human IgG (H + l)
Horseradish Peroxidase (Pierce, Rockford, USA) (secondary antibody)
was diluted 1:2500 with PBS-T and added to the membranes for a one-
hour incubation with gentle agitation on a STOVAll Belly dancer (Life
Science incorporated, Greensboro, NC, USA). Washing commenced as
described above.
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Proteins were visualised by ECl chemiluminescence using ECl
western blotting analysis system detection reagents (Amersham
Pharmacia Biotech Limited, Buckinghamshire, England). Hyperfilm ECl
chemiluminescence film (Amersham Pharmacia Biotech Limited,
Buckinghamshire, England)was exposed for 1 minute and developed.
A log graph of molecular weight (Mr) versus relative electrophoretic
mobility was drawn to determine detected proteins Mr. The distance
travelled by fragments of knownMr (from the full range rainbow marker)
were plotted on the log graph. Expressed Env protein Mr was then
determined by plotting the distances travelled by the proteins on the
graph constructed from known fragment Mr (Mathews and van Holde,
1990).
2.9 SEQUENCING OF ENV CONSTRUCTS
2.9.1 Cycle sequencing reactions
Sequencing was performed to acquire the nucleotide sequences of
selected env genes, as well as to determine the orientation in which
genes were inserted into the pCR3.1 plasmid vector. pCMVlink clones
were sequenced to ensure that the env gene sequences were intact.
Sequences were acquired using the ABI Prism™310 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Manufacturer's instructions
of the ABI PRISM™ Big Dye™ Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems, Foster city CA 94404) were followed
with three modifications. Firstly, the kit instructions suggest the use of
320 ng DNA in a sequencing reaction. Instead, 1 IJgplasmid DNA was
used. Secondly, a few sequencing reactions were performed using 4 !-II
(half reaction) of the Terminator ready reaction mix (TTRM) from the
ABI PRISM™ Big Dye™ Terminator Cycle Sequencing Ready Reaction
Kit instead of 8 !-II(full reaction) so as to limit reagent use. lastly, the
reactions contained 5 or 10 pmol primer (the kit specifies using 5 pmol
primer) and 5 x Sequencing Buffer (Applied Biosystems, Foster City,
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CA). A total of 19 primers were used to amplify the full-length env gene
(Table 3). The primers were designed by Sanders-Buell et al. (1995).
The T7 forward and BGH reverse primers anneal in the pCR3.1 vector,
and were used to sequence the ends of the genes, as well as to
determine the orientation of the genes in the pCR3.1 plasmid vector.
The pCMVseqF and pCMVseqR primers (Scriba T.J., unpublished)
anneal in the pCMVLink vector, and were used to sequence the ends of
the cloned genes to ensure intact restriction enzyme sites. Annealing
temperatures for primers were 5-10°C lower than the melting
temperatures (Tm) supplied by the manufacturers (Applied Biosystems,
Foster City, CA or Integrated DNA Technologies Inc., Coralville, lA,
USA).
Sequencing reactions were subjected to 25 cycles of a denaturing step
at 96°C for 10 seconds, an annealing step at the annealing temperature
indicated in Table 3 for 30 seconds, and an extension step at 60°C for
4 minutes. The products were then purified using the DyeEx Spin
protocol for Dye-Terminator Removal (QIAGEN, GmbH, Germany)
before inserting them into the ABI Prism™310 Genetic Analyzer.
2.10 PHYLOGENETICANALYSIS
2.10.1 Sequence assembly
The env gene nucleotide sequences were assembled using the Auto
Assembler 2.1 program (Applied Biosystems, Foster City, CA). Amino
acid sequences were predicted in DNA Strider (Marck, 1988) and open
reading frames were detected in the same program. The nucleotide
sequences were submitted to GenBank under accession numbers
AF391230 - AF391250 (Engelbrecht et a/., 2001). These sequences
included the sequences from our laboratory, as well as sequences
generated from clones created using the isolates listed in Table 1 by
Chiron Corporation (Emeryville, CA, USA).
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2.10.2 Sequence analysis
An amino acid alignment was constructed to manually search for
specific motifs and regions.
Table 3. Sequencing primers, their respective sequences and annealing
temperatures used in cycle sequencing reactions.
Annealing
Primer Sequence Tm
temp. (OC)
EOO 5'- TAG AAA GAG CAG AAG ACA GTG GCA ATG A -3' 5B.3°C 55°C
E05 5'- TAT TTG AGG GCT TCC CAC CCC C -3' 5B.4°C 55°C
E15 5'- CTC TCT CTC CAC CTT CTT CTT C -3' 54.7°C 50°C
E20 5'- GGG CCA CAC ATG CCT GTG TAC CCA CAG -3' 65PC 60°C
E30 5'- GTG TAC CCA CAG ACC CCA GCC CAC AAG -3' 65.7°C 60°C
E45 5'- CCT GCC TAA CTC TAT TCA C -3' 4B.7°C 45°C
E55 5'- GCC CCA GAC TGT GAG TTG CAA CAG ATG -3' 62.6°C 55°C
E60 5'- TAA TCA GTT TAT GGG ATC AAA GC -3' 49.BoC 45°C
E70 5'- GGG ATC AAA GCC TAA AGC CAT GTG TAA -3' 5B.1°C 55°C
EBO 5'- CCA ATT CCC ATA CAT TAT TGT G -3' 49.1°C 45°C
E120 5'- GTA GAA ATT AAT TGT ACA AGA CCC -3' 50.4°C 45°C
E160 5'- GTG GGA ATA GGA GCT GTG TTC CTT GGG -3' 62.6°C 55°C
E170 5'- AGC AGG AAG CAC TAT GGG -3' 50.1°C 45°C
E1BO 5'- GTC TGG TAT AGT GCA ACA GCA -3' 52.2°C 45°C
E260 5'- TTC AGC TAC CAC CGC TTG AGA GAC T -3' 59.2°C 53°C
T7
5'- GTAATA CGA CTC ACT ATA-3' 42.3°C 45°C
forward
BGH
5'- TAG AAG GCA CAG TCG AGG -3' 54.0°C 55°C
reverse
pCMV
5'- AGT CTG AGC AGT ACT CGT TG -3' 54.9°C 50°C
seqF
pCMV
5'- GCT GGC AAC TAG AAG GCA CA -3' 5B.BoC 53°C
seqR
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The alignment contained all the translated env gene sequences
generated in this study, translated sequences generated by Chiron
Corporation (Emeryville, CA, USA) for clones TV001c8.2, TV001c8.5,
TV002c12.1, TV006c9.1, TV006c9.2, TV008c4.3, TV008c4.4,
TV012c2.1, TV014c6.3, TV014c6.4 and TV019c5, translated
sequences for the pCMVLink constructs, and the amino acid sequences
for the B.FR.HXB2 and C.ZA.97ZA012 strains. The B.FR.HXB2
sequence was used to identify conserved glycosylation sites and
cysteine residues, and the remaining sequences were compared to the
C.ZA.97ZA012 sequence, as this was the first South African full-length
env sequence described in a near full-length molecular clone
(Rodenburg et al., 2001). The gp120 and gp41 regions, signal peptide,
variable loops (V1-V5), CD4 binding sites, fusion domain,
immunodominant region, tryptophan-rich sequence, membrane
spanning domain, and the intracellular cytoplasmic domain/tail were
identified in the sequences. Further, the crown sequence within the V3
loop and the fusogenic site within the fusion domain were also
identified. The phenotype of the sequences were predicted by locating
amino acids with specific charges at positions 11, 25, and 32 in the V3
loop (Bjërndat et aI., 1999). The overall charges of the V3 regions were
also determined (Bjërndal et aI., 1999; Treurnicht et aI., 2002). The
tetrapeptide crown sequences were further analysed to predict the
phenotype (Abebe et aI., 1999).
Hydrophobicity was determined for pCMVLink amino acid sequences in
the cases where amino acid differences from the original pCR3.1
sequences were observed. This was performed by determining whether
amino acids are hydrophilic or hydrophobic (Zubay, 1993).
2.10.3 Phylogenetic relationships
Phylogenetic relationships were determined for all env gene
sequences, as well as the sequences generated by Chiron Corporation
(Emeryville, CA, USA). The sequences from Chiron Corporation
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included TV001c8.2, TV001c8.5, TV002c12.1, TV006c9.1, TV006c9.2,
TV008c4.3, TV008c4.4, TV012c2.1, TV014c6.3, TV014c6.4 and
TV019c5. All the env sequences generated, as well as the sequences
from Chiron Corporation will collectively be referred to as the TV env
sequences from here on.
The subtypes of the TV env sequences were determined by comparing
the sequences to the reference strains from the Los Alamos HIV
sequence database (HIV Sequence Compendium, 2001). Phylogenetic
relationships of the TV env sequences were estimated from
comparisons to previously reported subtype C nucleotide sequences.
The sequences used to compare the TV env sequences to, as well as
their accession numbers and references are listed in Appendix A.
Nucleotide and amino acid sequences were aligned in ClustalX 1.81
(Higgins and Sharp, 1988; Thompson et aI., 1997). The alignment
parameters were set to 15.00 for gap opening and 6.66 for gap
extension and the lUB DNAweight matrix was used (default parameters
of program) when doing the nucleotide multiple alignments. Amino acid
alignments were performed using a gap opening of 10.00 and gap
extension of 0.20 and the Gonnet series protein weight matrix was used
(default parameters of program). Sequence alignments were manually
adjusted in Genedoc version 2.6 (Nicholas et aI., 1997; Nicholas and
Nicholas, 1997).
Pairwise evolutionary distances for nucleotide sequences were
estimated using Kimura's two-parameter method (Kimura, 1980) in the
DNADist program, and for amino acid sequences using the Dayhoff
PAM distance matrix (Dayhoff et aI., 1979) in the ProtDist program,
both from the PHYLIP package (Felsenstein, 1993; Felsenstein, 1989).
Phylogenetic trees were constructed by the neighbor-joining method
(Saitou and Nei, 1987) using the Neighbor program from the PHYLIP
package (Felsenstein, 1993; Felsenstein, 1989). The reliability was
estimated from 100 bootstrap replicates (Felsenstein, 1985).
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Phylogenetic trees were viewed in TreeView version 1.5.2 (Page,
1996).
Distances of the TV env sequences to subtype C sequences from
Botswana, India and previously published South African sequences
were used in statistical analysis. Intersample diversity observed for
strains from Botswana, India and previously published South African
sequences combined with the TV env sequences, as well as TV env
sequences on their own were compared to the variation seen when
compared to the subtype C consensus sequence from the Los Alamos
HIV sequence database (HIV Sequence Compendium, 2001). The
consensus sequence was based on HIV database alignments. The
intersample diversity for the TV env sequences was also compared to
the variation detected when compared to a generated South African
consensus. The South African consensus sequence was generated in
Genedoc version 2.6 (Nicholas et ai., 1997; Nicholas and Nicholas,
1997) from an alignment containing all the published South African
sequences in the Los Alamos HIV sequence database to date. The
mean distances of the sequences were estimated by the sum of all the
distances calculated in DNADist or ProtDist from the PHYLIP package
(Felsenstein, 1993 and 1989) divided by the number of distances using
Microsoft Excel 2000 software (Microsoft Corporation). As indicated
(Altman, 1991), the median is a value, which comes halfway when the
data are ranked in order. A percentile is the value below which a given
percentage of the values occur. The 25th and 75th percentiles, together
with the median divide the data into four equally populated subgroups.
The standard deviation (SD) quantifies the variability based on the idea
of averaging the distance each value is from the mean. A confidence
interval (Cl) is a range of values that can be confident includes the true
value. The median, 25th and 75th percentiles, SD for a specific
population (size, n) as well as Cl of 95 and 99% were calculated in
SigmaPIot 2002 for Windows, version 8.0 (SPSS Inc.) and used to
construct box plots for visual presentation of observed diversity.
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2.10.4 Analysis for intersubtype recombinants
The TV env sequences were analysed for any evidence of
recombination using Simplot version 2.5 (Lole et aI., 1999). The
program calculates and plots the percent identity of a query sequence
to a panel of reference sequences in a sliding window. It was found that
this method represents an excellent initial screening tool to identify
recombinant viral sequences (Gao et aI., 1998). The percentage
similarity between the TV env sequences and reference subtypes A-D,
F-H, J and K (HIV Sequence Compendium, 2001) was determined by
moving a window of 200 bp along the env gene alignment in 20 bp
increments (default parameters of program).
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INTRODUCTION
This chapter lists the results generated to characterise the env gene from
selected isolates and shows the expression obtained by transient transfection.
Clones were created, which were sequenced to obtain the full-length env
gene sequences. The sequences were analysed and phylogenetic
relationships were determined. Expressed proteins were visualised after
transient transfection in the absence and presence of Rev. All figures created
appear at the end of the chapter.
3.1 PCR AMPLIFICATION
3.1.1 Full-length gp160 env genes for pCR3.1 cloning
The env gene fragments from different isolates obtained by
amplification using the 9 kb PCR product as template were run
on a 0.8% agarose gel (Figure 12). All the PCRs were
successful and products of approximately 2500 bp in size were
generated, which correlates with the size of the env gene. The
negative control containing all the PCR reagents and primers
with no added template DNA showed only primer excess and no
amplification product, indicating that there was no contamination
in the PCR reactions.
3.1.2 Native env genes for directional cloning
The env gene fragments generated by amplification using the
pCR3.1 clones TV004cC300, TV006cE9 and TV018cF1027 as
templates were run on a 0.8% agarose gel (Figure 13). All the
PCRs were successful and products of approximately 2500 bp in
size were generated, which correlates with the size of the env
gene. A few non-specific fragments were visible; therefore the
PCR products were run on a large gel to enable the excision of
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the env fragments (described below). The negative control
containing all the PCR reagents and primers with no added
template DNA showed no amplification product, indicating that
there was no contamination in the PCR reactions.
3.2 CLONING EXPERIMENTS
3.2.1 Ligation and transformation reactions
The PCR products generated for pCMVLink constructs
contained non-specific fragments, and the products were
therefore run on a large agarose gel to allow the excision of the
env fragments. Figure 14 shows the large 0.8% agarose gel
where the fragments were separated.
The pUC19 control LB agar plates with antibiotic contained >200
colonies, therefore indicating that cells used were competent.
The transformation efficiency for the pCR3.1 cloning was 2 x 107
CFU/~g and 4 x 106 CFU/~g for the pCMVLink cloning. The LB
agar plate with no antibiotic harboured more than 200 colonies
for the cell only control, which indicated that the bacterial cells
used were viable. The re-ligation of linear plasmid vector without
the addition of insert was rare and showed a transformation
efficiency of 2 x 104 CFU/~g.
3.2.2 Screening of recombinant clones
Small-scale prepared plasmid DNA was visualised on 0.8%
agarose gels, and fragments migrating at a slower pace
compared to vector alone indicate possible positive clones and
were digested with restriction enzymes to verify insert presence.
An agarose gel showing pCR3.1 plasmid DNA is shown in
Figure 15. Miniprep DNA where no env insert was present
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displayed fragment sizes of approximately 5000 bp, which
correlated with the vector's 5060 bp size. Possible positive
clones were identified by fragments of approximately 7500 bp,
which correlated with the size of the vector (5060 bp) and the
addition of a 2500 bp insert.
An agarose gel showing pCMVLink plasmid DNA is shown in
Figure 16. Preps where no env insert was present displayed
fragment sizes of between4000 - 4500 bp, which correlated with
the vector's 4351 bp size. Possible positive clones were
identified by fragments of between 6500 - 7000 bp, which
correlated with the size of the vector (4351 bp) and the addition
of a 2500 bp insert.
Figure 17 shows pCR3.1 plasmid DNA that was digested with
EcoRt. Positive clones were identified by plasmid DNA showing
the excision of an approximately 2500 bp fragment, which
correlates with the size of the env gene. In total, 14 clones were
generated in the pCR3.1 vector for 7 different isolates. These
included 1 clone each for TV003 and TV004, 3 clones for
TV006, 2 clones for TV007, 4 clones for TV010, 2 clones for
rv013 and 1 clone for TV018.
Figure 18 shows pCMVLink plasmid DNA that was digested with
EcoRI and Xhol. Positive clones were identified by plasmid DNA
showing the excision of an approximately 2500 bp fragment,
which correlates with the size of the env gene. One clone was
selected each for TV004, TV006 and TV018 in expression
experiments. Table 4 gives a summary of all the clones
generated.
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Table 4. Summary of clones created.
Isolate Clone generated Plasmid vector
TV003 TV003cE260 pCR3.1
TV004cC300 pCR3.1
TV004
LinkTV004cC300 pCMVLink
TV006cE5 pCR3.1
TV006cE9 pCR3.1
TV006
TV006cF3 pCR3.1
LinkTV006cE9 pCMVLink
TV007cB104 pCR3.1
TV007
TV007cB105 pCR3.1
TV010cC3 pCR3.1
TV010cD7 pCR3.1
TV010
TV010cD9 pCR3.1
TV010cD10 pCR3.1
TV013cB20 pCR3.1
TV013
TV013cH17 pCR3.1
TV018cF1027 pCR3.1
TV018
LinkTV018cF1027 pCMVLink
The orientation of the genes present in the pCR3.1 vectors was
determined by digesting the positive clone plasmid DNA with
Ndel. Figure 19 shows a 0.8% agarose gel where different
fragment patterns are observed. Only the TV004cC300 clone
showed the predicted fragment pattern of a reversed orientation,
therefore yielding 2 fragments of approximately 2800 and 4700
bp each. The rest of the clones showed varying fragment
patters, as a result of the variability seen in env genes. The
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variability was therefore displayed by sequences having Ndel
restriction sites at different positions in the sequences, as well as
a varying number of Ndel restriction sites. TV003cE260 showed
3 fragments of approximately 1300, 1500 and 4700 bp each.
The restriction of TV006cE9, TV006cE5 and TV006cF3 yielded
3 fragments of approximately 650, 1500 and 5400 bp each. Both
the TV007cB104 and TV007cB105 clones showed only one
fragment of 2600 bp. The TV010cD7 clone showed 2 fragments
of approximately 1400 and 6200 bp each. The TV013cB20 and
TV013cH17 clones showed 3 fragments of 350,2500 and 4700
bp each. The restriction of TV018cF1027 yielded 3 fragments of
approximately 1300, 1500 and 4700 bp each. It was therefore
decided to confirm the orientation of the genes by sequencing.
Sequencing results indicated that all the clones showed an insert
of reversed orientation, except the TV006cE9 sequence, which
displayed the correct insert orientation. As the restriction of all
the TV006 clones yielded the exact same restriction pattern, it
can be assumed that all three of the clones (TV006cE9,
TV006cE5 and TV006cF3) contained the env gene insert in the
correct orientation.
The T7 promoter present in the pCR3.1 plasmids is constitutive,
which would probably result in the translation of the env genes
into proteins if the genes were cloned in frame. A possible
reason for so few clones containing the env gene in the correct
orientation may be that expressed proteins are toxic to the
bacterial cells. If the proteins are indeed toxic, very few clone
colonies will survive when grown on the agar plates, and
therefore most of the colonies selected for screening would
contain the gene in the reversed orientation. If this reactionwas
also taking place for the pCMVLink clones, it could explain why
so few colonies grew on the agar plates, as the genes are forced
to insert into the vectors in the correct orientation. This would
imply that the CMV promoter could promote translation of
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proteins in bacterial cells. It has been suggested that a cryptic
E.coli promoter is present within the CMV promoter (Invitrogen
Corporation (2002), personal communication, Carlsbad, CA,
USA), which would therefore allow the translation of proteins in
bacterial cells.
All constructs to be used in expression experiments were
screened to confirm env or rev insert presence. The restricted
DNA was visualised on an agarose gel and is shown in Figure
20. All the constructs showed the excision of an insert from the
vector yielding two fragments; one fragment was between 4000 -
4500 bp in size correlating with the size of the pCMVLink and
pCMVKm2 vectors (4351 bp), and another fragment displaying
the size of the respective inserts cloned into the vectors. A 2500
bp fragment was excised from the TV001c8.2, LinkTV004cC300,
LinkTV006cE9, and LinkTV018cF1027 constructs, confirming
the presence of the env gene. The pCMVLink o-gp140dv2
modified construct showed an excised insert of 2000 bp. The
pCMVLink gp120dv2 modified construct showed an excised
insert of 1500 bp. A 300 bp insert was excised from the rev
construct, which confirmed the presence of the rev gene.
3.3 EXPRESSION EXPERIMENTS
3.3.1 Culture and transfection of cell lines
Cultured 293 cells grew adherently and media was replaced
every 3-4 days as the amount of cells in a visual field increased
logarithmically from the day of subculture. The cells were
subcultered once a week as a confluence of 80-90% was
reached. In preparation for transfection, cells were plated into 6
well plates as described before. The cells reached a confluence
of 70-80% the day after plating, and the cells were subsequently
transfected.
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A preliminary transfection was performed with the pCMVLink 0-
gp140dv2 modified and pCMVLink gp120dv2 modified
constructs only to establish if the transfection method was
successful. As this transfection showed expression of Env
proteins, the cells were transfected with all the constructs
mentioned in the materials and methods section in one
experiment.
3.3.2 Detection of proteins
Harvested SNF and Iysates were run on SDS-PAGE gels to
visualise the expressed proteins. Protein Mr for the Env proteins
was calculated by plotting the distance travelled by the proteins
on a log graph of Mr versus relative electrophoretic mobility
(Mathews and van Holde, 1990) of the Full Range Rainbow
Marker (Roche Molecular Biochemicals, Manheim, Germany).
Figures 21-24 show the developed film for glycoproteins
detected in the SNF and prepared Iysates, as well as the
calculated Mr of the proteins in kDa respectively. Figures 25-28
show the developed film for native gp160 proteins detected in
the SNF and prepared Iysates when co-transfected with the rev
construct, and the calculated Mr of the proteins in kDa
respectively.
The native Env proteins had a Mr of approximately 160 kDa in
both the SNF and lysate preparations. The TV001 o-gp140 dv2
construct expressed a protein with a Mr of approximately 170
kDa in the SNF, and 145 kDa in the lysate. The TV001 gp120
dv2 construct showed a protein with a Mr of approximately 140
kDa in the SNF, and 105 kDa in the lysate.
Strong expression was detected for the TV001 o-gp140 dv2 and
TV001 gp120 dv2 constructs in both SNF and Iysates. The
TV001c8.2 construct showed expression of a gp160 Env protein
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in the presence as well as absence of Rev in both the SNF and
lysate preparations. An Env protein was detected in the SNF
from the LinkTV004cC300 construct in the presence of Rev only.
The lysate showed very low expression of the Env protein for
this construct in the absence of Rev, which was elevated in the
presence of Rev. No Env protein was detected in the SNF of
constructs LinkTV006cE9 and LinkTV018cF1027. The Iysates of
these constructs showed very low expression of the Env protein,
which was slightly increased in the presence of Rev.
3.4 SEQUENCINGOF ENV CONSTRUCTS
3.4.1 Cycle sequencing reactions
Cycle sequencing reactions were initially performed using 320
ng plasmid DNA, 8 ~I of the Terminator ready reaction mix
(nRM) from the ABI PRISM™ Big Dye™ Terminator Cycle
Sequencing Ready Reaction Kit, 5 pmol primer and 5 x
Sequencing Buffer. These reactions yielded unreadable
sequences. The plasmid DNA was increased to 1 ~g, which
resulted in the readability of a high percentage of the sequences.
The use of 4 ~I of the nRM didn't affect the readability of most
of the sequences. All the primers did not yield very good
sequences for all the genes. An approximate total of 11 primers
out of the 19 listed were used to sequence the individual genes,
as a few primers worked for some genes, and not for others.
Sequencing reactions that yielded unreadable sequences were
repeated using 1 ~g of plasmid DNA, 8 ~I nRM, 10 pmol primer
and 5 x Sequencing Buffer. These reactions increased the
readability of some of the sequences.
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3.5 PHYLOGENETIC ANALYSIS
3.5.1 Sequence assembly
After assembly of the sequences, the ends of the sequences,
which contained parts of the pCR3.1 sequence, were used to
determine the orientation of the genes in the pCR3.1 plasmid
vectors. All the clones showed an insert of reversed orientation,
except the TV006cE9 sequence, which displayed the correct
insert orientation. All the pCMVLink constructs
(LinkTV004cC300, LinkTV006cE9 and LinkTV018cF1027)
showed intact restriction enzyme sites. The env gene nucleotide
sequences from the pCR3.1 clones were submitted to GenBank
(Engelbrecht et ai., 2001), and the sequence names and
accession numbers are listed in Table 5.
Table 5. Summary of sequence names and accession numbers.
Sequence name Accession number
TV003cE260 AF931233
TV004cC300 AF391234
TV006cE9 AF391237
TV007cB104 AF391238
TV007cB105 AF391239
TV010cD7 AF391242
TV013cB20 AF391245
TV013cH17 AF391246
TV018cF1027 AF391249
3.5.2 Sequence analysis
Nucleotide sequence analysis revealed that all except one clone
contained env genes with open reading frames. The TV014c6.3
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clone had a T2G nucleotide substitution resulting in a M1Q
amino acid substitution. The clone also had a premature
truncation in the gp41 region, lacking 5 amino acids as a result
of a G2558T nucleotide substitution, which created a stop
codon. Both clones from isolate TV007 (TV007cB104 and
TV007cB105) also had a premature truncation in the gp41
region as a result of a C2410T nucleotide substitution, which
created a stop codon. All the clones from TV006 (TV006c9.1,
TV0069.2 and TV006cE9), as well as the TV010 clone
(TV010cD7) had a deletion of 2 amino acids in the C-terminal of
the signal peptide.
The pCMVLink clones created (LinkTV004cC300,
LinkTV006cE9 and LinkTV018cF1027) were also sequenced to
determine if the sequences varied from the original pCR3.1
clones. The LinkTV004cC300 had no nucleotide changes when
compared with the original TV004cC300 clone. The
LinkTV006cE9 sequence had a T2411C nucleotide change,
which resulted in a W804R amino acid change.
LinkTV018cF1027 had major sequence substitutions compared
to the original TV018cF1027 clone. There was a C1400T
substitution (resulting in a A467V amino acid change), a C1619T
substitution (resulting in a P540L amino acid change), and a
T1623G substitution, which resulted in a F541L amino acid
change. In addition to these amino acid changes, the last 5
amino acids at the C-terminal of the gp41 (EMLL) were
replaced with a SSFAI amino acid sequence, followed by an
insertion of 54 amino acids before a stop codon was detected.
Noncovalant intermolecular forces determine the three-
dimensional conformation of macromolecules (Zubay, 1993),
and assessing the hydrophobicity is therefore important to
determine if the conformations of proteins expressed by the
pCMVLink constructs which had amino acid substitutions, would
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be different from the conformations of proteins which would be
expressed by the original pCR3.1 clones. As no amino acid
changes were observed for the TV004cC300 clone, no effect on
conformation or folding of the expressed protein is predicted.
The LinkTV006cE9 clone had a W804R amino acid change. The
tryptophan in the original sequence was hydrophobic, and the
new arginine is hydrophilic. This should not have an effect on
conformation of the protein, as the change in hydrophobicity
involves only one residue. LinkTV018cF1027 had major
sequence substitutions compared to the original TV018cF1027
clone. The three amino acid substitutions within the sequence
(A467V, P540L, F541L) should have no effect on conformation,
as alanine, valine, proline, leucine, and phenylalanine are all
hydrophobic amino acids. In addition to these amino acid
changes, the last 5 amino acids at the C-terminal of the gp41
(EAALL) were replaced with a SSFAI amino acid sequence. This
change should not have any effect on conformation, as the
sequence is still hydrophobic for the last 3 amino acids in this 5
amino acid sequence. The insertion of 54 amino acids has no
pattern when looking at hydrophobicity. Hydrophobic amino
acids are distributed in between hydrophilic amino acids. This
insertion should have major effects on the conformation and
folding of the protein.
The predicted amino acid sequence alignment is shown in
Appendix B. The B.FR.HXB2 sequence contains a total of 21
cysteine residues in the full-length gp160 (HIV Sequence
Compendium, 2001). Eighteen of these residues are found
within the gp120, and the residual 3 in the gp41 region. The 21
cysteine residues were also detected in the full-length gp160
region from the TV env sequences. A near-perfect conservation
of the 18 cysteine residues in the gp120 was observed. The 2
cysteine residues in the immunodominant region of gp41 were
highly conserved, and the carboxyl-terminal gp41 cysteine
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residue was replaced with an arginine in clone TV013cH17. The
number of N-linked glycosylation sites in gp120 ranges from 18-
33, with a median of 25 (Korber et ai., 2001). The gp120 of
B.FR.HXB2 contains 24 possible N-(asparagine) linked
glycosylation sites and an additional 6 possible glycosylation
sites in the gp41 region (HIV Sequence Compendium, 2001).
The positions of these sites may shift or be deleted, but there is
always one or more new site(s) within 5-10 residues of the
described sites. Twenty-three of the possible glycosylation sites
were conserved in the TV env sequences. Three of these sites
were shifted within 5-10 residues from the described sites. Two
additional glycosylation sites were present in the TV env
sequences. They were situated at positions 442 and adjacent to
amino acid 459 (numbering according to B.FR.HXB2 strain).
Four out of the possible 6 glycosylation sites were conserved in
the gp41 protein sequence. The V1, V2, V4 and VS loops were
highly variable, with the V3 loop being more conserved with a
more variable region downstream from the loop. The CD4
binding sites were highly conserved in all the sequences. The
cleavage site for gp160 processing (Arg-X-Lys/Arg-Arg) was
intact in all the sequences. All the sequences showed highly
conserved tryptophan residues in the tryptophan-rich sequence.
All the above findings indicate that the env genes in the pCR3.1
vectors should be functional (except clone TV014c6.3), although
a previous study has reported that sequence analysis alone
cannot be used to identify potentially functional env clones (Gao
et ai., 1996). Results from the Gao et al. (1996) study indicate
that the biological activity of envelope constructs have to be
confirmed in the context of infectious virions. The tetrapeptide
crown sequence in the V3 region was GPGQ for all except one
of the sequences, where a RPGQ crown was observed for clone
TV018cF1027. Uncharged or negatively charged amino acid
residues were identified at positions 11, 25, and 32 of the V3
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loop. The total charge observed for the V3 loop region in the
sequences is shown in Figure 29.
3.5.3 Phylogenetic relationships
To determine the subtype classification of the TV env
sequences, a phylogenetic tree was constructed from the full-
length gp160 nucleotide sequences from an alignment of the TV
env sequences and subtype reference strains from the Los
Alamos HIV sequence database (HIV Sequence Compendium,
2001). The neighbor-joining tree in Figure 30 shows major
clusters containing sequences representative of the different
reference subtypes and CRFs (A1, A2, B, C, D, F1, F2, G, H, J,
K, and CRF01_AE, CRF02_AG, CRF03_AB, CRF04_CPX,
CRF05_DF, CRF06_CPX, CRF07 _BC, CRF08_BC,
CRF10_CD, CRF11_CPX, CRF12_BF, CRF13_CPX,
CRF14_BG, and group Nand 0). Bootstrap analysis strongly
supported the observed branching orders. The TV env
sequences appear to form a relatively tight, distinct cluster in the
tree. This cluster can be attributed to a bias that was introduced
by including a disproportionate number of sequences from
southern Africa, as only four other subtype C sequences were
used in the alignment. The group 0 sequences were used to
root the tree. More than one sequence was used in rooting the
tree to prevent possible bias tree topology as a result of identical
sequence artefacts (Sharp, P.M. (2001), personal
communication, University of Nottingham, United Kingdom).
Using more than one sequence to root a tree also ensures that
the node position of the root is more correct when sequences
used to root the tree are not very divergent from the rest of the
sequences in the tree. It is however common practise by HIV-1
researchers to use only one sequence to root a tree, as the node
position of the root is not a critical aspect in determining
phylogenetic relationships between sequences (Seoighe, C.
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(2002), personal communication, SANBI, University of the
Western Cape, RSA). All 21 env sequences from the 13 isolates
clusteredwith the subtype C reference strains.
A neighbor-joining tree constructed from an alignment of the TV
env sequences and 130 full-length subtype C env gene
sequences is shown in Figure 31. The subtype B reference
strains from the Los Alamos HIV sequence database (HIV
Sequence Compendium, 2001) were used to root the tree. The
TV env sequences and sequences from Botswana were
distributed across several subclusters. All except one of the
Indian strains (C.IN.94IN476, subtype followed by country of
isolation and then sequence name) were grouped together. The
sequences from Brazil were also grouped together.
Nucleotide distances of the TV env sequences to subtype C
sequences from Botswana, India and previously published South
African sequences are shown in Figure 32. The statistical
values used to construct the box plots are also shown. The TV
env sequences showed the least divergence from the residual
South African strains in the Los Alamos Database (mean value
of 11.48% with SO=1.27). The TV env sequences were further
more similar to the strains from India (divergence mean of
11.81% with SO=1.26), than to strains from Botswana
(divergence mean of 12.63%with SO=1.07).
Intersample diversity observed for strains from Botswana, India
and previously published South African nucleotide sequences
combined with the TV env sequences, compared to the variation
observed when compared to the subtype C consensus
sequence from the Los Alamos HIV sequence database (HIV
Sequence Compendium, 2001) is shown in Figures 33-35
respectively. The Botswana strains showed the highest
intersample diversity (mean value of 12.64% with SO=1.27) and
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showed the highest variation from the subtype C consensus
sequence (mean value of 8.15% with SO=0.77). All the South
African sequences in the Los Alamos HIV sequence database
showed a mean variation from the subtype C consensus of
8.03% (SO=0.77) and an intersample diversity mean of 11.86%
(SO=1.55). The Indian strains were the most similar to the
subtype C consensus (mean diversity of 6.99% with SO=1.03)
and showed an intersample diversity mean of 8.51% (SO=2.28).
The nucleotide sequences of the TV env sequences showed an
intersample divergence with a mean value of 12.00% (SO=1.66),
while the protein sequences showed an intersample divergence
with a mean value of 19.66% (SO=1.68).
The nucleotide distance observed between TV env sequences
and the subtype C consensus, as well as the generated South
African consensus is shown in Figure 36. Most of the TV env
sequences were more similar to the generated South African
consensus than to the subtype C consensus. The TV002c12.1,
TV004cC300, TV012c2.1, TV012c2.2 and TV018cF1027
sequences were more similar to the subtype C consensus. The
TV010c07 sequence showed the closest similarity to both the
subtype C consensus and generated South African consensus
sequences.
The nucleotide distance observed for the TV env sequences and
subtype reference strains (HIV Sequence Compendium, 2001) is
summarised in Table 6. The different nucleotide sequences for
env clones from isolates TV001, TV006, TV007, TV008, TV013,
and TV014 varied between 0-4%. The different protein
sequences for env clones from isolates TV001, TV006, TV007,
TV008 and TV013 varied between 0-4%. The variation between
clones form TV014 were not calculated, as the TV014c6.3 clone
does not have an open reading frame, as described earlier.
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2.5.4 Analysis for intersubtype recombination
The TV env sequences were analysed for any recombination.
Simplot windows were generated for each sequence and none
of the sequences showed intersubtype recombination and
showed the highest similarity to the subtype C reference strains
from the Los Alamos HIV sequence database (HIV Sequence
Compendium, 2001) (data not shown).
Table 6. Distances observed for the TV env sequences and subtype
reference strains and all subtype C strains. The number of sequences used
for analysis is indicated by n.
n Minimum distance Maximum distance Mean
Subtype SO
(%) (%) (%)
A1 and A2 8 15.63 22.77 20.30 1.79
B 4 17.77 23.27 20.87 1.41
C 130 8.26 18.02 12.51 1.93
D 4 17.48 23.87 21.12 1.65
F1 and F2 6 15.08 23.06 19.80 2.17
G 3 16.9 22.6 20.19 1.59
H 3 16.41 22.76 20.14 1.78
J 2 19.76 21.87 20.58 0.56
K 2 19.28 22.34 20.93 0.75
U 3 19.69 23.99 21.81 1.23
GROUP N 2 44.79 48.59 46.33 1.04
GROUPO 4 57.26 65.54 61.35 2.07
CPZ 5 44.72 68.12 50.53 7.56
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FIGURES
Figure 12. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the peR products generated. The products were run on the gel with
1 kb DNA Ladder as reference for fragment size (indicated by M). The
fragment sizes are indicated to the left of the figure. The products are
approximately 2500 bp in size (indicated by white arrow). Lanes 1-7 show the
products for isolates TV003, TV004, TV006, TV007, TV010, TV013 and
TV018 respectively. Lane 8 contains a negative control (all reagents except
template DNA).
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Figure 13. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the peR products generated. The 1 kb DNA Ladder (indicated by M)
fragment sizes are shown to the left of the figure. The 2500 bp env fragments
are indicated by the white arrow. Lanes 1-2 show the products for TV004, 3-4
show products for TV006, and lanes 5-6 show products for TV018. Lane 7
contains a negative control (all reagents except template DNA).
81
Stellenbosch University http://scholar.sun.ac.za
Figure 14. Photograph of a large ethidium-bromide stained 0.8% agarase gel
showing the separation of non-specific peR fragments. The 1 kb DNA Ladder
(indicated by M) fragment sizes are shown to the left of the figure. The 2500
bp env fragments are indicated by the white arrow. Lanes 1-2 show the
products for TV004, 3-4 show products for TV006, and lanes 5-6 show
products for TV018.
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Figure 15. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing miniprep DNA from pCR3.1 cloning procedures. A Supercoiled DNA
ladder was added as reference for fragment size (indicated by M). The
fragment sizes are indicated to the left of the figure. Lanes 1-4, 7 and 12
indicate DNA preps where no env insert is present as the fragment sizes are
approximately 5000 bp, which correlates with the vector's 5060 bp size
(indicated by white arrow). Lanes 5-6, and 8-11 show DNA where an env
insert might be present (indicated by white arrow), as the fragments are
approximately 7500 bp in size (vector of ± 5000 bp + insert of ± 2500 bp =
7500 bp).
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Figure 16. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing miniprep DNA from pCMVLink cloning procedures. A Supercoiled
DNA ladder was added as reference for fragment size (indicated by M). The
fragment sizes are indicated to the left of the figure. Lanes 1, 3, 5-8 and 11
indicate DNA preps where no env insert is present as the fragment sizes are
between 4000 - 4500 bp, which correlates with the vector's 4351 bp size
(indicated by white arrow). Lanes 2, 4,9, 10, and 12 show DNA where an env
insert might be present (indicated by white arrow), as the fragments are
between 6500 - 7000 bp in size (vector of ± 4000 to 4500 bp + insert of ±
2500 bp = 6500 to 7000 bp).
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Figure 17. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the EcoRI digested miniprep pCR3.1 plasmid DNA. M indicates the 1
kb DNA Ladder and fragment sizes are indicated to the left of the figure. Lane
1 contains undigested miniprep DNA. Lanes 2-3 and 8-9 show miniprep DNA
that did not contain the env insert and shows a fragment of approximately
5000 bp, which correlates with the 5060 bp size of the vector (indicated by
white arrow). Lanes 4-7 and 10-15 show DNA where the env insert was
excised from vector. The excised fragments are 2500 bp in length (indicated
by white arrow), which correlates with the length of the env gene.
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Figure 18. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the EcoRI and Xhol digested miniprep pCMVLink plasmid DNA. M
indicates the 1 kb DNA Ladder. Fragment sizes are indicated to the left of the
figure. Lane 3 shows miniprep DNA which did not contain the env insert and
shows only a fragment of between 4000 - 4500 bp (indicated by white arrow),
which correlates with the size of the pCMVLink vector of 4351 bp. Lanes 1-2
and 4-6 show DNA where the env insert was excised from vector. The excised
fragments are approximately 2500 bp in length (indicated by white arrow),
which correlates with the length of the env gene.
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Figure 19. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the Ndel digested miniprep pCR3.1 plasmid DNA. M indicates the
1kb DNA Ladder and fragment sizes are indicated to the left of the figure.
Lane 1 contains undigested miniprep DNA. Lanes 2-15 shows digestion
patters for clones TV003cE260, TV004cC300, TV006cE9, TV006cE5,
TV006cF3, TV007cB104, TV007cB105, TV010cC3, TV010cD7, TV010cD9,
TV01OcD10, TV013cB20, TV013cH17 and TV018cF1027 respectively.
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Figure 20. Photograph of an ethidium-bromide stained 0.8% agarose gel
showing the digested construct plasmid DNA. M indicates the 1kb DNA
Ladder and fragment sizes of the ladder are indicated to the left of the figure.
Lanes 1-7 show TV001c8.2, LinkTV004cC300, LinkTV006cE9,
LinkTV018cF1027, pCMVLink o-gp140dv2 modified, pCMVLink gp120dv2
modified and the TV010 rev construct respectively. The excised genes and
plasmid vector sizes are indicated to the right of the figure.
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Figure 21. Proteins detected in the SNF of transiently transfected 293 cells.
The Full range Rainbow Marker fragment sizes are indicated. Lane 1 contains
the HIV-1 SF2 recombinant gp120 positive control. The mock/negative
transfected SNF showing cellular glycoproteins appears in Lane 2. Lanes 3-4
contain pCMVLink o-gp140dv2 modified and pCMVLink gp120dv2 modified
respectively. Lanes 5-8 show the SNF from 293 cells transfected with the
native env gene constructs TV001c8.2, LinkTV004cC300, LinkTV006cE9, and
LinkTV018cF1027 respectively. The black arrow indicates the distance
travelled by the Env protein expressed from the TV001c8.2 construct in lane
5.
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Full range rainbow marker Calculated
Mr X 1000 Distance # Sample Distance Mrx 1000(kDa) (mm) (mm) (kDa)
250 8.5 1 SF2 gp120 positive control 15.5 145
160 14.5 2 TV001 o-gp140dv2 modified 13.5 170
105 19.5 3 TV001 gp120dv2 modified 16.0 140
75 25.0 4 TV001 c8.2 + Rev co-transfection 14.5 160
50 34.0
35 43.0
Figure 22. A shows a graph of the log Mr versus the relative distance
travelled by the different fragments of the Full Range Rainbow Marker
indicated by filled black diamonds. The distances travelled by the detected
Env proteins are plotted on the graph as open white squares and are
numbered. The numbers correspond with the respective proteins expressed
from constructs listed in B. The distances used to calculate the protein Mr are
also shown.
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Figure 23. Proteins detected in prepared Iysates from transfected 293 cells.
The Full range Rainbow Marker fragment sizes are indicated. Lane 1 contains
the HIV-1 SF2 recombinant gp120 positive control. The mock/negative
transfected cell lysate showing cellular glycoproteins appears in Lane 2.
Lanes 3-4 contain pCMVLink o-gp140dv2 modified and pCMVLink gp120dv2
modified respectively. Lanes 5-8 show the Iysates from 293 cells transfected
with the native env gene constructs TV001c8.2, LinkTV004cC300,
LinkTV006cE9, and LinkTV018cF1027 respectively. The black arrow indicates
the distance travelled on the gel by the gp160 proteins in lanes 5-8.
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Full range rainbow marker Calculated
Mrx 1000 Distance # Sample Distance Mrx 1000(kDa) (mm) (mm) (kDa)
250 11.0 1 SF2 gp120 positive control 15.0 145
160 14.5 2 TV001 o-gp140dv2 modified 15.0 145
105 19.0 3 TV001 gp120dv2 modified 19.0 105
75 24.5 4 TV001c8.2 14.0 170
50 33.5 5 LinkTV004cC300 13.5 165
35 42.0 6 LinkTV006cE9 13.5 165
30 49.0 7 LinkTV018cF1027 13.5 165
25 51.5
A Distance (mm)
Figure 24. A shows a graph of the log Mr versus the relative distance
travelled by the different fragments of the Full Range Rainbow Marker
indicated by filled black diamonds. The distances travelled by the detected
Env proteins are plotted on the graph as open white squares and are
numbered. The numbers correspond with the respective proteins expressed
from constructs listed in B. The distances used to calculate the protein Mr are
also shown.
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Figure 25. Proteins detected in the SNF of transiently transfected 293 cells
when the native env constructs were co-transfected with a rev construct. The
Full range Rainbow Marker fragment sizes are indicated. Lane 1 contains the
HIV-1 SF2 recombinant gp120 positive control. Lanes 2, 4, 6 and 8 show the
SNF from 293 cells transfected with the native env gene constructs
TV001c8.2, LinkTV004cC300, LinkTV006cE9 and LinkTV018cF1027
respectively. Lanes 3, 5, 7 and 9 show the SNF from the co-transfection with
the rev construct for constructs TV001c8.2, LinkTV004cC300, LinkTV006cE9
and LinkTV018cF1027 respectively. A black arrow shows the distance
travelled by the detected gp160 proteins in lanes 2, 3 and 5.
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Full range rainbow marker Calculated
Mr X 1000 Distance # Sample Distance Mrx 1000(kDa) (mm) (mm) (kDa)
250 11.0 1 SF2 gp120 positive control 17.0 143
160 15.5 2 TV001c8.2 15.5 160
105 19.0 3 TV001 c8.2 + Rev co-transfection 15.5 160
75 26.0 4 LinkTV004cC300 + Rev co- 15.5 160transfection
50 35.5
35 44.0
o 10 20 30 40
A Distance (mm)
Figure 26. A shows a graph of the log Mr versus the relative distance
travelled by the different fragments of the Full Range Rainbow Marker
indicated by filled black diamonds. The distances travelled by the detected
Env proteins are plotted on the graph as open white squares and are
numbered. The numbers correspond with the respective proteins expressed
from constructs listed in B. The distances used to calculate the protein Mr are
also shown.
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Figure 27. Proteins detected in the prepared cell Iysates when the native env
constructs were co-transfected with a rev construct. The Full range Rainbow
Marker fragment sizes are indicated. Lane 1 contains the HIV-1 SF2
recombinant gp120 positive control. Lanes 2, 4, 6 and 8 show the Iysates from
293 cells transfected with the native env gene constructs TV001c8.2,
LinkTV004cC300, LinkTV006cE9 and LinkTV018cF1027 respectively. Lanes
3, 5, 7 and 9 show the Iysates from the co-transfection with the rev construct
for constructs TV001c8.2, LinkTV004cC300, LinkTV006cE9 and
LinkTV018cF1027 respectively. A black arrow shows the distance travelled by
the detected gp160 proteins in lanes 2-9.
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Full range rainbow marker Calculated
Mrx 1000 Distance # Sample Distance Mrx 1000(kDa) (mm) (mm) (kDa)
250 10.0 1 SF2 gp120 positive control 15.0 145
160 14.0 2 TV001c8.2 13.5 170
105 18.5 3 TV001c8.2 + Rev co-transfection 13.5 170
75 24.0 4 LinkTV004cC300 14.0 165
50 33.5 5 LinkTV004cC300+ Rev co- 14.0 165transfection
35 42.0 6 LinkTV006cE9 14.0 165
30 49.5 7 LinkTV006cE9+ Rev co- 14.0 165transfection
25 52.5 8 LinkTV018cF1027 14.0 165
9
LinkTV018cF1027+ Rev co- 14.0 165transfection
Figure 28. A shows a graph of the log Mr versus the relative distance
travelled by the different fragments of the Full Range Rainbow Marker
indicated by filled black diamonds. The distances travelled by the detected
Env proteins are plotted on the graph as open white squares and are
numbered. The numbers correspond with the respective proteins expressed
from constructs listed in B. The distances used to calculate the protein Mr are
also shown.
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Charge Predicted
Phenotype
98TVOOlc8.2 CTRPNNNTRKSVRIGPGQAFYATNDVIGNIRQAHC +5 NSI
98TVOOlc8.5 CTRPNNNTRKSVRIGPGQAFYATNDVIGNIRQAHC +5 NSI
98TVOO3cE260 CTRPNNNTRKSIRIGPGQTFYATNGIIGNIRQAHC +6 NSI
98TVOO7cB104 CPRPNHNTRRSIRIGPGQAFYATGDIIGDIRQAHC +5 NSI
98TVOO7cB105 CPRPNHNTRRSIRIGPGQAFYATGDIIGDIRQAHC +5 NSI
98TV013cB20 CTRPNNNTRRSIRIGPGQAFYT-NDIIGDIRQAHC +4 NSI
98TV013cH17 CTRPNNNTRRSIRIGPGQAFYT-NDIIGDIRQAHC +4 NSI
98TVOO4cC300 CTRPNNNTRKSIRIGPGQTFYATGEIIGDIRQAHC +4 NSI
98TV018cFlO27: CTRPNNNTRRSMRIRPGQTFYATGEIIGDIRQAYC +4 NSI
98TVOO2c12.1 CTRPGNNTRKSVRIGPGQAFYATGDIIGDIRQAHC +4 NSI
98TV014c6.4 CTRPGNNTRKSVRIGPGQTFYATGDIIGDIRQAHC +4 NSI
98TVOO6c9.1 CTRPGNNTRQSIRIGPGQTFYATGDIIGDIRQAHC +3 NSI
98TVOO6c9.2 CTRPGNNTRQSIRIGPGQTFYATGDIIGDIRQAHC +3 NSI
98TVOO6cE9 CTRPGNNTRQSIRIGPGQTFYATGDIIGDIRQAHC +3 NSI
98TV012c2.1 CTRPNNNTRKSMRIGPGQTFYATGDIIGDIRQAHC +4 NSI
98TV012c2.2 CTRPNNNTRKSMRIGPGQTFYATGDIIGDIRQAHC +4 NSI
98TV01OcD7 CTRPNNNTRKSVRIGPGQTFYATGDIIGDIREAHC +4 NSI
98TVOO8c4.3 CTRPNNNTRKSIRIGPGQTFFATNDIIGDIRQAYC +3 NSI
98TVOO8c4.4 CTRPNNNTRKSIRIGPGQTFFATNDIIGDIRQAYC +3 NSI
98TV019c5 CTRPGNNTRKSIRIGPGQAFFATGAIIGDIRKAYC +5 NSI
Figure 29. The charges calculated for the V3 sequences and the predicted
phenotypes are indicated. The net charge was calculated by subtracting the
number of negatively charged amino acids (D or E) from the number of
positively charged amino acids (K, R or H). Amino acid charges where used
as described by Klotho, the Biochemical Compounds Declarative Database at
the Institute of Biomedical Computing, Washington University
(http://www.biocheminfo.org/klotho).
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Figure 30. Neighbor-joining phylogenetic tree analysis of full-length env sequences (-2500bp) from the reference
subtype sequences (AppendixA) and TV env sequences. The TV envsequences are boxed in grey. An indication of
the degree of sequence dissimilarity is shown on the horizontal axis and the subtype sequences on the vertical axis.
The percentage of bootstrap trees out of a 100 replications supporting a particular phylogenetic group by more than
75% is placed alongside the node considered. SubtypesA-D, F-H, J-K and Groups 0 and N have been indicated to
therightofthefigure. 98
10%
Stellenbosch University http://scholar.sun.ac.za
Figure 31. Neighbor-joining phylogenetic tree analysis of 130 full-length subtype C env nucleotide
sequences (-2500bp) and TV envsequences. The TV envsequences are boxed in grey. An indication
ofthe degree of sequence dissimilarity is shown on the horizontal axis and the sequence names on the
vertical axis. The percentage of bootstrap trees out of a 100 replications supporting a particular
phylogenetic group by more than 75% is placed alongside the node considered. Subtypes Band C 99
have been indicated to the right of the figure.
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Botswana India South Africa
vs. TV env sequences
B
TV env sequences versus
Statistics Botswana India South Africa
Mean (%) 12.63 11.81 11.48
SD 1.07 1.26 1.27
SE 0.03 0.09 0.13
95%CI (0.05700),12.57-12.69 (0.1803), 11.63-11.99 (0.2524), 11.23-11.74
99%CI (0.07490),12.56-12.71 (0.2378), 11.57-12.05 (0.3341),11.15-11.81
Size, n 1361 191 101
Minimum (%) 8.97 8.45 8.26
Maximum (%) 16.19 14.61 13.56
Figure 32. Nucleotide distance and corresponding statistics are shown in A
and B respectively. Distances recorded between the TV env sequences and
strains from Botswana, India, and South Africa are plotted as a percentage on
the vertical axis. The boundary of the box closest to zero indicates the zs"
percentile, a solid line within the box marks the median value, a dashed line
within the box shows the arithmetic mean, and the boundary of the box
farthest from zero indicates the 75th percentile. Whiskers above and below the
boxes indicate the 10th and 90th percentiles. Points above and below the
whiskers indicate the 5th and 95th percentiles. The calculated Cl used to
determine the range is shown in brackets. Size (n) indicates the number of
distances analysed.
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SubtypeC consensus Intersamplediversity
B
Statistics Botswana vs. subtype C
Intersample diversity
consensus
Mean (%) 8.15 12.64
SD 0.77 1.27
SE 0.09 0.03
95%CI (0.1844),7.97 - 8.34 (0.0651),12.58 - 12.71
99%CI (0.2449), 7.91 - 8.40 (0.0855),12.56 - 12.73
Size, n 71 1477
Minimum (%) 6.02 6.54
Maximum (%) 10.29 16.24
Figure 33. Nucleotide distance and corresponding statistics are shown in A
and B respectively. Distances in percentage between Botswana strains are
compared with distances to the subtype C consensus sequence. The
boundary of the box closest to zero indicates the zs" percentile, a solid line
within the box marks the median value, a dashed line within the box shows
the arithmetic mean, and the boundary of the box farthest from zero indicates
the 75th percentile. Whiskers above and below the boxes indicate the 10th and
90th percentiles. Points above and below the whiskers indicate the 5th and 95th
percentiles. The calculated Cl used to determine the range is shown in
brackets. Size (n) indicates the number of distances analysed.
101
Stellenbosch University http://scholar.sun.ac.za
A16,----------------------------------,
4
•
14
12
~ 10
~
.~ 8
Q)
.zo 6
•
2
O+-----------~--------~----------~
Subtype C consensus Intersample diversity
B
Statistics
India vs. subtype C Intersample diversity
consensus
Mean (%) 6.99 8.51
SD 1.03 2.28
SE 0.32 0.34
95%CI (0.7340),6.26 - 7.73 (0.6857),7.82 - 9.19
99%CI (1.0545), 5.94 - 8.05 (0.9161),7.59 - 9.42
Size, n 10 45
Minimum (%) 5.71 4.55
Maximum (%) 8.59 13.61
Figure 34. Nucleotide distance and corresponding statistics are shown in A
and B respectively. Distances in percentage between India strains are
compared with distances to the subtype C consensus sequence. The
boundary of the box closest to zero indicates the zs" percentile, a solid line
within the box marks the median value, a dashed line within the box shows
the arithmetic mean, and the boundary of the box farthest from zero indicates
the 75th percentile. Whiskers above and below the boxes indicate the 10th and
90th percentiles when the sample size permitted these calculations. Points
above and below the whiskers indicate the 5th and 95th percentiles. The
calculated Cl used to determine the range is shown in brackets. Size (n)
indicates the number of distances analysed.
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B
Statistics
South Africa and TV vs. Intersample diversity
subtype C consensus
Mean (%) 8.03 11.86
SD 0.77 1.55
SE 0.15 0.17
95%CI (0.3183),7.71 - 8.35 (0.3281), 11.53 - 12.19
99%CI (0.4314),7.60 - 8.46 (0.4348), 11.43 - 12.29
Size, n 25 88
Minimum (%) 6.61 4.38
Maximum (%) 9.12 14.67
Figure 35. Nucleotide distance and corresponding statistics are shown in A
and B respectively. Distances in percentage between all South African strains
are compared with distances to the subtype C consensus sequence. The
boundary of the box closest to zero indicates the 25th percentile, a solid line
within the box marks the median value, a dashed line within the box shows
the arithmetic mean, and the boundary of the box farthest from zero indicates
the 75th percentile. Whiskers above and below the boxes indicate the 10th and
90th percentiles. Points above and below the whiskers indicate the 5th and 95th
percentiles. The calculated Cl used to determine the range is shown in
brackets. Size (n) indicates the number of distances analysed.
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TV001c8.5
TV002c12.1
TV003cE260
TVOO4cC300
TVOO6cE9
TV006c9.1
TV006c9.2
TV007cB104
TV007cB105
TV008c4.3
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TV013cB20
TV013cH17
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TV012c2.2
TV014c6.3
TV014c6.4
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Figure 36. Nucleotide distances between TV env nucleotide sequences and
the subtype C consensus sequence appearing in the Los Alamos HIV
sequence Database (HIV Sequence Compendium, 2001), as well as the
consensus generated from all the South African sequences. The distance is
shown on the horizontal axis, and the different sequences on the vertical axis.
The legend indicates which colour is used to show the calculated distance.
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INTRODUCTION
At the end of 2002,42 million people were infected with HIV-1, and this infection
figure highlights the demand for the development of an effective vaccine to try
and stem the pandemic. This is especially critical for a developing nation such as
South Africa, where one out of every nine people is infected with HIV (UNAIDS
and WHO, 2002).
The env gene is an attractive target as immunogen to be included in a HIV
vaccine. The envelope elicits neutralising antibodies as it contains conformational
neutralising epitopes (Chanh et a/., 1986). Effector T-cell responses are also
generated by the CTL epitopes present in the Env protein (Takahashi et a/.,
1988). This protein will therefore be useful in creating a humoral and cellular
immune response in the host. A few obstacles need to be overcome if this gene
is used as a vaccine. Glycosylation shields the virus from the immune system,
and variable loops mask the neutralising antibody binding sites. The genes
therefore need to be modified to make them more immunogenic. In order to
generate codon-optimised oligomeric genes with their variable loops deleted to
expose antibody-binding sites, the native genes first need to be characterised.
Currently, 130 full-length subtype C env gene sequences appear in the Los
Alamos HIV sequence database (HIV Sequence Compendium, 2001). Excluding
the sequences generated by this study and Chiron Corporation (Emeryville, CA,
USA), only five subtype C env sequences from South Africa are listed
(Rodenburg et a/., 2001; van Harmelen et a/., 2001). At the beginning of this
study, only one full-length subtype C envelope gene sequence from South Africa
had been published (Rodenburg et a/., 2001). A shortage in characterised env
gene sequences from South Africa was therefore recognised, and this study
focussed on the characterisation of generated sequences, as well as the
expression of selected genes. These immunogens were created for possible use
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in a prime-boost vaccine modality. The env genes from recent circulating strains
in South Africa were cloned, sequenced and phylogenetically analysed. Selected
env genes were also transiently expressed to confirm intact genes with open
reading frames.
1.1 SEQUENCE ANALYSIS OF ENV GENES
It has been indicated that there are subtype-specific variations, which occur
within genomic regions of known regulatory function (Gao et aI., 1998).
Subtype C viruses are characterised by a premature truncation in their rev
open reading frame, an enlarged Vpu protein, a highly conserved subtype
C-specific LRLL motif in the Vpu protein, and three copies of a consensus
NF-KB binding site (Johansson et aI., 1995; McCormick-Davis et aI., 2000;
Salminen et aI., 1996; Scriba et aI., 2001; Scriba et aI., 2002). Subtype B
viruses show only two NF-KB binding sites (HIV Sequence Compendium,
2001), whereas CRF01_AE viruses have only one consensus NF-KB
binding site (Gao et aI., 1996b). Reports have suggested that a more rapid
transmission of subtype C in relation to the other subtypes can be due to
higher levels of promoter activity (possibly induced by the s= NF-KB binding
site) resulting in upregulation of viral transcription (Naghavi et aI., 1999;
Tong-Starksen et aI., 1990). Such changes in enhancer copy numbers and
regulatory proteins may manifest themselves only after multiple rounds of
replication in vivo. This could indicate that there are subtype-specific
differences in virus biology.
Subtype C specific variations have also been detected in the Env proteins.
The V3 loop, which is extremely variable in subtypes other than subtype C,
is more conserved in subtype C sequences (Ping et aI., 1999). This
conservation in the V3 loop was also detected in the TV env sequences,
which displayed a more variable region downstream from the V3 loop.
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There appear to be subtype-dependent differences in usage frequency for
certain coreceptors. The CXCR4-positive phenotype is significantly more
rare among subtype C isolates (Tscherning et al., 1998), therefore
indicating that subtype C viruses do not switch from an NSI phenotype to a
SI phenotype as disease progresses. Subtype C isolates obtained from
late-stage Ethiopian AIDS patients showed no CXCR4 usage in any of the
isolates (Bjorndal et al., 1999). This was also detected in South African
sequences from subtype C isolates (Treurnicht et al., 2002). The
tetrapeptide crown sequence identified in most of the subtype C sequences
is GPGQ. It has been indicated that this sequence is indicative of aNSI
phenotype (Abebe et al., 1999). Almost all of the TV env sequences
displayed a GPGQ crown sequence. Although the net charge observed for
the V3 loop was not <+5 for all the TV env sequences, uncharged or
negatively charged residues were found at positions 11, 25 and 32 of the
V3 loop. This also indicates that the sequences should have aNSI
phenotype (Bjërndal et al., 1999). The NSI phenotype was subsequently
confirmed in cell culture experiments for all the isolates using the parental
virus isolates (Treurnicht et al., 2002). These results strengthen the
observation that subtype C viruses isolated previously do not switch from a
NSI to SI phenotype, as the isolates used for generating env sequences
were from patients in all clinical disease stages determined according to the
WHO staging system for HIV infection and disease (Ufson et al., 1995).
However, our group has indicated that subtype C viruses from more recent
isolates have started following the same trend as other subtypes by
switching to CXCR4 usage and a SI phenotype (Janse van Rensburg et al.,
2002). Another recent study reported the isolation of SI subtype C viruses
from patients on antiretroviral therapy (Johnston et al., 2002). This may
indicate that the epidemic in South Africa is starting to mature (Janse van
Rensburg et al., 2002).
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1.2 PHYLOGENETIC RELATIONSHIPS OF ENVSEQUENCES
Since HIV-1 began its expansion in humans roughly 70 years ago (Korber
et al., 2000), it has diversified rapidly. Phylogenetic analysis of globally
circulating viral strains has identified three distinct groups of HIV-1. These
include M (major), 0 (outlier), and N (non-M and -0) (HIV Sequence
Compendium, 2001). Nine different subtypes have been proposed within
the group M viruses (subtypes A - 0, F - H, J, K) and CRFs have also been
identified. The various subtypes differ in their geographic dissemination,
and so the subtype designations are a powerful tool for tracking the course
of the global epidemie (Hu et al., 1996; WHO Network for HIV Isolation and
Characterization, 1994). The epidemic in Thailand for example was
believed to have resulted from a single introduction of HIV-1. Genetic
analysis however revealed that there were two distinct epidemics of
different origins. The intravenous drug users were infected with subtype B
prevalent in the Americas, and the sex workers were infected with the
CFR01_AE prevalent in Africa (Carr et al., 1996; Gao et al., 1996; Kalish et
al., 1995).
Tracking of the HIV-1 subtype C epidemic is critical, as this subtype
constitutes 47.2% of all circulating HIV viruses, and is the most commonly
transmitted subtype world-wide (Esparza and Bhamarapravati, 2000;
Osmanov et al., 2002). The subtype C strains are predominant in India
(South Asia), East and Southern Africa, and also circulate in China.
Subtype C sequences from the viruses circulating in these countries is
essential for phylogenetic analysis and in creating possible immunogens for
vaccine purposes. The diversity of the subtype C sequences also needs to
be evaluated, as this information should prove to be valuable in the design
of vaccine strategies.
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Phylogenetic analysis of sequences generated in this study clearly showed
that the sequences clustered with the subtype C reference strains with a
maximum bootstrap value of 100%. This strongly suggests that the isolates
used to generate the env genes are subtype C strains and not recombinant
forms. Recombination analysis also indicated that the sequences generated
in this study showed the closest similarity to subtype C reference strains
over the full-length of the genes. This is supported by previous studies in
which the accessory, regulatory and gag genes as well as the 5' long
terminal repeat (LTR) regions of these isolates were characterised as being
subtype C (Engelbrecht et al., 2001; Scriba et al., 2001; Scriba et al., 2002).
Full-length genome clone sequencing of TV001, TV002 and TV012
recently, further confirmed that the strains belong to subtype C and are not
recombinant farms (zur Megede et al., 2002).
It has been found that subtype C sequences from Botswana and South
Africa intermingle (Groenink et al., 1993). The sequences of these two
countries were also distributed across several subclusters in this study. This
highlights the concept that these infections represent a more longstanding
epidemic with multiple introductions from different geographic areas (Abebe
et al., 2001; Novitsky et al., 1999; van Harmelen et al., 1999). A recent
report contrasts with the finding that a starburst effect was seen for South
African sequences (Novitsky et al., 2002). The study showed that South
African sequences segregated as a separate, distinct subcluster. This may
have been due to a bias introduced by including a disproportionate number
of Botswana sequences in their analysis, as only 5 South African
sequences were used (zur Megede et al., 2002).
1.3 IMPLICATIONS OF THE OBSERVED DIVERSITY FOR VACCINE DESIGN
HIV-1 diversity has important implications for diagnosis, treatment and
development of vaccines. The sensitivity of serological and molecular
110
Stellenbosch University http://scholar.sun.ac.za
diagnostic tests may be affected by subtle changes in antigenic structure of
HIV-1 variants (Peeters and Sharp, 2000). There are indications of variation
in drug susceptibility within group M, as subtype F and G strains are less
susceptible to non-nucleoside reverse transcriptase inhibitors and protease
inhibitors respectively (Apetrei et al., 1998; Descamps et al., 1998).
Diversity has been considered a major problem for the development of a
vaccine. Currently, strains belonging to the same subtype can differ up to
20% in their Env proteins, and intersubtype distances can be as high as
35% (Gaschen et ai., 2002). The diversity is also continually increasing as a
result of mutations generated by reverse transcription, accompanied by a
high replication rate and rapid viral turnover (perelson et ai., 1997),
pressure for change coupled with tolerance of change (Korber et ai., 2001),
as well as recombination. The variation is put into perspective when one
considers that the influenza vaccine strain has to be replaced when less
than 2% amino acid change occurs in the circulating strains, as this can
cause a failure in cross-reactivity of the polyclonal response to the influenza
vaccine strain (Gaschen et ai., 2002).
The development of genetic subtype-specific vaccines are commendable
(Esparza and Bhamarapravati, 2000), as a vaccine homologous to the
circulating strains in a region is likely to provide better breadth, strength,
and durability of immune responses than a mismatched vaccine (Novitsky
et ai., 2002). For this reason, vaccine candidates currently employ a
particular viral strain isolated in a specific geographical region or clones
generated from these isolates, with the hope that they will be sufficiently
cross-reactive to protect against circulating viruses. However, this may be
an optimistic view, as HIV-1 Env proteins can differ in more than 30% of
their amino acids. To contend with diversity, country-specific vaccines are
being considered, but evolutionary relationships may be more useful than
regional considerations (Gaschen et ai., 2002). The lack of knowledge of
the potential immunological relevance of HIV-1 genetic subtypes should be
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addressed as well, as it has been shown that genetic subtypes do not seem
to strictly correspond to immunotypes. More than one genetic subtype could
share common protective epitopes, and it is possible that more than one
immunotype is contained within a single genetic subtype (Esparza and
Bhamarapravati, 2000). The type of immune response responsible for
protection also needs to be confirmed. In general, neutralising antibodies
seem to be more strain specific, whereas cell-mediated immune responses
are more cross-reactive (Ferrari et al., 1997).
If attempts are made to create a vaccine from an isolate or strain
representative of the circulating viruses in a population or geographic area,
certain difficulties will arise in areas such as countries in Africa, where
multiple subtypes are circulating concurrently. An alternative would be to
design cocktail vaccines containing multiple subtypes. These difficulties will
be downscaled when efficacy trials are performed to explore the possibility
of achieving cross-protection between different subtypes.
Recent studies indicate that either a consensus sequence or an ancestral
sequence reconstructed on the basis of an evolutionary model will have the
advantage of being central and most similar to currently circulating strains,
and might have the enhanced potential for eliciting cross-reactive
responses (Gaschen et al., 2002; Korber et al., 2001; Novitsky et al., 2002).
The data generated by Novitsky et al. (2002) illustrates that intersample
diversity observed for strains from Botswana, India and South Africa is
significantly higher than distances observed to the consensus sequences
generated. The assumption is made that a consensus sequence will be a
more extensive match to the circulating viruses in a specific region. The
data generated in this study also shows that intersample diversity is higher
compared to the distances seen to the subtype C consensus. As a concept,
a consensus sequence approach to vaccine design and development may
contain certain limitations. Substitutions of amino acids across HIV-1
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proteins are not independent (Bickel et aI., 1996; Korber et aI., 1993), which
indicates that artificial gene constructs might contain certain sequences that
are not found in wild-type viruses. Further, the incorporation of multiple
copies of numerous viral variants that correspond to minor amino acids in
generated and extended consensus sequences would yield very large
constructs, which would be unrealistic to generate for vaccine purposes.
These limitations can be overcome by preventing the inclusion of residue
combinations that rarely occur in virus populations, and construct sizes can
be decreased by including only immunodominant regions. However, the
concept of consensus-based vaccines still needs to be tested in regards to
the correlates of immune protection.
If it is proved to be more efficacious to use strain specific isolates or clones
rather than consensus sequences as immunogens, the TV env sequences
could be used as a base to generate more immunogenic constructs for
vaccine purposes. The intersample diversity observed for the amino acid
sequences generated in this study (mean value of 19.66%, SD=1.68) is
comparable to the variation recorded for the Env protein between all
subtype C strains (mean value of 20.02, SD=2.28) (Novitsky et aI., 2002).
This implies that any of the sequences generated in this study will be
representative of circulating subtype C viruses in South Africa. Selecting a
sequence with a short branch length relative to the common ancestor in
subtype C might be advantageous, as it would tend to be most similar to the
majority of sequences represented in the tree (Foley et aI., 2000). As the
TV010cD? clone showed the closest similarity to the subtype C consensus
sequence and the generated South African consensus, and showed the
shortest branch length to the subtype C ancestral sequence, this isolate
should be analysed further for functionality and immunogenicity for possible
use in vaccine development.
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1.4 PROTEIN EXPRESSION STUDIES
The second objective of this study was to express the proteins from the
selected isolates in mammalian cells to confirm intact genes and open
reading frames. Expression of the env genes is dependent on many factors,
which involve the synthesis of the proteins, regulation at posttranscriptional
level and the cleavage of the gp160 into gp120 and gp41 subunits.
The gp160 precursor is proteolytically cleaved into a gp120 and gp41
protein by a host furin or furin-like protease (Hallenberger et al., 1992) at an
Arg-X-Lys/Arg-Arg motif (Hosaka et al., 1991). Expression of envelope
proteins in mammalian cell-lines should therefore be characterised by
gp120 and gp41 protein fragments when analysed by SOS-PAGE. A group
studying the expression of a gp140 protein after transient transfection into
293T cells discovered that the gp140 proteins weren't cleaved into gp120
and gp41 subunits (Binley et al., 2000). They argued that cleavage didn't
occur as a result of the large amount of gp140 expressed during the
transient-transfection procedure. When exogenous furin was added by co-
transfection, the proteins were completely processed into the gp120 and
gp41 components. Cleavage of expressed envelope proteins was also
reported to be inefficient when recombinant Env is expressed at high levels
as full-length gp160 proteins (Binley et al., 2002). The Env proteins
expressed from the constructs designed in this study showed a Mr of
approximately 160kDa. No gp120 and gp41 subunits were observed,
therefore indicating that cleavage was inefficient as a result of cellular
proteases being saturated by the recombinant Env proteins, which was
expressed at high levels.
The expression of the env gene is regulated at posttranscriptional level by
the presence of the Rev protein (Dayton et al., 1988), as it contains aRRE.
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The Rev-mediated transport to the cytoplasm of unspliced and singly
spliced mRNAs possessing the RRE, is dependent on direct binding of Rev
(Malim et al., 1989). Most of the Env proteins expressed by the constructs
designed in this study showed Rev dependence. It has been shown that
expression of Rev dependent env genes in recombinant vectors can be
increased when the genes are made Rev-independent (Corbet et al.,
2000b). This has also been shown to be effective for elevating expression
levels of gag constructs (zur Megede et al., 2000). Therefore, the
expression levels of the constructs in this study can be improved in future
studies if the genes are modified to be Rev-independent.
The ER has a 'quality control' system that ensures that proteins do not
leave this compartment before they have reached their native state (Doms
et al., 1993; Hurtley and Helenius, 1989; Ou et al., 1993). Failure to reach
the native state results in the retention of the protein in the ER or in a cis-
Golgi compartment (Crise et al., 1990), and subsequently in the aggregation
or proteolytic degradation in the cytosol (Kimura et al., 1996; Klausner and
Sitia, 1990; Lippincott-Schwartz et al., 1988; Willey et al., 1988; Yang et al.,
1998). Aggregation is a consequence of the poor solubility characteristics of
folding intermediates and incorrectly folded proteins (Doms et al., 1993).
Studies have indicated that inefficient cleavage of the signal peptide of HIV-
1 is directly responsible for the ER retention of the protein (Li et al., 1996)
as a result of aggregation and misfolding (Rottier et al., 1987). A more
recent study has also shown that cleavage of the signal peptide is a crucial
step in determining the efficiency of subsequent folding and intracellular
transport of viral glycoprotein (Li et al., 2000). As the C-terminal of the
LinkTV006cE9 construct has a deletion of 2 amino acids and an 125Yamino
acid substitution, cleavage might be abrogated, resulting in misfolding and
aggregation of the protein. Furthermore, there are several instances in
which viral membrane proteins with mutations in the cytoplasmic domain
are also retained in the ER (Doms et al., 1988; Doyle et al., 1985; Parks
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and Lamb, 1990). The TV018cF1027 construct has a 54 amino acid
insertion containing 4 cysteine residues at the C-terminal of gp41 , which are
further likely to induce misfolding, aberrant interchain disulfide bonding, and
aggregation (Segal et ai., 1992; Wilcox et ai., 1988). Interchain disulfide
bonds in the ectodomains of viral proteins are necessary not only for
stability of the final protein, but also for folding and maturation (Doms et ai.,
1993). Very low levels of expression were detected for the LinkTV006cE9
and LinkTV018cF1027 constructs in the lysate preparations, but no
expression was seen in the SNF. It is therefore likely that the Env proteins
expressed by both the LinkTV006cE9 and LinkTVO18cF1027 constructs
were retained in the ER or other early compartments of the secretory
pathway. If this were the case, these proteins would not be secreted into the
SNF and were probably being degraded in the cytosol. The degradation
could explain why the levels of expression detected in the Iysates were so
low.
The Env precursor has a Mr of 160 kDa after asparagine-linked, high-
mannose sugars are added to the precursor during synthesis of the protein
(Allan et ai., 1985; Robey et ai., 1985). The precursor is subsequently
transported to the cis compartment of the Golgi apparatus (Willey et ai.,
1991), where high mannose ER-acquired amino (N)-linked oligosaccharide
side chains are modified to more complex forms (Dewar et al., 1989;
Ratner, 1992; Stein and Engleman, 1990). Proteins detected in the Iysates
of both the TV001 o-gp140 dv2 modified and TV001 gp120 dv2 modified
constructs were smaller (approximately 145 and 105kDa respectively) than
proteins observed in the SNF (approximately 170 and 140kDa respectively).
Asparagine-linked high-mannose sugars were probably still in the process
of being added to the proteins during synthesis, or the sugars still had to be
modified to more complex forms (Dewar et ai., 1989; Ratner, 1992; Stein
and Engleman, 1990), which would increase the Mr of the proteins secreted
into the SNF.
116
Stellenbosch University http://scholar.sun.ac.za
CONCLUSION
This study has shown that expression of selected env genes were Rev
dependent and that cleavage into gp120 and gp41 subunits might have been
abrogated as a result of cellular furin-like protease saturation. Further, this study
has generated much needed subtype C South African env gene sequences. The
sequences are not recombinant and represent sequences from isolates
harbouring a NSI phenotype. Subtype C-specific variations were detected in the
Env proteins, which included a more conserved V3 loop. Phylogenetic analysis
showed that the sequences intermingled with the Botswana strains and that they
were distributed across several subclusters in the phylogenetic tree. This
highlights the concept that these infections represent a more longstanding
epidemic with multiple introductions from different geographic areas. The
sequences displayed a variation similar to the variation observed between all the
different subtype C sequences. The env gene of the TV010 isolate may be
valuable for vaccine design, as it is the most similar to the subtype C consensus
compared to the other generated sequences, and shows the shortest branch
length to the subtype C ancestral sequence.
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APPENDIX A
This section shows the sequences used in the alignments. The sequence common
names, accession numbers, subtype of the sequences, sampling country of the
sequences and the articles in which the sequences were first described are listed.
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Sequences with references used in alignments. Table adapted from the Los Alamos Database (HIV Sequence Compendium, 2001) and
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi.
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A1 U51190 A1.UG.92UG037 Uganda Gao, F J ViroI70(3}: 1651-1657 (1996)
A2 AF286238 A2.CD.97.CDKTB48 Democratic Gao, F ARHR 17(8}: 675-688 (2001)
republic of Congo
A2 AF286237 A2.CY.94CY017 -41 Cyprus Gao, F ARHR 17(8}: 675-688 (2001)
A2 AF286241 A2.CD.97CDKS10 Democratic Gao, F ARHR 17(8}: 675-688 (2001)
republic of Congo
A2 AF286240 A2.CD.97CDKFE4 Democratic Gao, F ARHR 17(8}: 675-688 (2001)
republic of Congo
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B M17451 B.US.RF United States Stareich, BR Cell 45(5}: 637-648 (1986)
B U63632 B.US.JRFL United States O'Brien, WA Nature 348(6296}: 69-73 (1990)
B U21135 B.US.wEAU160 United States Ghosh, S Unpublished
C AB023804 C.931N101 India Mochizuki, N ARHR 15(14}: 1321-1324 (1999)
C AF067154 C.931N999 India Lole,KS J Virol 73(1}: 152-160 (1999)
C AF067155 C.951N21068 India Lole,KS J ViroI73(1}: 152-160 (1999)
C AF067157 C.931N904 India Lole,KS J ViroI73(1}: 152-160 (1999)
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C AF067159 C.941N11246 India Lole,KS J ViroI73(1}: 152-160 (1999)
C AF110959 C.96BW01 B03 Botswana Novitsky, VA J Virol 73(5}: 4427-4432 (1999)
C AF110960 C.96BW01B21 Botswana Novitsky, VA J Virol 73(5}: 4427-4432 (1999)
C AF110961 C.96BW01B22 Botswana Novitsky, VA J Virol 73(5}: 4427-4432 (1999)
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C AF110962 C.96BW0402 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
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C AF110965 C.96BW0409 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110966 C.96BW0410 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110967 C.96BW0502 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110968 C.96BW0504 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110969 C.96BW1104 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
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C AF110975 C.96BW15C05 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110976 C.96BW16B01 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110977 C.96BW16D14 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110978 C.96BW1626 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110979 C.96BW17A09 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
C AF110980 C.96BW17B03 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999) I
I
C AF110981 C.96BW17B05 Botswana Novitsky, VA J Virol 73(5): 4427-4432 (1999)
,
C AF219262 C.FIN9126 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000) .
C AF219263 C.FIN9149 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000)
C AF219264 C.FIN9158 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000)
C AF219266 C.FIN9210 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000)
C AF219269 C.FIN9277 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000)
C AF219270 C.FIN9307 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000)
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tC AF219274 C.FIN9401 Finland Liitsola, K Scand J Infect Dis 32(5): 475-480 (2000) I
C AF286223 C.941N476 India Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286224 C.96ZM651 Zambia Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286225 C.96ZM751 Zambia Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286227 C.97ZA012 South Africa Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286228 C.98BR004 Brazil Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286231 C.981N012 India Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286232 C.981N022 India Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286233 C.981S002 Israel Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286234 C.98TZ013 Tanzania Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF286235 C.98TZ017 Tanzania Rodenburg, CM ARHR 17(2): 161-168 (2001)
C AF290027 C.96BW06H51 Botswana Ndung'u, T Virology 278(2): 390-399 (2000)
C AF290028 C.96BW06J4 Botswana Ndung'u, T Virology 278(2): 390-399 (2000)
C AF290029 C.96BW06J7 Botswana Ndung'u, T Virology 278(2): 390-399 (2000)
C AF290030 C.96BW06K18 Botswana Ndung'u, T Virology 278(2): 390-399 (2000)
C AF321081 C.FR.CMBA France Lemiale, F Unpublished
C AF321523 C.BW.MJ4 Botswana Ndung'u, T J Virol 75(11): 4964-4972 (2001)
C AF361874 C.97TZ04 Tanzania Hoelscher, M AIDS 15(12): 1461-1470 (2001)
C AF361875 C.97TZ05 Tanzania Hoelscher, M AIDS 15(12): 1461-1470 (2001)
C AF391230 C.98TV001 c8.2 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391231 C.98TV001c8.5 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391232 C.98TV002c12.1 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391233 C.98TV003cE260 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391234 C.98TV004Cc300 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391235 C.98TV006c9.1 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391236 C.98TV006c9.2 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
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C AF391237 C.98TV006cE9 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391238 C.98TV007cB104 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391239 C.98TV007cB105 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
,
C AF391240 C.98TV008c4.3 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391241 C.98TV008c4.4 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391242 C.98TV010cD7 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391243 C.98TV012c2.1 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
,
C AF391244 C.98TV012c2.2 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001) I
C AF391245 C.98TV013cB20 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
:
C AF391246 C.98TV013cH17 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001) i
C AF391247 C.98TV014c6.3 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391248 C.98TV014c6.4 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391249 C.98TV018cF1027 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF391250 C.98TV019c5 South Africa Engelbrecht, S ARHR 17(16): 1533-1547 (2001)
C AF443074 C.96BWM015 Botswana Novitsky, V J ViroI76(11): 5435-5451 (2002)
C AF443075 C.96BWM032 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443076 C.98BWMC122 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443077 C.98BWMC134 Botswana Novitsky, V J ViroI76(11): 5435-5451 (2002)
C AF443078 C.98BWMC14A3 Botswana Novitsky, V J ViroI76(11): 5435-5451 (2002)
C AF443079 C.98BWM01410 Botswana Novitsky, V J ViroI76(11): 5435-5451 (2002)
C AF443080 C.98BWM018D5 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443081 C.98BWM036A5 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443082 C.98BWM037D5 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443083 C.99BW393212 Botswana Novitsky, V J Virol 76( 11): 5435-5451 (2002)
C AF443084 C.99BW46424 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443085 C.99BW47458 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
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C AF443086 C.99BW47547 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
C AF443087 C.99BWMC168 Botswana Novitsky, V J Viral 76(11): 5435-5451 (2002)
C AF443088 C.00BW07621 Botswana Novitsky, V J Viral 76(11): 5435-5451 (2002)
C AF443089 C.00BW076820 Botswana Novitsky, V J Virol 76(11): 5435-5451 (2002)
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APPENDIX B
An alignment of the complete Env protein from TV Env sequences is shown in this
section. The 4 pCMVLink clones are also shown in the alignment. The TV env
sequences are compared to the C.ZA.97ZA012 sequence (Also see Appendix A).
The B.FR.HXB2 sequence was used to identify conserved glycosylation sites and
cysteine residues. The subtype C reference strains are also added (HIV Sequence
Compendium, 2001). Dots denote sequence identity with the C.ZA.97ZA012
sequence, while dashes represent gaps introduced to optimise the alignment. Carets
indicate glycosylation sites previously identified in the B.FR.HXB2 sequence. The
signal peptide, V1, V2, V3, V4, and V5 variable loops, CD4-binding residues and
sites, fusion domain/peptide, immunodominant region, tryptophan-rich sequence,
membrane-spanning domain and intracellular cytoplasmic domain/tail are indicated
above the sequences. A blue box indicates the deletion observed at the C-terminal of
the signal peptide for the TV006 sequences (TV006cE9, TV006c9.1, TV006c9.2 and
LinkTV006cE9). Yellow boxes indicate the glycosilation sites observed in the
sequences. A purple box indicates the crown of the V3 loop. The fusogenic site of
the fusion peptide is indicated in a green box. Amino acid changes observed in the
LinkTV006cE9 and LinkTV018cF1027 sequences are shown in open boxes.
Triangles at positions 11, 25, and 35 of the V3 loop indicate amino acids assessed
for SI/NSI phenotype.
B-1
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B.FR.HXB2
C.ZA.97ZA012
C.IN.95IN21068
C.BW.96BW0502
C.BR.92BR025
C.ET.ETH2220
TV007cB104
TV007cB105
TV014c6.4
TV014c6.3
TV008c4.3
TV008c4.4
TV019c5
TV013cB20
TV013CH17
TV006cE9
LinkTV006cE9
TV006c9.1
TV006c9.2
TV004cC300
LinkTV004cC300
TV003cE260
TV012c2.1
TV012c2.2
TV018cF1027
LinkTV018cF1027
TVOOlc8.2
TVOOlc8.5
TV002c12.1
TV010cD7
OJ
I
I\,)
Signal peptide ---II-l",~ gp120 start
* * * AAAMRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNM
MRVRGIPRNWPQW-WMWGILGFWMIIICRVVGNMWVTVYYGVPVWTDAKTTLFCASDTKAYDREVHNVWATHACVPTDPNPQEIVLENVTENFNM
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......... Q - .....•...... N•• -----------------------NATVNY----NNT-S.D ..•••. YV••...... K
........••..•......... AM.KVDPT.. HFKLYK--------CYYLHST---------------------.GD ...•••.•••. V .... T.
170
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TV001c8.2
TV001c8.5
TV002c12.1
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OJ
I
.J::o.
~ V2100p"'
AAA *AAA * * * AAA AAA * AAA *
KEYAFFYKLDIIPID----------NDT--T8YKLT8CNTSVITQACPKV8FEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRP
QGYALFYRPDIVLLKENR--NN8--NNS---EYILINCNASTITQACPKVNFDPIPIHYCAPAGYAILKCNNKTFSGKGPCNNVSTVQCTHGIKP
TV L P. DNEEQE -- .S. --GY. R ....• T.A T ....................•••. N.T H•••..........
·VH L P. Q---------G .•• --N .. R ....• T.A 8 T ..........• Q •. N .T ....•••.... A .
KVH L P. -----K.E. -8 .T. --GD. R ....• T.A 8 ....................•••. N.T ....•••....... T ..
KA L P .N---------- .G. --TD. R ....• T •......... 8L R .••.•• T H•••..........
·V 8. D----------.S. ---T. R ....• T T ....................•••. N.T T •••..........
·V 8. D----------. S. ---T. R ....• T •......... T ....................•••. N.T T •••..........
KE L P .NNGNP8---EG. S. --EK. R. T ..• T •......... 8 T ..........•••. N.T H •••..........
KE L P . NNGNP8 - - - EG. S • - - EK . R ....• T •......... 8 T ..........•••. N •T H •••..........
KE L P.N. -------KD.K. --T .CR ....• T •......... 8. E ...................••. N.T ....•••..........
KE L P .N . - - - - - - - KD. K. - -T .. R ....• T •......... S . E ..................•••. N •T ....•••..........
GV L P. --------NDT ••• --R .. R ....• T •......... 8 T ..........•••.•• T ....•••..........
NT 8 P .N---------- .R. --- .......• T •......... 8 ....................•.•. N.T Q•••..........
NT 8 P. N- - - - - - - - - •R. - - - .......• T •......... 8 ....................•••. N. T Q•••..........
-KKKQV .ALFYR. DIVQFD----ND. S. ----. R ....• T.A T ....................••.. N.T 8 •• G .
-KKKQV .ALFYR. DIVQFD----ND.S. ----. R ....• T.A T ....................•••. N.T S •• G .
-KKKQV .ALFYK. DIIQLD----ND.S.DN8G. R ....• T.A T ....................•••. N.T S •••..........
·V L QFD- - - - - .. - - - •S • - - - - . R ....• T •A T ....................•••. N •T S •••..........
·V L P .N. -NN8. 8. --.F .E--- .R ....• T.A T ....................•••. N.T 8 ••...........
·V L P.N. -NN8. S. --.F .E---. R ....• T.A T ....................••.. N.T S •••..........
RVS. -------FFY.L. IVPL. ENN.E. --QK. R .. S .• T •......... T T ..........•••. N.T H•.•..........
· E L P. E--E-------. S. ---K. R T.A S ....................•••. N.T ....•••..........
· E L P. E--E-------. S. ---K. R ....• T.A S ....................•••. N.T .....••..........
IE LG .. P .. ------ENKL.S. --- .. R ....• T.A S ....................•.•. N.T ....•••..........
IE LG .. P .. ------ENKL. S. --- .. R T .A 8 ....................•.•. N.T ....••...........
KE L P.N .. 8D------.F. ----. R ....• T •......... 8 ....................•••. N.T Y •••..........
KE L P . N .. SN- - - - - - •F • - - - - . R ....• T 8 D .......•... N •T Y .•...........
KEN L P .NNR.NG. INN--------. R ....• T .A S P ....•. K.N. I .....••..........
KVH L P . - - - - - - - - NG8 • S • - - - .. R ..... T •......... 8 ....................•.•. N •T ... Q •••..........
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CD
I
Ol
V3100p
""" """ """ "*" """.... Crown .... .... *""" """VVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRSPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASK
VVSTQLLLNGSLAEKEIIIRSENLTDNVKTIIVHLNKSVEIVCTRPNNNTRKSMRIGPGQ-TFYATGDIIGDIRQAYCNISGSKWNETLKRVKEK
·.......••.... GG QP ..................••
·.........•.. KG A. I Q P .K V .
........•••... E K •••..........• E •... N ••...•••......•
· G.T F ..•...A. I Q .•E T S E .
- .••.•........•. H •••• ED QN .SK .
- E I .NK .E ..S ..QG .SK .
-A E H R.A ..K ..QE. GK.
- H .••• EE K •. Q •••••
· K AQ E R. P H. • . . . . . . -A H E K ..Q ..SK.
· K AQ E R. P H. • . . . . . . -A H E K ..Q ..SK.
· E A .I Q G. •....... •- H ED ...•.. QW. GK .
· E A .I Q G. .•...... - H ED QW. GK .
· A E ..R. ...............• - N KDD ..K ..Q ..A ..
· EG .......•... A E ..R. ............... •- N KDD ..K •. Q ..A ..
· K A .......• E •. A G. ........ -A A K EGE ..R •. Q ..GR .
·........•.... ED.R E •..•••..••• Q ..K. ...... ...... -A ..TN- H RAE .• N ..A .
· ED .R •••• S •E •..••....•• Q •. K. . • • . . . • • • . . • • • . • • - A .. TN - H RAE .• N ..A ..•.•
·........••... GD .......•... A .I E G Q. ... - H AG SK .
· GD .......•... A. I E G Q ....•... - H AG SK .
· GD A. I E G Q. ... - H AG SK .
· GD ........•.. A. I E G Q. ...• .- H AG SK .
·........•.......................... E R. .............•. - E H .T ..SQN ..R ..Q ..S ..
·........•............•............. E R. .............• - E H .T ..SQN ..R ..Q ..S ..
·........•.... E A .I E. ................... ...- NG H EE K ..QQ .GK .
· E A .I E T. ............. .- H EKQ Y ..S ..
·.........•... E ........•... A .I E T ...............•.. - H EKQ Y ..S ..
· E K E , R ..•.- E K ..EDQ ..K S ..
· E K ..~ E R.·..- E K ..EDQ ..K S ..
· EG E.T E N ..............•..• -A N H TD K ..QQ .MI<.
·........•.... EG E .T E N -A N H TD K ..QQ .MI< •
• •.••••.• , •... E ••.•.•.•••••.•.•..••• E ••.. K •..• G ••• , . . . • . • • -A ...•.....••... H .••• KNE .• T •• Q .. S .•
· G A F .Q ...................•... - H KE N ..QE .SK .
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IJJ,
0)
CD4
binding
CD4 CD4 V4 loop CD4 I >
AAA I I * *AAA AAA AAA AAA * I
LREQFGNNKT-IIFKQSSGGDPEIVTHSFNCGGEFFyCNSTQLFNSTW-----FNST-WSTEGSNNT-EGSDTITLPCRIKQIINMWQKVGKAMY
LQENYNNNKT-IKFAPSSGGDLEITTHSFNCRGEFFyCNTTRLFN--------NNAT------------EDETITLPCRIKQIINMWQGVGRAMY
.A.H. P- ••• -. I .NS ......................•.• G ..• RTY----MP.D. -----KSNSSSNP.AN E .
· .. H. S-K.A- .. CE .......................••. Q STY--SPSF .G. ---ENKLNGT------ T K .
.A.H. P- •• A- KH.....................••• S ..• STY----TP.S. ------ENITGT .. SI .
· .KH. P- ••• -. E. K G......••• N ..• STK------------LELFNSS--T. LN Q .
.G.H. P- ••• - H .....................•••...• STY----MP. V. -----ESNGTESNVTM E .
.G. H. P- ••• - H .....................•••...• STY----MP. V. -----ESNGTESNVTM E .
.G. L. P- ••• -. E.K .......................••• Q ..• STY------.S. ----QMHNDTGSNST- .
.G. L. P- ••• -.E. K ........................•• Q ..• STY------. S. ----QMHNDTGSNST- .
·GKH. P- •• -N. T. R .......................•••...• HTY----LF .G. ----GVPNNTTPS I E .
·GKH. P- •• -N. T. R .......................•••...• HTY----LF .G. ----GMPNSTTPS I E .
.A.H. PG- .R- P G ......••• Q ..• RTYNTTQLF .G. ----YSSNDT-ES. F. -- E .
· . KL. -- ••• -. V. E. H .....................•••...• IT-EVQRNV .D. -------NGT------ F E .
· .KL. -- ••• -. VLE.H .....................•••...• IT-EVQRNV .D. -------NGT------ F E .
·G.H. P- ••• - H M.............•• S ..• SSY------ .T.GLFNSN------NGS .
·G.H. P- ••• - H M.............•• S ..• SSY------ .T.GLFNSN------NGS .
·G. H. P- ••• - H M............••• S ..• SSY------. T .DLFNSN------NGSA .
·G.H. P- ••• - H M............•.• S ..• SSY------ .T.GLFNSN------NGS .
·K.H. P- ••• - E .......................••• G ..• RTF------. S. YMH----NSTN-N. SI E .
·K.H. P- ••• - E .......................••• G ..• RTF------. S. YMHNSTNNDS-----I E .
.A.H. P- ••• - E G ........• G ..• GTY------ .H.TEGNS--NST------ RE .
·K.H. P- ••• - NS G......••• A ..• GIY-----S.G. ---NST-NTT-----V QY .
·K.H. P- ••• - NS G......•.• A ..• GIY-----S.G.NS-----TNTT----V QY .
·R.H. P- ••• - E. P E STY----MP .G. ES-----NTS----K .. I .
·R. H. P- ••• - E. P .....................••• E STY----MP .G. ES-----NTS----K .. I .
.G.H. P- ••• -.Q.K .HA M.............•• N ..• STY---HS .• G. Y-KYNG-NSS----SP Q R Q. T.
.G.H. P- ••• - E.HA M..............• N ..• STY---YPK.G. Y-KYNG-NSS----LP Q R Q .
· .. L. P- .S.G H G......•.. D STY-----S.G.CT-NGT--CMSNNT. R Q E .
·K.H. P- ••• -. T. K.H P I. S ......•.• G ..• GTY----MP .G. --------DKSNDTSP .
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TV008c4.3
TV008c4.4
TV01ge5
TV013eB20
TV013CH17
TV006cE9
LinkTV006eE9
TV006c9.1
TV006e9.2
TV004eC300
LinkTV004eC300
TV003eE260
TV012c2.1
TV012e2.2
TV018eFl027
LinkTV018cFl027
TV001e8.2
TVOOle8.5
TV002e12.1
TV010eD7
(JJ
I
-.....I
~ t-- V5100p ----t gp120 ..,~ gp41
..... Fusion domain/peptide
* AAA AAA 81..
APPISGQIRCSSNITGLLLTRDGG-----NSNNES-EIFRPGGGDMRDNWRSELyKyKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLG
APPIAGNITCKSN.ITGLLLVRDGG------EDNKTEEIFRPGGGNMKDNWRSELyKYKVIELKPLGIAPTGAKRRVVEREKRAVGIGAVFLGFLG
· E .K ••...•••......... EDKNNT .T - .T T .
·......••. E .••..... T ----KTGP.D. - N E C .
· E.I ••...•••.... T ------TGMHDT E K .
· E.I.M ...•••.... T A-----K. PHS.K E KP A- .
· ....••••• T .•••.......•. -----T ..• T. - N T ...•. A A L .••.•
· ....••••. T .•••......... -----T ..• T. - •.............. N T A A L .••••
·......•....••.......... -NTNDT-- .G.- E L .
·.....•••...••.......... -NTNDT-- .G.-G E G L .
·.....••..T .•.•.........----NSGK •T. ...................................A. .......................
·..T ..•••.T .•••......... ----NSG .•T A .
· K .•.•.N .•........... -EDNNT-E.D. -.T .
......•••...•••.... T ---NIT--.E.-.TS E .
·.....••....•.•.... T ---NIT- -.E .- .T E .
·......••. N. S ---NIT- -.S. - E N T .
·.....•.•. N.S ---NIT- -.S. - E N T .
·.....••.. N.S ---NTT-- .S.- E S N T .
·.....•••. N.S ---NTT-- .S. -. T E N T.........•
......•.•...•••......... --ENGT--.N.- NK ••.•••••••••..••••••••••
......•••...•••......... --ENGT--.N.- NK •....•.•••••.••..•••••••
·.......•...•••......... -ESNDS-- .NNI R .
·......••.....•.... T -EGNGTN---.D A Q K A- .
·......••...•••.... T -EGNGTN---. D A Q K A- .
·.....•... Q .•.•.... T EES----KSNGT A E .
· Q .•.•.... T EES----KSNGT V E .
·......•....•.•.... T --FNTT---NNT. T K .
· .....•••...•••.... T F--NNTN- .D •.• T K K .
·.....••....••..... T D--NNT. T----. T A .
·.......•...•...... T E------ N. T T .
524
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TV001c8.2
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TV002c12.1
TV010cD7
III
I
CX)
~ I- Immun~ominant __Jregion --,
* * ÁÁÁ ÁÁÁ
: AAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAlEAQQHLLQLTVWGIKQLQARlLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWS-NKS
AAGSTMGAASLTLTVQARQLLSSIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLICTTNVPWNSSWS-NKS
· .•..•••• , .•.••.•••••• G ••.•.•..•.••.•.••.••..•.••. , •..•..•.•.••..•.•..•••.••••..•. A ..•••••. - •••
• ••...•..•••..•••• L •.• G ••... N •...••...••.•••.••.•••.•.•..•..•.••..••......•.•.•.•. A ..••••.. - •••
.••.•.••.•••.••. V •.••• G •••••••.•.••.•.••.•••..••.••.•.•..•..••••..••..•....•.•..•. A •..••••. - •••
.••.••••..••..•...•••• G ••...••....•.••••.•••.••.•••.•.•..•••. H ..••.•..•.....•.•... A .•.•••.. - •••
· ..•.•••••..•..•.••••. G •.••..••....•...••.••••..•••.•••.••.......••..•...•..•.••.• A ••.••••• - •••
•.••...•••••••.••...•. G •.•...••....•...•..•...•..••.•••.•••...•...•.••.•.•..•..••• A ..••••.. - •••
•.••.•.••.••••.••••.•. G •••••.••....•••. Y •.•••.•.•••.• A •.•.•.•.. Q ..•.••.•.••..••••• T ..•••••• - •••
•.••.••••..•••..•.•.•. G ••••.•.•....••••..•.•..••.••.• A ••..•.... Q ..•...••.•...••..• T ..•••••• - •••
· , G , ...................................• A •.. - •••
• ••••..••.•••.•••••..• G •••••••••••••.••••.•.•..•.••..•••••...•..•.•....••..•...•.••..•••••• - •••
.•••••.•• , ..•..••..••. G ..•...• , ....•.•.••. '" ..•.• , ••••••.••.••.•.•.•.•..•.....•.. A ..•••••• - •••
• .•••..•.•..•..••.•••. G •.••..••.•.•..•..•.•...••.•••. A •••••••.••..•••..•.•..•..•.. A ...••••. - •••
•..••..••...••.••••••. G •.••..••.•...••....••..•..••.• A •..•.....•..•..•.•••.•••••.. A ..••••.. - •••
· A G A A -S ..
· A G A A -So .
.............. A G T A A ....•... -•..
· A ..A R G A A -•.•
........... A ..A G P.A -..•
........... A ..A G P.A ....•... -•••
•.•••..••.•.••.••.•.•. G •••••••••••••..••..••..•...•.•.•..•..•.....•••.•.•.••.••••• A ...•••.• - •••
· G ................•......•................................... A ...• N •.. - •••
•.•..•••••.••.•..••••• G ••...•..•.••...•..•....•••..••.•..•.•.•.••.......••••....•. A •..• N •.• - •••
•.•.•.••...••.•...• ~.G .....•.•...•...•..•.•.••...•••....•.•.•.•........•.•....... A ...•••.. - •••
· .•...••. , ..•. " •....• G ...•..•...•....•...••.•.•...••......•.••....•....•..•.•••.• A •••••••. - •••
•.••...•.•..•...•....• G ...•..•.....•..•......•....••. A •..•.•.•..•..•..•.•..•...... A ..••••.. - •••
•.•••..••.•..••.••..•. G ...•..••..•....•...•..••.•.••. A ••.••••••..•..•..•...••.••.. A ..•••••. - •••
•.••.•.••...•••••....• G •..•••.•..••...••.•••.••••..•. A •..•...•. Q ••....•.•.••••..•..• L .•••.. - •••
M .••.•.•. , ..••.••••..• G .•••.• K •...•...••.•.••.•••.••. A ••.•• K ••.•.•.•......••.•.••• A .••••••. N •••
618
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OJ
I
CD
L- Tryptophan-rich __J Membrane-spanning
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APPENDIXC
This section contains the article that resulted from this study.
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Sequence Note
Genetic Analysis of the Complete gag and env Genes of HIV
Type 1 Subtype C Primary Isolates from South Africa
SUSAN ENGELBRECHT,! TANIA DE VILLIERS,! CANDICE C. SAMPSON,! JAN ZUR MEGEDE,2
SUSAN W. BARNETT,2 and ESTRELITA JANSE VAN RENSBURG!
ABSTRACT
South Africa has one of the fastest growing HIV-1 epidemics, with an estimated 4.7 million people infected.
To better understand the genetic diversity of this epidemic and its potential impact on vaccine development,
we have cloned and sequenced the complete gag and env genes of 13 primary virus isolates. Phylogenetic anal-
ysis of our sequences and 69 complete ellv genes from the Los Alamos and GenBank databases revealed mul-
tiple subclusters within subtype C. The V3 loop region was relatively conserved in all our strains when com-
pared with other subtypes, but the region immediately downstream was highly variable. No intersubtype
recombinant forms were observed when comparing the gag and env sequences. Characterization of the com-
plete gag and env genes enabled us to select specific strains for further vaccine development.
MORE THAN 36.1 MILLION PEOPLE are infected with HIV.with 25.3 million living in sub-Saharan Africa.' Cur-
rently South Africa has one of the fastest growing HIV -I epi-
demics, with an estimated 4.7 million people infected out of a
total population of 40.6 million. The prevalence rate varies from
region to region, with the highest rate in KwaZulu-Natal
(36.2%) and the lowest in the Westem Cape Province (8.7%).2
A safe and effective HIV vaccine, which can be used for both
therapeutic and preventative immunization, is required to stop
the pandemic. The Env glycoprotein contains the major func-
tional domains for the two most important functions in the vi-
ral life cycle: viral attachment and fusion to target cells. The
diversity of HIV-I envelope proteins and its complex interac-
tion with the immune system poses one of the major obstacles
to HIV vaccine development. The more conserved gag gene en-
codes a major structural protein, which contains several cyto-
toxic T cell (CTL) epitopes. Gag-specific CTL responses are
important in controlling viral load during acute infection and
asymptomatic stages of the infection.
Phylogenetic analysis has shown that HIV-I can be classi-
fied into three major groups: M, N, and O. The M group viruses
are responsible for the majority of HIV -I infections and can be
subdivided into subtypes A to K and circulating recombinant
forms (CRFs), in which the env gene exhibits an average nu-
cleotide divergence of 25%.3 Subtype C viruses constitute 56%
of all circulating viruses and are the most commonly transmit-
ted subtype worldwide." Although many partial env and gag
gene sequences from South Africa have been published.>" no
complete env and gag sequences have been described, other
than in the publication of one nearly full-length molecular
clone." The objective of this study was to amplify, clone, and
sequence the complete env and gag genes of 13 HIV-I subtype
C primary isolates to generate a set of reference reagents for
studies of virus-induced pathogenesis and for vaccine develop-
ment.
Samples from HIV-I-infected patients were obtained during
1998 and 1999 from Tygerberg Hospital in the Westem Cape.
Viruses were isolated from patient peripheral blood lympho-
cytes (PBMCs) and cocultured with cord blood lymphocytes.ê-"
All the isolates were of the non-syncytium-inducing (NSI) phe-
notype and used CCR5 as their principal co-receptor.!?
Polymerase chain reaction (PCR) amplification of the gag
'Department of Medical Virology, University of Stellenbosch and Tygerberg Hospital, Tygerberg 7505, South Africa.
2Chiron Corporation, Emeryville, California 94608.
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and env gene fragments was done by using proviral DNA as
template with the following primer pairs:
GagF:
GagR:
Env-st:
Env-end:
GCTAGAAGGTCTAGAATGGGTGCGAGAGCG
AGTIGCCCCCGAA TICTT ATIGTGACGAGGII
GAAAGAGCAGAAGACAGTGGCAA
CTTTTTGACCACTIGCCACCCAT
using the Expand high-fidelity PCR system (Roche Molecular
Biochemicals, Mannheim, Germany). The gag and env PCR
products were cloned either into pCR 3.1, using the Eukaryotic
TA cloning kit (Invitrogen, Carlsbad, CA), or into pGEM-T-
Easy. The pCMVlink (Chiron, Emeryville, CA) or pcDNA3.1 (_)
(Invitrogen) vector was used for directional cloning. Sequenc-
ing reactions were done with the ABI Prism BigDye Termina-
tor Cycle Sequencing Ready reaction kit (Applied Biosystems,
Foster City, CA) and run on an ABI 310 genetic analyzer (Ap-
plied Biosystems).
Sequence assembly was performed with either DNAMAN
version 4.0 (Lynnon BioSoft, Vaudreuil-Dorion, Quebec,
Canada) or Auto Assembler (Applied Biosystems). Nucleotide
sequences were aligned with reference sequences from the Los
Alamos HIV sequence database and phylogenetic trees were
constructed as previously described.V'-'? Sequence analyses re-
vealed that all except one clone of isolate TVOI4 had intact
open reading frames, suggesting the presence of functional env
genes. Both clones of isolate TV007 had a premature trunca-
tion of the gp41 region. All except one clone of TV006 had in-
tact gag open reading frames.
In the trees constructed from the gag and env nucleic acid
sequences (Fig. l A and B), major clusters can be observed con-
taining sequences representative of the different subtypes and
CRFs (AI, B, C, D, FI, F2, G, K, and Hand CRFOI AE,
CRF02_AG, CRF03_AB, CRF05_DF, and CRF04_CPX, and
CRF06_CPX). Bootstrap analysis strongly supported these
branching orders. All 21 env sequences from the 13 patients
clustered with the subtype C reference strains (Fig. IA). Inter-
subtype nucleotide distances for our isolates and all other sub-
types varied between 21 and 30% (data not shown). The clone
sequences for isolates TVooI, TV002, TV003, TVOO4, TV007,
TV008, TVOIO, TVOI2, TV013, TVOI4, TVOI8, and TVOI9
varied between 1-4 and 4-6% for TV006.
The env and gag sequences of the isolates clustered with the
subtype C reference strains, strongly suggesting that our iso-
lates are subtype C strains and not recombinant forms. This is
supported by a previous study in which the accessory genes of
these isolates were also characterized as being subtype C. 10 The
diversity among our isolates was comparable to the diversity
ENGELBRECHT ET AL.
seen among the C subtypes as a whole. The subtype C gag se-
quences varied between 6 and 13%, while the intersubtype vari-
ation within the M group ranged between 8 and 19%. The high-
est variation within gag was seen in the pI7 matrix protein
(8-25%).
Phylogenetic analysis of 90 complete subtype C env se-
quences from South Africa, Botswana, India, China, Somalia,
Zambia, Burundi, Ethiopia, Djibouti, Uganda, and Brazil indi-
cated several subclusters within subtype C (Fig. 2). A distinct
starburst effect was observed with a high degree of divergence
between the South African isolates. Unlike the Indian and Chi-
nese isolates, the South African and Botswana isolates were dis-
tributed across several subclusters, suggesting multiple intro-
ductions into the region. The env sequences of our isolates
varied between 10 and 14%, while the levels of nucleotide di-
vergence of the Botswana and Indian subsets were 13-17 and
6-20%, respectively. The calculated average intrasubtype dif-
ferences between South African subtype C sequences and those
of Indian and Botswana origin were in the range of 12-21 and
11-20%, respectively. Results from earlier studies suggested a
close similarity between strains from India and southern
Africa.12,13 Our results suggest that the Indian epidemic may
have originated from southern Africa. Geographic clustering
was observed for sequences from several adjacent East African
countries: Djibouti, Ethiopia, Uganda, Somalia, and Burundi.
The VI to V5 loops are highly variable regions of the viral
genome.' Compared with sequencing results of other subtypes,
the V3 loop of our strains was more conserved, but with a more
variable region downstream of the loop (Fig. 3). This was also
found by another group.!" The highly conserved N-Iinked gly-
cosylation site proximal to the first cysteine residue, observed
in all HIV -1 subtypes except subtype C,3 was also absent in the
V3 regions of our strains. The tetrapeptide crown sequence of
the loop was GPGQ for all our C subtypes. Uncharged or neg-
atively charged amino acid residues at positions 11, 25, and 32
were identified in all our isolates, suggesting an NSI pheno-
type.I" which was confirmed subsequently in cell culture ex-
periments using the parental virus isolates (F.K. Treurnicht et
al., submitted).
As with the accessory genes.!? phylogenetic analyses of our
env and gag sequences revealed no recombinant forms, and
multiple subclusters within subtype C with a high degree of di-
versity, the latter indicating multiple independent introductions
of strains of this subtype into southern Africa. The molecular
characterization of these functional env and gag genes derived
from primary South African HIV -I isolates will enable us to
select candidate subtype C antigens for further vaccine devel-
opment.
FIG. 1. Phylogenetic tree analysis of South African HIV -I sequences and Los Alamos HIV database reference sequences. The
South African Tygerberg Virology (TV) sequences are indicated in boldface italic lettering. The subtype reference designation
is indicated in boldface roman lettering. (A and B) The neighbor-joining method for tree construction is based on the complete
(A) gag gene (-1500 bp) and (B) env gene (-2500 bp). An indication of the degree of sequence dissimilarity is shown on the
horizontal axis, and the subtypes are indicated on the vertical axis. The number of bootstrap trees out of 1000 replications sup-
porting a particular phylogenetic group by more than 90% is placed alongside the node considered.
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FIG. I. Continued.
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FIG.2. Phylogenetic tree analyses of all the HIV-I subtype C complete env gene sequences. The neighbor-joining method for
tree construction is based on the complete env gene (-2500 bp). An indication of the degree of sequence dissimilarity is shown
on the horizontal axis. The number of bootstrap trees out of 1000 replications supporting a particular phylogenetic group by more
than 90% is placed alongside the node considered.
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FIG. 3. Alignment of the complete Env protein from South African HIV -I subtype C sequences compared with the subtype C reference strains IN21068, 96BW05.02, ETH2220,
and 92BR025.8 from the Los Alamos Database. Dots denote sequence identity with the IN21068 sequence, while dashes represent gaps introduced to optimize alignments. Carets
indicate possible glycosylation sites present in most of the sequences. Asterisks show positions of cysteine residues. The V I, V2, V3, V4, and V5 variable loops, as well as the sig-
nal peptide and CD4-binding residues and sites, are indicated above the sequences. Triangles at positions Il, 25, and 35 of the V3 loop indicate amino acids assessed for SIINSI
phenotype.
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DVISLWDQSLKPCVKLTPLCVTLECRN--------VNSTGNGTHSKTyNESM---------K-EIKNCSFNATTVIKDKKQTVyALFyKLDIVPLDNEEQENDSN
.1 K -------- ..A.N.INSMIDNSNK-----------G.M V ..ELR.R ..E.H R ..V Q-------G.
.1 G N.NA-------IK.N.K---VT---.N.------INSAND.M I ..ELR RKA N--NGS----
.1 , H.S----------.R.IDyN-----.RTDN-------MGG M ..EVR ..REK.H R K--NESS--.
....................... N.TD--------T.V R.VTG--.STNNTNGTGlyNIE.M ELR HKE R NE----.SD.
.1 N.TD--------T.V R.VTGNT.DTNIANAT--yKyE.M ELR HKE NE----.SN.
.1 N.T----------.A.V.yN--N.S--------------KDM YV ..ELR KKEN R N.---RKNG.
.1 N.S.----------NVK.A.N.---------------M-K.M T ..I ..ELR ..RKQE EE-------.
.1 N.S.----------NVK.A.N.---------------M-K.M T ..1 ..ELR ..RKQE EE-------.
.1 E N.KA---------.V.V.T.NFNDS------------MIEQMR I ..ELR KQ IQ ------D.
.1 E N.KANVTVKTNA-.V.V.T.NFNDS------------MIEQMR I ..ELR KQ R QF ..------D.
.1 E N.TD---------.V.V.T.SLTVSPTV---NIT-----EQ.R I ..ELR KQ R QF ..------D.
.1 R.V.-------- ..A.S.A.S.SSATSDN-------PMNG V ..E.R.R.KE P.V.S ..--------.
TV007cB105 : .1 R.V.-------- ..A.S.A.S.SSATSDN-------PMNG V ..E.R.R.KE P.V.S ..--------.
TV010cD7 : .1 AMC.VD.TLCHFKLyK-------CyyL-------HS-TIG-----------D T L T.K.H V ---NGS---.
TV01BcF1027: .1 N ..----------.V.--V.TNNDN.VTY--NNS---IPE I ..E.R KIE R.G KENKL----.
TV014c6.3 : .1 TG-VK----AT.NSS---ATNSS.VTNN---------D E HKE R N.GNPSEG-.
TV014c6.4 : .1 , TG-VK----AT.NSS---ATNSS.VTNK---------D E HKE R N.GNPSEG-.
TVOOBc4.3 : .1 N.SD-VI----PS.V.-.T.-VTHN.ITD---------.E.MR ..T ..I ..E.T SKE ..I ..R ..V NE---KD--.
TVOOBc4.4
TV019c5
TV003cE260
TV004cC300
TV013cH17
TV013cB20
.1 N.SD-VI----PS.V.-------VTHNNIMD-------.E.MR 1 ..E.T SKE ..I ..R ..V NE---KD--.
....................... N.TD-VD-----K EMYRKTTND.G----NDT-IDR--.M D.Q TG R ---NDT---.
.1 N.-V-------.T.N-----------------------.MT DVR R.S.F ..R NENN-----.
.1 Q N.TT----------V.---------.STV--NNTR----G.MR M ..EVR Q V NE-NNSDS ..
.1 N.T.-----AINT.A.STT.T.A.ATSTIATSTYDNN--G T ..E.R NT RS N--------.
.1 N.T.-----AINT.A.STT.T.A.ATSTIATSTYDNN--G T ..E.R NT RS N--------.
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K. ---TE .....•... TV ......• S. E .••...•.••..•........••..... N •... I •.......•.•......•• I .. E ....•.•••. O.A ••.••••
N • - - - RE .•...•... TM S .•••..... T ............•• S ....• N ...•....•....•••••.•..••..• KE •.••• K 0 •A ••.•.••
E.---QK •••• S ••.. TI .•.....•..•••.... T ....•••...•......•....•••••••..•......•••....••. EE •••...••••• A. I .••••
F. ----E .......•.. M•.•.•••••.•.....•.......••........•... S •..........••.•.......••••. KE •••.•••...•.••.•••.
R. ----E. I .....•. TI •..•••• S F .........•...... Q •..•....••••••••••••.•••••• EO. R S.E •. I .••••••
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FIG. 3. Continued.
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AAA A*A AAA'" ...... *AAA AAA AAA AAA AAA I I * *AAA AAA
NQPVEIMCTRPDNNTRKSIRIGPGQTFYATGDIIGDIRQAHCNISEDKWNETLQNVSKKLAEHFPNKT-IIFNSSSGGDLEITTHSFNCRGEFFYCNTSGLFNRT
.K .. K. V. V .. N V ..•....•...• E Y. I .NKTE .• S •.. G E •.. SK.A-. KCEP ......•••.........•.•. D .• Q S.
• ES ... T .... S ..•. E •.••..•..•.•...•.•......•.•.. E .•. K .•. K. KE •• QK •..•.. - . E . KP ..•.•.•.•.•.•.• G •.•.•..•. N .•. S •
· ES ..• N .•.. N .•..••.•..•.• A .•.•. E .•.•.•......• RTA .• K •.. E. G ..•.•..•.• A-. K.AKH •.•...••..•.•.•...•...•. S •.. S.
.ES N N. '" .. V .•.... A N. V .• N T. R •. K .•. Q.M .•. G ..•.•.• - .Q.KPHA •.••••. M•.•••.•...•...• N ..• S.
.ES •.. N .••• N •.••.• V .••••. A •••. N. V .• N ••.....•. T. R •. K .•• Q.M .•• G .•.••.• - .K. EPHA ••.••.• M•••••.•...•.••• N .•• S.
· ESI •. K ••.• G .•.... V •.•..• A •.•.•.•.••.....•..• KNE •. T ..• R .. Q •. Q. L ••. S.G. K.APH •.•.•••••..••• G ..•.•... TD •.. S.
· ES ..• T .... N ....•• M•..•..•... " .......•.•.••.• KQ. DQ.• YR .• E •. K .••.•.• -. K .•.•.•..•.•••••.•. G••.•.•.•. A .•. GI
· ES .•• T ...• N .••.•• M•.•.....•.•...•.•..•.•.•..• KQ. DQ.. YR .. E .• K .•..•.. -. K .•.•.•....•.•..... G •.•.•.•.• A ..• GI
• ES ••. V •..• G .•.. Q ....••....•.•.•.•.••...•.... AG ••.•.• KR ....• G••.•.•• -. K.APH .•....•• M.•.•......•.•.• S ... SS
· ES V G.••. Q •.••.••.•.••.•...•••.......• AG •...•. KR .•.•. G - . K. APH •.•.•••. M•..••.••...•.•• S .•. SS
• ES .•. V •..• G .•.. Q .•...•......•.•..•...•.••.•. AG .•.... KR •.•.• G ...••.• -. K.APH .•...••. M.•.•.••••...•.• S ..• SS
.ESI .. R. P .. NH •.. R .••..•.• A ...•.....•..•.•..•.• S K .•. R , .G ...•.•. -. K.APH .....•.•.••.•.•......... K ..• S.
· ESI .. R. P .. NH •.. R .....•.. A ........•.•..•.•..•. S K .. , R G ..•..•. -. K.APH •....•.•.•.••.•........• K •.• S.
• . SI .. V •... N V •..•......••.•.•.•• E KE ..• N E ...•. K .. Y - . T. KPH •.•. P •.•.•.. I . S .•......•..•• G.
· ES V N ..•. R.M .. R .•....... E Y .K. " .Q .. K .. RR .. E .. R •... D .. -.K. EPP .....•••....•.•....•.•.• E ••. S.
· KS V ..•. G ...•.. V ..•...........•.•..•.•.•• T •....•.•. W. G .•. G • L ••.•. - • E • KP .•...••.•..•.•••••.•.•••. Q ••. S •
• KS V ..•• G V •.•.....•••.•.•.••••....• T •.••.•.•• W. G .•. G• L •.••. - . E • KP .•.•.•••••••••••••.•••.•. Q ••• S •
• ESIR .••... N .•..•.••.••.•.. F .• N •.•...••. Y .••. K. D .. K .•. RIAE .• GK •••.. N-. T. RP •.•..•.•.•.•..•.•........ R .•. H.
.ESIR. V N ..... , •..•..... F .• N •....•... Y •••• K. D •. K ... R.AE .. GK ••... N-. T .RP .•...••••.•.••......•...• R •.• H.
• ESIA G .....•..•.... A. F ..• A K. Y GE .. R .•. R. GR G. R-. R.APP ....•..•.•.... G ....•.•. TQ •....
· ES V N NG N ...•..•... ER .. K Q. G ..•.....•.. - . K. EP ......•.•.•..•. G .•..•...•.•.• G.
· ES I .. R N ................•.. E .•.•...... T .. SQN •. R R .. E •. K .•...•. - . K. EP ......••.•.•....•...•......•..•
D.S .K. V .•.. N .. , .R .•...... A .• TN- •....•....•... RAE .• N .. AK.KE •. EKLY- ... -. VLEPH .•..•.•.••.•.•....•.•. , TK ... I.
· . S. K. V N ...• R ....•... A .. TN- , .RAE .. N .. AK.KE .• EKLY- ..• -. V. EPH ..•....•.•..•.•.••...•. TK •.. I.
FIG. 3. Continued.
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CD4< V4100p CD4 I- binding -t I--- VS loop -----t
""" """ """ * I """* """ """ """yMP-----NDTKS-NSSSNPNANIT----IPCRIKQIINMWQEVGRAMyAPPIEGKITCRSNIT--GLLLVRDGGEDKNNTETNKT--ETFRPGGGDMRDNWRSE
·S---------P. F .GTE.KL- .G.--IT. T K A.NL ..E.D ..-- T ---KTG-P. D.--. I N.
K---------LELF T.L-- ----LQ G I.M -- T AK--EPH--STK--. I E ....•......
.T.-----.S.E--.ITGTE.SI ..---- G IL -- T ---TGM--HD.--.I E .
.HSN----.G.y-KyNG-----.SSSPITLQ.K VR G ..Q.T A.N '" ..--.I ..T F--.T.--.N.-- .
·Y.K---- .G.y-KyNG-----. SSLPITLQ. K VR G ..Q A.N --. I..T F-- -N. D.-E .
·SNGT-CT. G.CMS--------. N.ERITLQ A.N -- T D-------. N.ET .
.------S.G.--- ..T-----.T.-VITLQY ..R G '" A.N -- ..I.T G-.G.--.TD--.I A .
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FIG. 3. Continued.
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SEQUENCE DATA
Nucleotide sequences were submitted to GenBank under ac-
cession numbers AF391230-AF391270.
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